

CURRICULUM VITAE
DANIELE PIOMELLI, PharmD PhD MD (h.c.)

Home Address:

Phone:

Work Address:

Phone:

Fax:

E-mail:

ACADEMIC BACKGROUND

1977	Degree in Classical Studies, Lyceum 'Sannazzaro', Naples, Italy
1982	Pharm.D., <i>magna cum laude</i> ; University of Naples, Italy
1988	Ph.D. in Pharmacology, Columbia University, New York

PROFESSIONAL EXPERIENCE

2018-present	Distinguished Professor, Anatomy and Neurobiology, University of California Irvine
2018-present	Director, UCI Center for the Study of Cannabis
2017	Co-founder, Exxel Pharmaceuticals Inc., Vancouver, Canada
2017-18	Visiting Professor, University of Parma, Italy
2015	Co-founder, Neokera Pharmaceuticals LLC, Irvine, California
2012	Co-founder, Thesan Pharmaceuticals, Inc., San Clemente, California
7/12-2018	Professor, Anatomy and Neurobiology, University of California Irvine
1/07-8/16	Founding Director, Department of Drug Discovery and Development, Italian Institute of Technology, Genoa, Italy
7/05-present	Louise Turner Arnold Chair in the Neurosciences
2000-07	Founder, Kadmus Pharmaceuticals, Inc., Irvine, California
7/00-7/12	Professor, Pharmacology; University of California, Irvine
9/98-7/00	Associate Professor, Pharmacology; University of California, Irvine
2/95-9/98	Senior Fellow and Lab Head; The Neurosciences Institute, San Diego, California
8/92-2/95	Directeur de Recherche, INSERM; Paris, France
9/90-8/92	Chargé de Recherche, INSERM; Paris, France
5/88-8/90	Postdoctoral Associate, The Rockefeller University, New York
12/87-5/88	Postdoctoral Fellow, Columbia University, New York

ACTIVITIES TO PROMOTE SCIENCE AND ENHANCE SCIENTIFIC COMMUNICATION

Sep 2024	Invited speaker, Webinar of Cannabis Rescheduling, organized by the University of California Berkeley's Cannabis Research Center.
Jul 2024	Invited speaker, NIDA Summer Research Internship Program. July 9 th , 2024
Apr 2023	Invited speaker, California Cannabis Research Briefing, organized by the University of California's Office of the President and Department of Cannabis Control. April 28, 2023.
May 2022	Invited speaker, "The effects of cannabis use on individuals, and the research into this

- matter for medicinal and therapeutic purposes". Presentation to the Commission for Transversal Affairs of the Belgian Senate. May 23, 2022.
- Feb 2022 Invited keynote speaker, The Emerald Conference, Coronado, California, February 28, 2022.
- Nov 2021 Invited speaker, Colloquium "Le cannabis en Polynésie: entre justice, santé et économie, une question de société." Organized by the Government of French Polynesia and the University of French Polynesia. Papeete (Tahiti), November 16-17, 2021.
- Oct 2021 Interviewee, PBS Nova documentary 'The cannabis question'.
- Aug 2020 Invited speaker, Royal Government of Morocco, presentation on Cannabis to the Commission for Morocco's Development, August 6, 2020.
- Feb 2019 Invited speaker, Centinela Hospital Medical Center, Inglewood, California. "The health impact of cannabis."
- Feb 2019 Invited speaker, University of California Center Sacramento. "The medical and legal challenges of cannabis legalization."
- Oct 2018 Invited keynote speaker, National Association of State Controlled Substances Authorities (NASCSA), Scottsdale, AZ.
- Sep 2018 Invited speaker, 'The State of Cannabis' conference, Los Angeles, CA.
- Sep 2018 Invited speaker, legislative briefing on 'Cannabis and Post-Traumatic Stress Disorder: an Assessment of the Evidence', Washington, DC. (Sponsors, Hon. Luis Correa and Hon. Jared Polis).
- May 2018 Invited speaker, Cannabinoids in Medicine CME/CE conference, Los Angeles, California.
- Mar 2018 Invited speaker, Democratic Attorney General Association, 2018 Spring Policy Conference, Santa Fe, New Mexico. Panel on 'The emerging Attorney General role in cannabis markets.'
- Jan 2018 Invited speaker, legislative briefing on 'Health Focus on Cannabis' California State Capitol, Sacramento, CA. (Sponsor: Public Health Advocates).
- Jul 2016 Expert witness, Senate Judiciary Committee's Subcommittee on Crime and Terrorism, Hearing on Medical Marijuana (Invited by Hon. Lindsey Graham)
- May 2015 Invited speaker, legislative briefing on 'The effects of marijuana on the brain' Washington, DC (Sponsor: Dana Foundation).

ACTIVITIES TO PROMOTE DIVERSITY AND REMOVE DISPARITIES IN SCIENCE

- 2014-present Mentor, NIDA Summer Research Internship Program
- 2016 Mentor, UCI Bridges to Baccalaureate Summer Program
- 2013 Mentor, UCI Bridges to Baccalaureate Summer Program
- 2014-2017 Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellowships to Promote Diversity in Health-Related Research (Parent F31 - Diversity)- Recipient: James Lim, Department of Anatomy and Neurobiology, University of California Irvine
- 2009-2010 President's Dissertation Year (PDY)- Recipient: Carlos Solorzano, Department of Pharmacology and Toxicology, University of California Irvine
- 2008-2009 Faculty Mentor Program (FMP)- Recipient: Emmanuel Dotsey, Department of Pharmacology and Toxicology, University of California Irvine

SOCIETY MEMBERSHIPS

- Fellow, American College of Neuropsychopharmacology (ACNP)
- Member, American Association for the Advancement of Science (AAAS)
- Member, American Chemical Society (ACS)
- Member, The American Physiological Society (APS)

Member, The American Society for Biochemistry and Molecular Biology (ASBMB)
Member, American Society for Pharmacology and Experimental Therapeutics (ASPET)
Member, International Cannabinoid Research Society (ICRS)
Member, The New York Academy of Science (NYAS)
Member, Society of Biological Psychiatry (SBP)
Member, Society for Neuroscience (SFN)
Member, Società Italiana di Farmacologia (SIF)

DOMESTIC AND INTERNATIONAL COMMITTEE MEMBERSHIPS

2022-24	Member, California Department of Public Health High-Potency THC Think Tank.
July 2023	Vice-Chair, National Institute of Diabetes and Digestive and kidney Diseases, Special Emphasis Panel ZDK1 GRB-Q (O1)
May 2023	Chair, National Cancer Institute, Special Emphasis Panel ZCA1 TCRB-V (A1).
2018-present	Member, National Advisory Council, Center for Medicinal Cannabis Research at the University of California, San Diego.
Mar 2018	Chair, NIH Program Project Review (PAR-16-393) Pharmacology of drugs of abuse during pregnancy (P01).
Jun 2017	Invited participant, NIH Opioid Meeting, Medications Development for Opioid Use Disorders and for Overdose Prevention/Reversal." NIH campus, Bethesda, Maryland.
2017	Member, Expert Review Committee, Innovation Fund of Canada Foundation for innovation.
Nov 2016	Chair, NIDA Special Emphasis Panel (ZDA1 GXM-A (14)), Improved Technologies and Ligands for Non-Invasive Brain Imaging (R41/R42)
Nov 2016	Chair, NIH Special Emphasis Panel (ZRG1 IFCN-L (56)), Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects
June-Dec 2016	Member, National Academies of Sciences, Engineering and Medicine, Committee on the Health Effects of Marijuana
Dec 2015	Committee Meeting, ACNP Publication & 54 th Annual Meeting; Hollywood, FL.
July 2014	Chair, NIH Special Emphasis Panel (ZRG1 MDCN-R 40 P)
2012-2015	Member, Italian National Committee for Biosafety, Biotechnology and Life Sciences (an Advisory Committee to the Prime Minister of Italy)
2012-2015	Member, Scientific Committee of the Innovative Medicine Initiative (IMI)-European Commission/European Federation of Pharmaceutical Industries and Associations
2007-2011	Member, National Advisory Council on Drug Abuse (National Institutes of Health)
Jun 2001	ad hoc member; NIAAA Board of Counselors
May 2001	ad hoc member; NIH Centers Review Committee
May 2001	ad hoc member; NIH Program Projects Review Committee

AWARDS AND HONORS

April 2022	<i>Annual Lecturship in Toxicology</i> , American Academy of Forensic Sciences
April 2022	<i>Pioneer in Medicinal Cannabis Research Award</i> , the Center for Medicinal Cannabis Research, University of California San Diego.
Sept 2017	<i>The Ester Fride Award for Basic Research</i> , The International Association for Cannabinoid Medicines
Sept 2017	<i>The Mechoulam Award</i> , The International Cannabinoid Research Society
Dec 2015	Fellow, American College of Neuropsychopharmacology
Nov 2012	Honorary Medical Doctoral degree, Goethe University, Frankfurt, Germany
Sept 2012	<i>European Lipid Science Award</i> , European Federation of Lipid Science
Aug 2009	Chair, Gordon Research Conference, Cannabinoid Function in the CNS, Biddeford, ME

Apr 2009 National Alliance for Research on Schizophrenia and Depression (NARSAD)
Distinguished Investigator Award
April 2008 Chair, NIDA Scientific Director Review, Baltimore, MD
May 2005 National Alliance for Research on Schizophrenia and Depression (NARSAD)
Distinguished Investigator Award
Oct. 2003 Member of the NIDA Delegation to the Office of Drug Control Policy (ONDCP)
July 2002 Chancellor Scholar; University of California, Irvine
July 2002 *International Kemali Foundation Prize in Neurosciences*
May 2002 Grass Traveling Fellowship
Sept 2001 NIH Independent Investigator Award
June 2001 Course Director; International School of Immunology, "Ruggero Ceppellini"
June 1999 National Alliance for Research on Schizophrenia and Depression (NARSAD)
Independent Investigator Award

EDITORIAL CONSULTANCIES

EDITOR-IN-CHIEF

Cannabis and Cannabinoid Research (2016-present)

EDITORIAL BOARD

American Journal of Physiology – Endocrinology and Metabolism
CNS Drug Reviews (member, Editorial Board 2004-2007)
Current Opinion in Pharmacology (Guest Editor, Neurosciences, Vol. 9, issue 1, February 2009)
Il Farmaco (member, Editorial Board 2004-2006)
Neuropharmacology (member, Editorial Board, 2005-2011)
Pharmacological Research (member, Editorial Board)

REVIEWER

American Journal of Psychiatry
Biochimica Biophysica Acta
Cannabis and Cannabinoid Research
Cell
Current Drugs
European Journal of Biochemistry
FEBS Letters
International Journal of Pain
Journal of Biological Chemistry
Journal of Neurochemistry
Journal of Neuroscience
Journal of Pharmacology and Experimental Therapeutics
Life Sciences
Molecular Pharmacology
Nature
Nature Medicine
Nature Neuroscience
Neuroendocrinology
Neuron
Neuropsychopharmacology
New England Journal of Medicine
Journal of Pharmacological Research
Pharmacology, Biochemistry and Behavior
Proceedings of the National Academy of Sciences

Psychopharmacology
Science
Trends in Molecular Medicine
Trends in Pharmacological Sciences

PROFESSIONAL CONSULTANCIES

Aelis Farma; Bordeaux, France (member, Scientific Advisory Board)
Allergan; Irvine, CA
Angelini Pharmaceuticals; Rome, Italy
Archer Daniels Midland Company; Chicago, Illinois
Aventis; Strasbourg, France (ad hoc member, Scientific Advisory Board)
Bayer AG; Düsseldorf, Germany
Evotec GmbH
Ferring Pharmaceuticals; San Diego, CA
Health Research Board; Dublin, Ireland (grant reviewer)
Human Frontier Research Organization; Strasbourg, France (grant reviewer)
Israeli Academy of Science (grant reviewer)
Italian Ministry of Research and University; Rome, Italy (grant reviewer)
FSD Pharma, Toronto, Canada.
Novartis; Basel, Switzerland
Parke-Davis/Jouvenail; Paris, France
Pfizer; Groton, NJ
Roche Bioscience; Palo Alto, CA
Science Foundation Ireland (grant reviewer)
Therapix Biosciences Ltd., Israel (member, Scientific Advisory Board)
The Wellcome Trust; London, United Kingdom (grant reviewer)
U.S. National Science Foundation; Washington, DC (grant reviewer)
University of Genoa, PhD Program in Chemistry (member, Advisory Board)
University of Insubria, PhD Program in Biology and Medicine (member, Advisory Board)

PATENTS

1. Piomelli D., Beltramo M.; **Methods of treating mental diseases, inflammation and pain.** Application PCT/US97/22063 (11.25.1997); Priority US 08/764,104 (12.06.1996)
2. Calignano A., La Rana G., Giuffrida A., Piomelli D.; **Control of pain with endogenous cannabinoids.** Application PCT/US99/11905 (05.28.1999); Priority US 60/087,289 (05.29.1998)
3. Makriyannis A., Lin S., Piomelli D., Goutopoulos A.; **Preparation of arachidonyl amine amides as inhibitors of the anandamide transporter and their use as analgesics.** Application PCT/US99/12900 (06.09.1999); Priority US 60/088,568 (06.09.1998)
4. Piomelli D.; **Cannabinoid receptor agonists for treatment of cough without psychoactive effects.** Application PCT/US99/12900 (05.23.2001); Priority US 60/206,591 (05.23.2000)
5. Makriyannis A., Lin S., Piomelli D.; **Inhibitors of the anandamide transporter as analgesic agents.** Application US 09/328,742 (06.06.1999)
6. Piomelli D., Duranti A., Tontini A., Mor M., Tarzia G.; **Preparation and use of carbamates for modulation of anxiety through blockade of anandamide hydrolysis.** Application PCT/US2003/031844 (10.07.2003); Priority US 60/417,008 (10.07.2002)

7. Piomelli D., De Fonseca F., Fu J., Gaetani S.; **Combination therapy for controlling appetites.** *Application PCT/US2003/025760 (08.15.2003); Priority US 60/405,047 (08.20.2002)*
8. Fu J., Gaetani S., Piomelli D.; **Compounds, compositions and therapeutic uses of oleoylethanolamide-like compounds and modulators of PPAR- α .** *Application PCT/US2004/021394 (07.01.2004); Priority US 60/485,062 (07.02.2003)*
9. Fu J., Gaetani S., Piomelli D.; **Compounds, compositions and therapeutic uses of oleoylethanolamide-like compounds and modulators of PPAR- α .** *Application US 10/884,617 (07.01.2004), Priority US 60/485,062 (07.02.2003), US 60/336,289 (10.31.2001), US 60/279,542 (3.27.2001)*
10. Piomelli D., Duranti A., Tontini A., Mo, M., Tarzia G., Hohmann A.G.; **Methods, compositions, and compounds for modulation of monoacylglycerol lipase, pain, and stress-related disorders.** *Application PCT/US2006/ 016843 (04.26.2006); Priority 60/676,532 (04.28.2005)*
11. Piomelli D., Rodríguez de Fonseca F.; **Dietary and other compositions, compounds, and methods using fatty acid ethanolamides for reducing body fat, controlling appetite, and modulating fatty acid metabolism.** *Application PCT/US2004/034609 (10.18.2004); Priority US 60/512,471 (10.16.2003)*
12. Piomelli D., Rodríguez de Fonseca F.; **Dietary and other compositions, compounds, and methods using fatty acid ethanolamides for reducing body fat, controlling appetite, and modulating fatty acid metabolism.** *Application US 10/968,561 (10.18.2004); Priority US 60/485,062 (07.02.2003), US 60/336,289 (10.31.2001), US 60/279,542 (3.27.2001)*
13. Piomelli D., LoVerme J.; **Compounds and methods for treating non-inflammatory pain using PPAR- α agonists.** *Application PCT/US2005/013858 (04.22.2005); Priority US 60/565,196 (04.23.2004)*
14. Piomelli D., Rodríguez de Fonseca F.; **Methods, compounds and compositions for reducing body fat and modulating fatty acid metabolism.** *Application US 10/099,134 (04.04.2005); Priority US 60/336,289 (10.31.2001), US 60/279,542 (3.27.2001)*
15. Piomelli D.; **A novel treatment for cough.** *Application US 11/225,345 (9.12.2005); Priority US 60/206,591 (05.23.2000)*
16. Piomelli D., Tarzia G. Mor M., Duranti A., Tontini A.; **Composition and methods of inhibiting N-acylethanolamine-hydrolyzing acid amidase.** *Application PCT/US2008/079621 (10.10.2008); Priority US 60/979304 (10.11.2007)*
17. Piomelli D., Duranti A., Tontini A., Mor M., Tarzia G.; **Modulation of anxiety through blockade of anandamide hydrolysis.** *Application PCT/US2003/031844, (10.07.2003); Priority US 60/417,008 (10.07.2002)*
18. Piomelli D., Clapper J., Moreno-Sanz G., Duranti A., Tontini A., Mor M., Tarzia G.; **Peripherally Restricted FAAH Inhibitors.** *Application PCT/US2011/045114 (07.22.2011); Priority US 61/368,500 (07/28/2010)*

19. Piomelli D., Bandiera T., Mor M., Tarzia G., Bertozzi F., Ponzano S.; **Disubstituted beta-lactones as inhibitors of N-acylethanolamine-hydrolyzing acid amidase (NAAA)**. *Application PCT/US2012/066421 (11.21.2012); Priority US 61/562,862 (11.22.2011)*
20. Piomelli D., Moreno-Sanz G., Bandiera T., Mor M., Tarzia G.; **Meta-substituted biphenyl peripherally restricted FAAH inhibitors**. *Application PCT/US2012/51478 (08.17.2012); Priority US 61/525,636 (08.19.2011)*
21. Piomelli D., Reggiani A., Bertorelli R., Sasso O.; **Use of Inhibitors of Fatty Acid Amide Hydrolase (FAAH) to improve wound healing**. *Application US 61/618,426 (03.30.2012)*
22. Piomelli D., Astarita G., Avanesian A., Cavalli A.; **Methods of treatment, diagnosis and monitoring for methamphetamine toxicity which target ceramide metabolic pathways and apoptosis**. *Application PCT/US2013/034834 (04.01.2013); Priority US 61/618,361 (03.30.2012)*
23. Piomelli D., Realini N., Mor M., Pagliuca C., Pizzirani D., Scarpelli R., Bandiera T.; **Acid ceramidase inhibitors and their use as medicaments**. *Application PCT/EP2013/060846 (05.27.2013); Priority IT MI2012A000921 (05.28.2012)*
24. Piomelli D., Realini N., Mor M., Pagliuca C., Pizzirani D., Scarpelli R., Bandiera T.; **Acid ceramidase inhibitors and their use as medicaments**. *Application PCT/EP2013/060729 (05.24.2013); Priority IT MI2012A000923 (05.28.2012)*
25. Piomelli D., Fu J., Bottegoni G., Cavalli A., Bandiera T.; **Inhibitors of anandamide transport and their therapeutic uses**. *Application PCT/US2012/40531 (06.01.2012); Priority US 61/492,293 (06.01.2011)*
26. De Vivo M., Scarpelli R., Cavalli A., Migliore M., Piomelli D., Habrant D., Favia A.; **Multitarget FAAH and COX Inhibitors and Therapeutical uses thereof**. *Application PCT/EP2013/066197 (08.01.2013); Priority PCT/EP2012/065336 (08.06.2012)*
27. Piomelli D., Mor. M., Tarzia G., Bertozzi F., Nuzzi A.; **Amide derivatives of Lactam Based N-Acylethanolamine Acid Amidase (NAAA) Inhibitors**. *Application US 61/799,470 (03.15.2013)*
28. Piomelli D., Bandiera T., Bertozzi F., Nuzzi A., Fiasella A., Ponzano S., Pagliuca C., Reggiani A. M.; **Carbamate derivatives of lactam based NAAA inhibitors**. *Application US 61/799,637 (03.15.2013)*
29. Bottegoni G., De Simone A., Ruda G.F., Cavalli A., Bandiera T., Piomelli D.; **Dual modulators of fatty acid amide hydrolase (FAAH) enzyme and modulators of the D3 dopamine receptor (D3DR), and their use as medicaments**. *Application US 61/847,807 (07.18.2013)*
30. Daniele Piomelli, Tiziano Bandiera, Rita Scarpelli; **Inhibitors of fatty acid amide hydrolase (FAAH) enzyme with improved oral bioavailability and their use as medicaments**. *Application PCT/US15/024753 (04.07.2015)*
31. Daniele Piomelli, Rita Scarpelli, Marco Migliore, Miguel Garcia Guzman, Roger Heim; **Piperazinyl methanone NAAA inhibitors**. *Application PCT/US17/032981 (05.16.2017)*
32. Daniele Piomelli, Hamid Moradi, Kamyar Kalantar-Zadeh, Hamid Moradi; **Methods of treating renal disease**. *Application US 62/537,776 (07.27.2017)*

33. Daniele Piomelli, Yannick Fotio; Allostatic agents for preventing transition from acute to chronic pain. Publication number: 20240252486

SELECTED INVITED PRESENTATIONS

October, 2024	Invited seminar speaker, University of Texas San Antonio, Department of Cellular and Integrative Physiology.
October 2023	Keynote Speaker, Mediterranean Neuroscience Society Meeting, Carthage, Tunisia.
September 2023	Keynote Speaker, International Headache Society Meeting, Seoul, Republic of Korea.
March 2018	Invited Speaker and Session Chair, Keystone Symposia, Dublin, Ireland
October 2018	Keynote Speaker, Second UC-wide Drug Discovery Symposium, Los Angeles, CA.
December 2017	Invited Speaker, American College of Neuropsychopharmacology (ACNP), Palm Springs, CA. Panel on "Fatty Acid Amide Hydrolase (FAAH) as a Therapeutic Target in Psychiatric and Addictive Disorders".
November 2017	Invited Speaker, American College of Rheumatology (ACR), ACR/ARHP Annual Scientific Meeting, San Diego, CA. Panel on "The Potential for Cannabinoids as Therapeutic Agents"
October 2017	Chair and Invited Speaker, 15th International Conference on Bioactive Lipids in Cancer, Inflammation, and Related Diseases, Puerto Vallarta, Mexico. Panel "
October 2017	Invited Speaker, ITMAT 12th Annual International Symposium, Perelman School of Medicine, University of Pennsylvania, Philadelphia
September 2017	Keynote Speaker, International Association for Cannabinoid Medicines (IACM), Cologne, Germany
September 2017	Invited Speaker, Bordeaux Neurocampus Conference, Scientific Inaugural of the New Neuroscience Research, University of Bordeaux, Past, Present and Future of Brain Research, Bordeaux, France
June 2017	Invited Presenter, Pathophysiology of Posttraumatic Stress Disorder (PTSD): Rethinking Drug Targets State of Science Summit (SOSS), Shepherdstown, West Virginia.
May 2017	Invited Speaker, American Psychiatric Association, San Diego, CA.
May 2017	Invited Speaker, The Eleventh National Clinical Conference on Cannabis Therapeutics, Patients out of time national conference, Berkeley, CA
April 2017	Invited Speaker, Indian Gaming Tradeshow & Convention, SD, CA.
December 2016	Invited Speaker, Medical University of South Carolina, Addiction Seminar Series; Charleston, SC.
November 2016	Invited Speaker, Yale University, Cannabis in Medicine Mini-symposium, "Therapeutic potential of the endocannabinoid system"; New Haven, CT.
October 2016	Invited Speaker, Vanderbilt Brain Institute, Seminars in Neuroscience Series: Brain, Mind, and Society, "The endocannabinoid synapse"; Nashville, TN.
October 2016	Invited Speaker, Canadian Centre on Substance Abuse – National Research Agenda on Cannabis, "The Endocannabinoid System"; Ottawa, Ontario, Canada.
September 2016	Invited Speaker, The Foundation for Peripheral Neuropathy International Research Symposium – Advances in Neuropathy: Emerging Therapies, "Basic Science of Cannabis and Analgesia I"; Chicago, IL.
June 2016	Invited Speaker, American Society of Clinical Pharmacology (ASCP), Medical Marijuana: Promise and Peril Session, "Therapeutic Potential of the Cannabis System"; Scottsdale, AZ.
March 2016	Invited Speaker, Cannabinoid Summit, UMSOM; Baltimore, MD.

January 2016	Invited Speaker, NIAAA Intramural Research Seminar Series; Bethesda, MD.
November 2015	Chair, Zardi Gori Foundation Meeting: Drug dependence meeting on drug abuse and mental disease, Session: "Cannabinoids"; Milan, Italy.
November 2015	Invited Speaker, 8 th Novo Nordisk Foundation Conference, "Lipid sensing and the gut-brain axis"; Copenhagen, Denmark.
October 2015	Grandes Conférences Center for Interdisciplinary Research of Biology (CIRB) du College de France, "Matière grasse à pensée Comment la nouvelle science des lipids va changer les neurosciences"; Paris, France.
October 2015	Plenary Lecturer and Invited Speaker, 37 ^o Congress Società Italiana di Farmacologia (SIF), "The endocannabinoid synapse" and "Endocannabinoid-based drugs for pain control"; Naples, Italy.
September 2015	Plenary Lecturer and Chair of "Pain" Session, Cannabinoid Conference, "Unhealthy skepticism: the future of endocannabinoid-based therapeutics"; Sestri Levante (Genova), Italy.
July 2015	Invited Speaker, Society for Study of Ingestive Behavior Annual Meeting, "Intestinal lipid-derived signals that sense dietary fiber"; Denver, CO.
June 2015	Invited Speaker, ESMEC-European School of Medicinal Chemistry, "New avenues in pain therapeutics", Urbino, Italy.
May 2015	Discussion Leader, Gordon Research Conference, "From phytocannabinoids to cannabinoid medicines: novel signaling principles in health and disease"; Lucca (Barga), Italy.
May 2015	Invited Speaker, Fifth International Meeting of the Special Interest Group on Neuropathic Pain, "FAAH inhibition: a new therapeutic target for neuropathic pain"; Nice, France.
May 2015	Invited Speaker, Hotchkiss Brain Institute Friday Seminar Series, "Peripheral gating of pain signals by endogenous lipid mediators"; Calgary, Canada.
March 2015	Invited Speaker, NIDA Steve Goldberg Symposium, "Steve and I -- 15 years of scientific collaboration and friendship"; Baltimore, MD.
December 2014	Invited Speaker, International symposium at Heidelberg Castle, "Mechanisms of Disturbed Emotion Processing in Borderline Personality Disorder: Cannabinoids"; Heidelberg, Germany.
November 2014	Invited Speaker, Harvard Medical School, "Peripheral gating of pain signals by endogenous lipid mediators"; Boston, MA.
October 2014	Invited Speaker, Endocannabinoid Pharmacology Meeting, "New tricks for an old dog: unexpected new functions for peripheral FAAH"; Bern, Switzerland.
May 2014	Invited Speaker, American Asthma Foundation Annual Research Meeting, "NAAA inhibition as a therapeutic strategy for asthma"; San Francisco, CA.
March 2014	Invited Speaker, Keystone Symposium, "The thrifty lipids: endocannabinoid regulation of energy balance"; Dublin, Ireland.
March 2014	Invited Speaker, 15 th International Winter Eicosanoid Conference, "Peripheral gating of pain signals by endogenous analgesic lipids"; Baltimore, Maryland.
February 2014	Invited Seminar Speaker, Department of Pharmacology, University of Texas Health Sciences Center "A feeling for fat. How lipid signals control dietary fat intake"; San Antonio, TX.
November 2013	Invited Seminar Speaker, Department of Biochemistry, University of Washington, "A feeling for fat. How lipid signals control dietary fat intake"; Seattle, WA.
November 2013	Invited Speaker, The Neuroscience Institute Meeting "So many lipids, so little time! A journey in the physiology and pharmacology of lipid-mediated signaling"; San Diego, California.
September 2013	Invited Speaker, Pharmaceutical Institute, ETH; Zurich, Switzerland.
September 2013	Invited Speaker, Institute of Pharmacology, University of Zurich; Zurich, Switzerland.

August 2013	Invited Speaker, Gordon Conference Cannabinoid Function in the CNS “Dual FAAH-Cox inhibitors – potent analgesic and anti-inflammatory agents devoid of COX-mediated toxicity”; Waterville Valley, NH.
May 2013	Invited Speaker, Japan Society of Nutrition and Food Science Meeting “Fat-sensing lipids: the role of oleoylethanolamide in the control of fat-induced satiety”; Nagoya, Japan.
May 2013	Invited Seminar Speaker, Department of Psychological and Brain Sciences; UC Santa Barbara, CA.
March 2013	Invited Speaker, Keystone Symposium, “Lipid sensing and the gut-brain axis”; Alberta, Canada.
January 2013	Invited Seminar Speaker, UF College of Medicine, “The Endocannabinoid system as a source for new therapies”; Gainesville, FL.
January 2013	Invited Speaker, Department of Pharmacology; UC San Diego, CA.
2013	Chair, NIDA Special Emphasis Panel on Multisite Clinical Trials (ZDA1 SXC-E 03)
December 2012	Invited Speaker, 51st ACNP Annual Meeting, “Endocannabinoid System as a Therapeutic Target for Stress-related Disorders”; Hollywood, FL.
November 2012	Invited Speaker, Dies Academicus Lipid Conference – Goethe Universitat, “Reisebilder – images of a grand tour from bench to clinic”; Frankfurt, Germany.
October 2012	Invited Speaker, 22 nd Neuropharmacology Conference: Cognitive Enhancers, “What did I eat for breakfast? Gut satiety factors and cognition control”; New Orleans, LA.
September 2012	Keynote Speaker, 3rd International Workshop on Expression, Structure and Function of Membrane Proteins, “The Endocannabinoid System: New Tools Lead to New Insights”; Florence, Italy.
September 2012	Plenary Speaker, 10 th European Federation of Lipid Science, “Lipid-mediated Signaling as a Source of New Medicine”; Cracow, Poland.
September 2012	Plenary Speaker, European Behavioral Pharmacology Society (EBPS) “Eating Behaviour and Obesity”, “Lipid signals as fat sensors: the role of oleoylethanolamide in energy balance”; Lecce, Italy.
July 2012	Invited Speaker, ICRS Meeting, NIDA-NIH Symposium “Role of Cannabinoid System in Nicotine Addiction”, Freiburg, Germany.
June 2012	Chairman and Presenter, The 1st Italian Drug Discovery Summit, “The role of public research organizations in R&D”; Milan, Italy.
June 2012	Invited Speaker, Department of Pharmacology, Vanderbilt University, “The endocannabinoid system as a target for therapeutic drug”; Nashville, Tennessee.
June 2012	Invited Speaker, “Targeting Pain with Novel Therapeutics” World Pharma conference, “The Endocannabinoid System: New Insights into its Role in the Control of Pain”; Philadelphia.
June 2012	Plenary Speaker, IX Congresso Nazionale di Chimica degli Alimenti (ChimAlSi), “A role for oleoylethanolamide in the regulation of fat-induced satiety”; Ischia, Italy.
April 2012	Invited Speaker, University of Urbino; Urbino, Italy.
April 2012	Invited Speaker, UC Systemwide Proof of Concept Award; San Francisco.
April 2012	Plenary Speaker, NPCF, “Endogenous lipid amides as homeostatic regulators of pain and inflammation”; Riccione, Italy.
March 2012	Invited Speaker, Pain Consortium Seminar, “Endocannabinoid control of pain signaling”; Imperial College; London, England.
March 2012	Plenary Speaker, Therapeutic Insight by Defined Health, Bio Europe Spring; Amsterdam, Netherlands.
February 2012	Invited Speaker, Department of Psychiatry, Yale University; New Haven.
February 2012	Invited Speaker and Chairman, 1 st International Workshop on Palmitoylethanolamide: “Biochemistry, Pharmacology and Therapeutic Use of a Pleiotropic Anti-inflammatory Lipid Mediator”, Pozzuoli, Italy.

October 2011	Chairman, Biotech Workshop 2011, "Drug discovery in Italy: challenges and opportunities"; Milan, Italy.
October 2011	Plenary Speaker, Centre Europeen de Calcul Atomique et Moleculaire Workshop: "Innovative Approaches to Computational Drug Discovery", Lausanne, Switzerland.
October 2011	Invited Speaker, Workshop: The Obese Species, "Fats sensing fats – the roles of lipid signals in the control of energy balance"; Erice, Italy.
September 2011	Plenary Speaker, 12 th International Conference on Bioactive Lipids in Cancer Inflammation and Related Diseases, Washington.
September 2011	Plenary Speaker, International Association for Cannabinoid Medicines, 2011, Bonn, Germany.
June 2011	Invited Seminar Speaker, ULLA Summer School, Parma, Italy.
June 2011	Invited Seminar Speaker, University Tor Vergata, "From discovery to marketing authorization of new medicines"; Rome, Italy.
June 2011	Invited Speaker, National Institute on Drug Abuse, Baltimore, Maryland.
June 2011	Invited Speaker, American Diabetes Association 71 st Scientific Sessions, San Diego, California.
June 2011	Invited Speaker, The Science of Stress: Focus on the Brain, Bad Habits and Chronic Disease Conference, "Endocannabinoids and New Medication Targets for Stress, Pain and Addictive Behaviors"; Yale University, New Haven CT.
May 2011	Invited Speaker, Neuroscience School of Advanced Studies (NSAS), "An introduction to the endocannabinoid system"; San Quirico d'Orcia, Italy.
May 2011	Invited Discussion Leader, Gordon Conference Cannabinoid Function in the CNS, "Chemical and Genetic Tools targeting the Endocannabinoid System Introduction"; Le Diablerets, Switzerland.
April 2011	Invited Speaker, Department of Pathology, Columbia University College of Physicians & Surgeons, New York, NY.
April 2011	Invited Speaker, Experimental Biology Meeting; Washington, DC.
February 2011	Invited Speaker, NIDDK Intramural, Phoenix, Arizona.
January 2011	Invited Speaker, Università degli Studi di Firenze – Dipartimento di Farmacologia Preclinica e Clinica, Firenze, Italy.
January 2011	Invited Speaker, Università degli Studi di Firenze – Facoltà di Farmacia, Firenze, Italy.
December 2010	Invited Speaker, 49 th Annual ACNP Meeting, Miami, FL.
November 2010	Invited Panelist, Mind the Bridge Foundation: Venture Camp 2010 – Trip to Silicon Valley and back, "Bridging Research into Business"; Milan, Italy.
November 2010	Invited Speaker, 1 ^o Conferenza Nazionale sulla Ricerca Sanitaria, Cernobbio, Italy.
August 2010	Invited Speaker, 13 th World Congress on Pain; Montréal, Canada.
July 2010	Invited Speaker, International Cannabinoid Research Society, Sweden.
June 2010	Invited Speaker, Scuola Superiore Sant'Anna, Pisa, Italy.
June 2010	Invited Speaker, Keystone Symposium, Kyoto, Japan.
June 2010	Invited Speaker, The intestinal wall – "the" regulatory interface in energy homeostasis, Ascona, Switzerland.
May 2010	Plenary Speaker, Naples Pain Conference: Research and therapy for human and animal suffering, Naples, Italy.
May 2010	Invited Speaker, 28 th Camerino-Cyprus Noordwijkerhout Symposium-Trekking through Receptor Chemistry, Camerino, Italy.
October 2009	Invited Speaker, Obesity Society Annual Scientific Meeting; Washington, DC.
October 2009	Symposium Chair, Society for Neuroscience 39 th Annual Meeting; Chicago, Illinois.
October 2009	Invited Speaker, Society for Neuroscience NIDA Mini-Convention; Chicago, Illinois.
September 2009	Invited Speaker, Falk Symposium; Glasgow, UK.
July 2009	Invited Speaker, The XXIII Congresso Nazionale Società Chimica Italiana; Sorrento, Italy.

June 2009	Invited Speaker, Digestive Disease Week (DDW); Chicago, Illinois.
May 2009	Invited Speaker, Department of Pharmacology, University of Washington; Seattle, Washington
April 2009	Invited Speaker, Defined Health's 9 th annual Therapeutic Insight conference; New York, NY.
February 2009	Invited Speaker, American Academy of Forensic Sciences; Denver, Colorado.
December 2008	Invited Speaker, American College of Neuropsychopharmacology (ACNP); Scottsdale, Arizona.
September 2008	Invited Speaker, Leopoldina Symposium; Frankfurt, Germany.
August 2008	Invited Speaker, 6 th James Black Conference; St. Andrew's, Scotland.
June 2008	Plenary Lecture, Molecular Mechanisms in Neuroscience; Milan, Italy.
April 2008	Invited Speaker, 10 th International Neuroscience Winter Conference; Sölden, Austria.
March 2008	Invited Speaker, 2 nd Singapore Lipid Symposium; Singapore
December 2007	Invited Speaker, American College of Neuropsychopharmacology (ACNP) 46 th Annual Meeting; Boca Raton, FL.
November 2007	Chairman, 17 th Neuropharmacology Conference; San Diego, California.
November 2007	Moderator, Society for Neuroscience Press Conference; San Diego, California.
October 2007	Invited Speaker, Global Health in the 21 st Century (Embassy of Italy); Washington, DC.
October 2007	Invited Speaker, Gordon Research Conference/Cannabinoid Function in the CNS; Les Diablerets, Switzerland.
June 2007	Invited Speaker, Congresso Nazionale della Società Italiana di Farmacologia; Cagliari, Italy.
June 2007	Invited Speaker, College on Problems of Drug Dependence (CPDD); Quebec City, Canada.
April 2007	Invited Speaker, American Society for Pharmacology & Experimental Therapeutics (ASPET); Washington, DC.
March 2007	Invited Speaker, National Institute on Drug Abuse (NIDA), Intramural Research Program (IRP) Seminar Series; Baltimore, Maryland.
January 2007	Invited Speaker, Banff Inflammation Workshop; Banff, Alberta, Canada.
January 2007	Invited Speaker, Keystone Symposium, "Oleylethanolamide: Links dietary fat absorption to satiety"; Keystone, Colorado.
November 2006	Invited Speaker, American College for Advancement in Medicine (ACAM); Palm Springs, California.
September 2006	Grollman Lecture, University of Maryland; Baltimore, Maryland.
July 2006	Symposium Chair, CIMP; Chicago, Illinois.
June 2006	Invited Speaker, International Cannabinoid Research Society (ICRS) 16 th Annual Symposium on the Cannabinoids; Budapest, Hungary.
April 2006	Invited Speaker, 4 th National Cannabis Clinical Therapeutics Conference; Santa Barbara, California.
March 2006	Invited Speaker, Keystone Symposium; Santa Fe, New Mexico.
March 2006	Invited Seminar Speaker, Yale University; New Haven, Connecticut.
February 2006	Invited Speaker, Australian Neuroscience Society (ANS); Sydney, Australia.
November 2005	Invited Speaker, American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition; Nashville, Tennessee.
November 2005	Invited Speaker, NIDA, Frontiers in Addiction Research; Washington, DC.
November 2005	Symposium Chair, Society for Neuroscience (SfN) 35 th Annual Meeting; Washington, DC.
November 2005	Invited Speaker, Cannabinoids in the Liver Symposium, Columbia University; New York, New York.

October 2005	Invited Speaker, California Society of Addiction Medicine (CSAM); Long Beach, California.
September 2005	Invited Speaker, Ascona Workshop "Peripheral-Central Interactions in Control of Food Intake and Energy Balance"; Ascona Switzerland.
September 2005	Symposium Chair, 5 th International Meeting on Metabotropic Glutamate Receptors (mGlu); Taormina, Sicily, Italy.
August 2005	Symposium Chair, NIDA, Cellular Biology of Addiction Course; Cold Spring Harbor, New York.
July 2005	Invited Speaker, Gordon Research Conference; Lewiston, Maine.
June 2005	Invited Speaker, National Conference of Italian Society of Pharmacology; Naples, Italy.
June 2005	Invited Speaker, American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference; San Francisco, California.
April 2005	Invited Speaker, NIDA, Pride 2005 World Drug & Violence Prevention Conference; Cincinnati, Ohio.
January 2005	Invited Speaker, University of Cincinnati, Ohio.
December 2004	Invited Speaker, The Scripps Research Institute; La Jolla, CA.
November 2004	Invited Speaker, Harvard Medical School; Boston, Massachusetts.
October 2004	Invited Speaker, Society for Neuroscience (SfN) 34 th Annual Meeting; San Diego, California.
September 2004	Invited Speaker, 2 nd James Black Conference, Churchill College; Cambridge, U.K.
September 2004	Invited Speaker, 43 rd Karolinska Institutet Nobel Conference; Stockholm, Sweden.
September 2004	Invited Speaker, First International Symposium on Advances in Neuroscience; Parghelia, Calabria.
July 2004	Invited Speaker, Peptide Receptors Conference; Montréal, Canada.
June 2004	Invited Speaker, NIDA Symposium on Targeted Lipidomics; Paestum, Italy.
June 2004	Chairman, CMCR, Future Directions in Cannabinoid Therapeutics II: From the Bench to the Clinic, ("New Trends in Cannabinoid Therapeutics"); Paestum, Italy.
June 2004	Invited Speaker, American Diabetes Association's 64 th Scientific Session; Orlando, Florida.
May 2004	Invited Speaker, NIDDK, Lipid Metabolism and the Physiology of Obesity Meeting; Washington, DC.
May 2004	Symposium Chair, Spring Pain Research Conference; Grand Cayman, BWI.
April 2004	Invited Speaker, Pharmacology Seminar Series, University of Minnesota; Minneapolis, Minnesota.
April 2004	Invited Speaker, NIDA, Targeted Lipidomics: Signaling Lipids and Drugs of Abuse; Washington, DC.
April 2004	Invited Speaker, NIDA, Medications Development for Cannabis Dependence Meeting; Rockville, MD.
October 2003	Invited Speaker, NIDA, Baltimore, MD .
August 2003	Invited Speaker, Karolinska Institutet Department of Neuroscience; Stockholm, Sweden.
June 2003	Inaugural Lecture, Congresso Nazionale della Società Italiana di Farmacologia; Trieste, Italy.
November 2002	Dale Melbourne Herklotz Lecture; Irvine, CA.
November 2002	Chairman, Symposium on Endocannabinoids, Society for Neuroscience Annual Meeting; Orlando, FL.
October 2002	Invited Speaker, University of Buffalo Department of Pharmacology; Buffalo, NY.
November 2001	Invited Speaker, H. Schneiderman Memorial Lecture; Irvine, CA.
August 2001	Invited Speaker, NIDA Symposium on Cannabinoids: Chemistry and Biology; Washington, DC.
July 2001	Invited Speaker, World Biological Psychiatry Meeting; Berlin, Germany.

June 2001	Invited Speaker, CIMP Congress Meeting; Banff, Canada.
June 2001	Invited Speaker, Karolinska Institutet Department of Neuroscience; Stockholm, Sweden.
September 2000	Invited Speaker, Irvine Medical Scientist Lecture; Irvine, CA.
May 2000	Invited Speaker, Université de Montreal Conference Annuelle de Pharmacologie et Psychiatrie; Quebec, Canada.
April 1999	Invited Speaker, University of Naples Medical School "Luigi Minale" Memorial Lecture; Naples, Italy.
August 1998	Invited Speaker and Visiting Professor, University of Riberão Preto Department of Pharmacology; Sao Paulo, Brazil (Visiting Professor of Neuropharmacology).
April 1998	Invited Speaker, University of Naples Department of Pharmacology; Naples, Italy (Visiting Professor of Neuropharmacology).
November 1997	Invited Speaker, Society for Neuroscience Annual Meeting Symposium ("Functional Role of Cannabinoids"); New Orleans, LA.
November 1997	Invited Speaker, Karolinska Institutet Department of Neurosciences; Stockholm, Sweden.
July 1997	Invited Speaker, American Society for Neurochemistry Annual Meeting Satellite Symposium ("Lipid Mediators in the Nervous System"); New Orleans, LA.
December 1996	Invited Speaker, CNS Research: Sandoz Pharma; Basel, Switzerland.
June 1995	Invited Speaker, International Society for Neurochemistry Symposium ("Lipid Mediators in Synaptic Transmission"); Tokyo, Japan.
August 1993	Invited Speaker, International Society for Neurochemistry Round Table ("Regulation of neuronal excitability by eicosanoids and other lipid mediators"; Montpellier, France.
November 1991	Invited Speaker, Society for Neuroscience Annual Meeting Symposium ("Lipid Mediators in Synaptic Transmission"); New Orleans, LA.
September 1991	Invited Speaker, Symposium ("Chemical Signalling in the Basal Ganglia"); Cambridge, United Kingdom.
June 1990	Invited Speaker, The Royal Society Sandoz Symposium ("The Eicosanoids in the Brain") London, UK.
April 1990	Invited Speaker, FASEB Symposium ("The Comparative Physiology of the Eicosanoids"); Washington DC, USA.

PEER-REVIEWED PUBLICATIONS

<http://www.ncbi.nlm.nih.gov/sites/myncbi/daniele.piomelli.1/bibliography/40700007/public/?sort=date&direction=descending>

(Google Scholar, accessed April 2024)

H-index: 110

Total number of citations: 65,174 (total), 16,762 (since 2019)

i10-index: 406

1. **D. Piomelli** and B. Tota, 1983. Different distribution of serotonin in an elasmobranch (*Scyliorhinus stellaris*) and in a teleost (Conger conger) fish. **Comp Biochem Physiol C** 74, 139-142. PMID: 6132758
2. A. Pinto and **D. Piomelli**, 1983. Vasoconstrictory effects of adrenalin on the perfused head of the eel (*Anguilla Anguilla* L.). **Comp Biochem Physiol C** 76, 209-213. PMID: 6139251

3. P. Ghiara, L. Parente and **D. Piomelli**, 1983. The cyclooxygenase pathway in the avascular heart of the frog, *Rana esculenta* L. **Gen Pharmacol** 15, 309-313. PMID: 6436138
4. **D. Piomelli**, 1985. Leukotrienes in teleost fish gills. **Naturwissenschaften** 72, 276-277. PMID: 18443728
5. **D. Piomelli**, A. Pinto and B. Tota, 1985. Divergence in vascular actions of prostacyclin during vertebrate evolution. **J Exp Zool** 233, 127-131.
6. **D. Piomelli**, S. J. Feinmark and P.J. Cannon, 1987. Leukotriene biosynthesis by canine and human coronary arteries. **J Pharmacol Exp Ther** 241, 763-770. PMID: 3598901
7. **D. Piomelli**, A. Pinto, C. Sannino and B. Tota, 1987. Antagonistic actions of prostaglandins E₂ and F₂ alpha on the isolated lung of the frog, *Rana Esculenta* L. **Comp Biochem Physiol C** 87, 21-22. PMID: 2885133
8. **D. Piomelli**, A. Volterra, N. Dale, S. Siegelbaum, E.R. Kandel, J.H. Schwartz and F. Belardetti, 1987. Lipoxygenase metabolites of arachidonic acid as second messengers for presynaptic inhibition of *Aplysia* sensory cells. **Nature** 328, 38-43. PMID: 2439918
9. **D. Piomelli**, E. Shapiro, S.J. Feinmark and J.H. Schwartz, 1987. Metabolites of arachidonic acid in the nervous system of *Aplysia*: possible mediators of synaptic modulation. **J Neurosci** 7, 3675-3686. PMID: 3119791
10. **D. Piomelli**, E. Shapiro, S.J. Feinmark, and J.H. Schwartz, 1988. Formation and biological activity of 12-ketoeicosatetraenoic acid in the nervous system of *Aplysia*. **J Biol Chem** 263, 16591-16596. PMID: 3182804
11. E. Shapiro, **D. Piomelli**, S.J. Feinmark, S. Vogel, G. Chin and J.H. Schwartz, 1988. The role of arachidonic acid metabolites in signal transduction in an identified neural network mediating presynaptic inhibition in *Aplysia*. **Cold Spring Harb Symp Quant Biol** 53, 425-433. PMID: 3151176
12. **D. Piomelli**, E. Shapiro, R. Zipkin, J.H. Schwartz and S.J. Feinmark, 1989. Formation and action of 8-hydroxy-11,12-epoxy-5,9,14-icosatrienoic acid in *Aplysia*: a possible second messenger in neurons. **Proc Natl Acad Sci U S A** 86, 1721-1725. PMCID: PMC286773
13. **D. Piomelli**, S.J. Feinmark, E. Shapiro, and J.H. Schwartz, 1989. 12-keto-eicosatetraenoic acid. A biologically active eicosanoid in the nervous system of *Aplysia*. **Ann N Y Acad Sci** 559, 208-218. PMID: 2774398
14. S.J. Feinmark, **D. Piomelli**, E. Shapiro and J.H. Schwartz, 1989. Biologically active metabolites of the 12-lipoxygenase pathway are formed by *Aplysia* nervous tissue. **Ann N Y Acad Sci** 559, 121-130. PMID: 2505651
15. **Piomelli D**, Feinmark SJ, Shapiro E, Schwartz JH. 12-keto-eicosatetraenoic acid. A biologically active eicosanoid in the nervous system of *Aplysia*. **Ann N Y Acad Sci**. 1989;559:208-18. PMID: 2774398.
16. **Piomelli D**, Shapiro E, Zipkin R, Schwartz JH, Feinmark SJ. Formation and action of 8-hydroxy-11,12-epoxy-5,9,14-icosatrienoic acid in *Aplysia*: a possible second messenger in neurons.

Proc Natl Acad Sci U S A. 1989 Mar;86(5):1721-5. PubMed PMID: 2493649; PubMed Central PMCID: PMC286773.

17. **D. Piomelli**, J.K. Wang, T.S. Sihra, A.C. Nairn, A.J. Czernik, and P. Greengard, 1989. Inhibition of Ca^{2+} /calmodulin-dependent protein kinase II by arachidonic acid and its metabolites. **Proc Natl Acad Sci U S A** 86, 8550-8554. PMCID: PMC298320

18. **D. Piomelli** and P. Greengard, 1990. Lipoxygenase metabolites of arachidonic acid in neuronal transmembrane signalling. **Trends Pharmacol Sci** 11, 367-373. PMID: 2122564

19. **D. Piomelli**, 1991. The metabolism of arachidonic acid in the nervous system of the mollusk, *Aplysia californica*. **Am J Physiol** 260, R844-R848. PMID: 1903603

20. A. Calignano, **D. Piomelli**, T.C. Sacktor and J.H. Schwartz, 1991. A phospholipase A₂-stimulating protein regulated by protein kinase C in *Aplysia* neurons. **Brain Res Mol Brain Res** 9, 347-351. PMID: 1645437

21. **D. Piomelli** and P. Greengard, 1991. Bidirectional control of phospholipase A₂ activity by Ca^{2+} /calmodulin-dependent protein kinase II, cAMP-dependent protein kinase, and casein kinase II. **Proc Natl Acad Sci U S A** 88, 6770-6774. PMCID: PMC52170

22. **D. Piomelli**, C. Pilon, B. Giros, P. Sokoloff, M.P. Martres and J.C. Schwartz, 1991. Dopamine activation of the arachidonic acid cascade as a basis for D₁/D₂ receptor synergism. **Nature** 353, 164-167. PMID: 1909771

23. **D. Piomelli**, 1991. One route to religious ecstasy. **Nature** 349, 362.

24. M. Ruat, E. Traiffort, R. Leurs, J.M. Arrang, G. Kouyoumdjian, J. Tardivel-Lacombe, **D. Piomelli**, G. Diaz and J.C. Schwartz, 1992. Molecular biology and pharmacology of histamine receptor subtypes. **Clin Neuropharmacol** 15, 149A-150A. PMID: 1498787

25. E. Traiffort, M. Ruat, J.M. Arrang, R. Leurs, **D. Piomelli** and J.C. Schwartz, 1992. Expression of a cloned rat histamine H₂ receptor mediating inhibition of arachidonate release and activation of cAMP accumulation. **Proc Natl Acad Sci U S A** 89, 2649-2653. PMCID: PMC48719

26. V. Di Marzo and **D. Piomelli**, 1992. Participation of prostaglandin E₂ in dopamine D₂ receptor-dependent potentiation of arachidonic acid release. **J Neurochem** 59, 379-382. PMID: 1351931

27. **D. Piomelli**, 1993. Arachidonic acid in cell signaling. **Curr Opin Cell Biol** 5, 274-280. PMID: 7685181

28. **D. Piomelli** and V. Di Marzo, 1993. Dopamine D₂ receptor signaling via the arachidonic acid cascade: modulation by cAMP-dependent protein kinase A and prostaglandin E₂. **J Lipid Mediat** 6, 433-443. PMID: 8395253

29. T.S. Sihra, **D. Piomelli** and R.A. Nichols, 1993. Barium evokes glutamate release from rat brain synaptosomes by membrane depolarization: involvement of K⁺, Na⁺, and Ca²⁺ channels. **J Neurochem** 61, 1220-1230. PMID: 7690845

30. V. Di Marzo, D. Vial, P. Sokoloff, J.C. Schwartz and **D. Piomelli**, 1993. Selection of alternative G_i-mediated signaling pathways at the dopamine D₂ receptor by protein kinase C. **J Neurosci** 13, 4846-4853. PMID: 7693893
31. Aliotta, G., **D. Piomelli** and A. Pollio, 1993. Le piante narcotiche e psicotrope in Plinio e Dioscoride. *Annali dei Musei Civici di Rovereto*, 9, 99-114 (in Italian).
32. **D. Piomelli** and A. Pollio, 1994. A study in Renaissance psychotropic plant ointments. **Hist Philos Life Sci** 16, 241-273. PMID: 7724723
33. V. Di Marzo, A. Fontana, H. Cadas, S. Schinelli, G. Cimino, J.C. Schwartz and **D. Piomelli**, 1994. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. **Nature** 372, 686-691. PMID: 7990962
34. **D. Piomelli**, 1994. Eicosanoids in synaptic transmission. **Crit Rev in Neurobiol** 8, 65-83. PMID: 8124731
35. **D. Piomelli** and A. Pollio, 1994. Medicinal plants. **Nature** 371, 9. PMID:8072535
36. F. Désarnaud, H. Cadas and **D. Piomelli**, 1995. Anandamide amidohydrolase activity in rat brain microsomes. Identification and partial characterization. **J Biol Chem** 270, 6030-6035. PMID: 7890734
37. D. Vial and **D. Piomelli**, 1995. Dopamine D₂ receptors potentiate arachidonate release via activation of cytosolic, arachidonate-specific phospholipase A₂. **J Neurochem** 64, 2765-2772. PMID: 7760057
38. L. Venance, **D. Piomelli**, J. Glowinski and C. Giaume, 1995. Inhibition by anandamide of gap junctions and intercellular calcium signalling in striatal astrocytes. **Nature** 376, 590-594. PMID: 7637807
39. A. Fontana, V. Di Marzo, H. Cadas and **D. Piomelli**, 1995. Analysis of anandamide, an endogenous cannabinoid substance, and of other natural N-acyl ethanolamines. **Prostaglandins Leukot Essent Fatty Acids** 53, 301-308. PMID: 8577784
40. C.-H. Lammers, P. Schweitzer, P. Facchinetti, J.-M. Arrang, S.G. Madamba, G.R. Siggins and **D. Piomelli**, 1996. Arachidonate 5-lipoxygenase and its activating protein: prominent hippocampal expression and role in somatostatin signaling. **J Neurochem** 66, 147-152. PMID: 8522947
41. H. Cadas, S. Gaillet, M. Beltramo, L. Venance and **D. Piomelli**, 1996. Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. **J Neurosci** 16, 3934-3942. PMID: 8656287
42. E. di Tomaso, M. Beltramo and **D. Piomelli**, 1996. Brain cannabinoids in chocolate. **Nature** 382, 677-678. PMID: 8751435
43. H. Cadas, S. Schinelli and **D. Piomelli**, 1996. Membrane localization of N-acylphosphatidylethanolamine in central neurons: studies with exogenous phospholipases. **J Lipid Mediat Cell Signal** 14, 63-70. PMID: 8906547

44. A. Touwaide, A. Pollio, G. Aliotta, **D. Piomelli** and N.G. De Santo, 1997. Medicinal plants for the treatment of urogenital tract pathologies according to Dioscorides' De Materia Medica. **Am J Nephrol** 17, 241-247. PMID: 9189241
45. E. Di Tomaso, H. Cadas, S. Gaillet, M. Beltramo, F. Désarnaud, L. Venance and **D. Piomelli**, 1997. Endogenous lipids that activate cannabinoid receptors. Formation and inactivation. **Adv Exp Med Biol** 407, 335-340. PMID: 9321973
46. H. Cadas, E. di Tomaso and **D. Piomelli**, 1997. Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. **J Neurosci** 17, 1226-1242. PMID: 9006968
47. M. Beltramo, E. di Tomaso and **D. Piomelli**, 1997. Inhibition of anandamide hydrolysis in rat brain tissue by (E)-6-(bromomethylene) tetrahydro-3-(1-naphthalenyl)-2H-pyran-2-one. **FEBS Lett** 403, 263-267. PMID: 9091314
48. N. Stella, A. Estellés, J. Siciliano, M. Tencé, S. Desagher, **D. Piomelli**, J. Glowinski and J. Prémont, 1997. Interleukin-1 enhances the ATP-evoked release of arachidonic acid from mouse astrocytes. **J Neurosci** 17, 2939-2946. PMID: 9096130
49. N. Stella, P. Schweitzer and **D. Piomelli**, 1997. A second endogenous cannabinoid that modulates long-term potentiation. **Nature** 388, 773-778. PMID: 9285589
50. M. Beltramo, N. Stella, A. Calignano, S.Y. Lin, A. Makriyannis and **D. Piomelli**, 1997. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. **Science** 277, 1094-1097. PMID: 9262477
51. A. Calignano, G. La Rana, M. Beltramo, A. Makriyannis and **D. Piomelli**, 1997. Potentiation of anandamide hypotension by the transport inhibitor, AM404. **Eur J Pharmacol** 337, R1-R2. PMID: 9389389
52. A. Calignano, G. La Rana, A. Makriyannis, S.Y. Lin, M. Beltramo and **D. Piomelli**, 1997. Inhibition of intestinal motility by anandamide, an endogenous cannabinoid. **Eur J Pharmacol** 340, R7-R8. PMID: 9537804
53. A. Giuffrida and **D. Piomelli**, 1998. Isotope dilution GC/MS determination of anandamide and other fatty acylethanolamides in rat blood plasma. **FEBS Lett** 422, 373-376. PMID: 9498819
54. A. Calignano, G. La Rana, A. Giuffrida and **D. Piomelli**, 1998. Control of pain initiation by endogenous cannabinoids. **Nature** 394, 277-281. PMID: 9685157
55. **D. Piomelli**, M. Beltramo, A. Giuffrida and N. Stella, 1998. Endogenous cannabinoid signaling. **Neurobiol Dis** 5, 462-473. PMID: 9974178
56. M. Beltramo and **D. Piomelli**, 1998. Trick or treat from food endocannabinoids? **Nature** 396, 636-637.
57. A. Giuffrida, L.H. Parsons, T.M. Kerr, F. Rodríguez de Fonseca, M. Navarro and **D. Piomelli**, 1999. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. **Nat Neurosci** 2, 358-363. PMID: 10204543

58. M. Beltramo and **D. Piomelli**, 1999. Anandamide transport inhibition by the vanilloid agonist olvanil. **Eur J Pharmacol** 364, 75-78. PMID: 9920187
59. **D. Piomelli**, M. Beltramo, S. Glasnapp, S.Y. Lin, A. Goutopoulos, X-Q Xie and A. Makriyannis, 1999. Structural determinants for recognition and translocation by the anandamide transporter. **Proc Natl Acad Sci U S A** 96, 5802-5807. PMCID: PMC21941
60. F.M. Leweke, A. Giuffrida, U. Wurster, H.M. Emrich and **D. Piomelli**, 1999. Elevated endogenous cannabinoids in schizophrenia. **Neuroreport** 10, 1665-1669. PMID: 10501554
61. A. Straiker, N. Stella, **D. Piomelli**, K. Mackie, H.J. Karten and G. Maguire, 1999. Cannabinoid CB1 receptors and ligands in vertebrate retina: localization and function of an endogenous signaling system. **Proc Natl Acad Sci U S A** 96, 14565-14570. PMCID: PMC24476
62. M. Beltramo, F. Rodríguez de Fonseca, M. Navarro, A. Calignano, M.A. Gorriti, G. Grammatikopoulos, A.G. Sadile, A. Giuffrida and **D. Piomelli**, 2000. Reversal of dopamine D₂ receptor responses by an anandamide transport inhibitor. **J Neurosci** 20, 3401-3407. PMID: 10777802
63. A. Giuffrida, F. Désarnaud and **D. Piomelli**, 2000. Endogenous cannabinoid signaling and psychomotor disorders. **Prostaglandins Other Lipid Mediat** 61, 63-70. PMID: 10785542
64. M. Beltramo and **D. Piomelli**, 2000. Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol. **Neuroreport** 11, 1231-1235. PMID: 10817598
65. **D. Piomelli**, A. Giuffrida, A. Calignano, and F. Rodríguez de Fonseca, 2000. The endocannabinoid system as a target for therapeutic drugs. **Trends Pharmacol Sci** 21, 218-224. PMID: 10838609
66. A. Giuffrida, F. Rodríguez de Fonseca and **D. Piomelli**, 2000. Quantification of bioactive acylethanolamides in rat plasma by electrospray mass spectrometry. **Anal Biochem** 280, 87-93. PMID: 10805525
67. **D. Piomelli** and A. Giuffrida, 2000. Reply: cannabinoid paths to anti-diarrheal drugs. **Trends Pharmacol Sci** 21, 373.
68. A. Calignano, I. Katoná, F. Désarnaud, A. Giuffrida, G. La Rana, K. Mackie, T.F. Freund and **D. Piomelli**, 2000. Bidirectional control of airway responsiveness by endogenous cannabinoids. **Nature** 408, 96-101. PMID: 11081515
69. A. Giuffrida, F. Rodríguez de Fonseca, F. Nava, P. Loubet-Lescoulié and **D. Piomelli**, 2000. Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404. **Eur J Pharmacol** 408, 161-168. PMID: 11080522
70. A. Calignano, G. La Rana, P. Loubet-Lescoulié and **D. Piomelli**, 2000. A role for the endogenous cannabinoid system in the peripheral pain initiation. **Prog Brain Res** 129, 471-482. PMID: 11098711
71. A. Guiffrida and **D. Piomelli**, 2000. The endocannabinoid system: a physiological perspective on its role in psychomotor control. **Chem Phys Lipids** 108, 151-158. PMID: 11106788

72. **D. Piomelli**, 2000. Pot of gold for glioma therapy. *Nature Medicine* 6, 255-256. PMID: 10700220
73. A. Giuffrida, M. Beltramo and **D. Piomelli**, 2001. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. *J Pharmacol Exp Ther* 298, 7-14. PMID: 11408519
74. A. Calignano, G. La Rana and **D. Piomelli**, 2001. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. *Eur J Pharmacol* 419, 191-198. PMID: 11426841
75. N. Stella and **D. Piomelli**, 2001. Receptor-dependent formation of endogenous cannabinoids in cortical neurons. *Eur J Pharmacol* 425, 189-196. PMID: 11513837
76. F. Rodríguez de Fonseca, M. Navarro, R. Gómez, L. Escuredo, F. Nava, J. Fu, E. Murillo-Rodríguez, A. Giuffrida, J. LoVerme, S. Gaetani, S. Kathuria, C. Gall and **D. Piomelli**, 2001. An anorexic lipid mediator regulated by feeding. *Nature* 414, 209-212. PMID: 11700558
77. F. Rodríguez de Fonseca, M.A. Gorriti, A. Bilbao, L. Escuredo, L.M. García-Segura, **D. Piomelli** and M. Navarro, 2001. Role of the endogenous cannabinoid system as a modulator of dopamine transmission: implications for Parkinson's disease and schizophrenia. *Neurotox Res* 3, 23-25. PMID: 15111259
78. **D. Piomelli**, 2001. The ligand that came from within. *Trends Pharmacol Sci* 22, 17-19. PMID: 11165666
79. **D. Piomelli**, 2001. Cannabinoid activity curtails cocaine craving. *Nature Medicine* 7 1099-1100. PMID: 11590424
80. W. Schäbitz, A. Giuffrida, C. Berger, A. Aschoff, M. Schwaninger, S. Schwab and **D. Piomelli**, 2002. Release of fatty acid amides in a patient with hemispheric stroke: a microdialysis study. *Stroke* 33, 2112-2114. PMID: 12154273
81. T.P. Dinh, D. Carpenter, F.M. Leslie, T.F. Freund, I. Katona, S.L. Sensi, S. Kathuria and **D. Piomelli**, 2002. Brain monoglyceride lipase participating in endocannabinoid inactivation. *Proc Natl Acad Sci U S A* 99, 10819-10824. PMCID: PMC125056
82. R. Gómez, M. Navarro, B. Ferrer, J. Trigo, A. Bilbao, I. Del Arco, A. Cippitelli, F. Nava, **D. Piomelli** and F. Rodríguez de Fonseca, 2002. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. *J Neurosci* 22, 9612-9617. PMID: 12417686
83. H. Schuel, L. J. Burkman, J. Lippes, K. Crickard, E. Forester, **D. Piomelli** and A. Giuffrida, 2002. N-Acylethanolamines in human reproductive fluids. *Chem Phys Lipids* 121, 211-227. PMID: 12505702
84. I. Del Arco, M. Navarro, A. Bilbao, B. Ferrer, **D. Piomelli** and F. Rodríguez de Fonseca, 2002. Attenuation of spontaneous opiate withdrawal in mice by the anandamide transport inhibitor AM404. *Eur J Pharmacol* 454, 103-104. PMID: 12409011
85. T.P. Dinh, T.F. Freund and **D. Piomelli**, 2002. A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. *Chem Phys Lipids* 121, 149-158. PMID: 12505697
86. S. Kathuria, S. Gaetani, D. Fegley, F. Valiño, A. Duranti, A. Tontini, M. Mor, G. Tarzia, G. La Rana, A. Calignano, A. Giustino, M. Tattoli, M. Palmery, V. Cuomo and **D. Piomelli**, 2003.

Modulation of anxiety through blockade of anandamide hydrolysis. **Nat Med** 9, 76-81. PMID: 12461523

87. S. Gaetani, F. Oveisi and **D. Piomelli**, 2003. Modulation of meal pattern in the rat by the anorexic lipid mediator oleoylethanolamide. **Neuropsychopharmacology** 28, 1311-1316. PMID: 12700681

88. T.F. Freund, I. Katona and **D. Piomelli**, 2003. Role of endogenous cannabinoids in synaptic signaling. **Physiol Rev** 83, 1017-1066. PMID: 12843414

89. G. Tarzia, A. Duranti, A. Tontini, G. Piersanti, M. Mor, S. Rivara, P.V. Plazzi, C. Park, S. Kathuria and **D. Piomelli**, 2003. Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors. **J Med Chem** 46, 2352-2360. PMID: 12773040

90. J. Fu, S. Gaetani, F. Oveisi, J. LoVerme, A. Serrano, F. Rodríguez de Fonseca, A. Rosengarth, H. Luecke, B. Di Giacomo, G. Tarzia and **D. Piomelli**, 2003. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR- α . **Nature** 425, 90-93. PMID: 12955147

91. G. Tarzia, A. Duranti, A. Tontini, G. Spadoni, M. Mor, S. Rivara, P.V. Plazzi, S. Kathuria and **D. Piomelli**, 2003. Synthesis and structure-activity relationships of a series of pyrrole cannabinoid receptor agonists. **Bioorg Med Chem** 11, 3965-3973. PMID: 12927857

92. B. Ferrer, N. Asbrock, S. Kathuria, **D. Piomelli** and A. Giuffrida, 2003. Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias. **Eur J Neurosci** 18, 1607-1614. PMID: 14511339

93. K. Chen, A. Ratzliff, L. Hilgenberg, A. Gulyás, T.F. Freund, M. Smith, T.P. Dinh, **D. Piomelli**, K. Mackie and I. Soltesz, 2003. Long-term plasticity of endocannabinoid signaling induced by developmental febrile seizures. **Neuron** 39, 599-611. PMID: 12925275

94. P.B. Sparling, A. Giuffrida, **D. Piomelli**, L. Roskopf and A. Dietrich, 2003. Exercise activates the endocannabinoid system. **Neuroreport** 14, 2209-2211. PMID: 14625449

95. **D. Piomelli**, 2003. The molecular logic of endocannabinoid signalling. **Nat Rev Neurosci** 4, 873-884. PMID: 14595399

96. E. Murillo-Rodriguez, C. Blanco-Centurion, C. Sanchez, **D. Piomelli** and P.J. Shiromani, 2003. Anandamide enhances extracellular levels of adenosine and induces sleep: an *in vivo* microdialysis study. **Sleep** 26, 943-947. PMID: 14746372

97. S. Gaetani, V. Cuomo and **D. Piomelli**, 2003. Anandamide hydrolysis: a new target for anti-anxiety drugs? **Trends Mol Med** 9, 474-478. PMID: 14604824

98. F. Oveisi, S. Gaetani, K.T.-P. Eng and **D. Piomelli**, 2004. Oleoylethanolamide inhibits food intake in free-feeding rats after oral administration. **Pharmacol Res** 49, 461-466. PMID: 14998556

99. D. Fegley, S. Kathuria, R. Mercier, C. Li, A. Goutopoulos, A. Makriyannis and **D. Piomelli**, 2004. Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. **Proc Natl Acad Sci U S A** 101, 8756-8761. PMCID: PMC423268

100. N. Hájos, S. Kathuria, T. Dinh, **D. Piomelli** and T.F. Freund, 2004. Endocannabinoid transport tightly controls 2-arachidonoyl glycerol actions in the hippocampus: effects of low temperature and the transport inhibitor AM404. *Eur J Neurosci* 19, 2991-2996. PMID: 15182306
101. A.I. Gulyas, B.F. Cravatt, M.H. Bracey, T.P. Dinh, **D. Piomelli**, F. Boschia and T.F. Freund, 2004. Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. *Eur J Neurosci* 20, 441-458. PMID: 15233753
102. M. Guzmán, J. LoVerme, J. Fu, F. Oveisi, C. Blázquez and **D. Piomelli**, 2004. Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor α (PPAR- α). *J Biol Chem* 279, 27849-27854. PMID: 15123613
103. M. Mor, S. Rivara, A. Lodola, P.V. Plazzi, G. Tarzia, A. Duranti, A. Tontini, G. Piersanti, S. Kathuria and **D. Piomelli**, 2004. Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. *J Med Chem* 47, 4998-5008. PMID: 15456244
104. **D. Piomelli**, 2004. The endogenous cannabinoid system and the treatment of marijuana dependence. *Neuropharmacology* 47 Suppl 1, 359-367. PMID: 15464150
105. A. Giuffrida, F.M. Leweke, C.W. Gerth, D. Schreiber, D. Koethe, J. Faulhaber, J. Klosterkötter and **D. Piomelli**, 2004. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. *Neuropsychopharmacology* 29, 2108-2114. PMID: 15354183
106. T.P. Dinh, S. Kathuria and **D. Piomelli**, 2004. RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. *Mol Pharmacol* 66, 1260-1264. PMID: 15272052
107. E. Basso, A. Duranti, M. Mor, **D. Piomelli**, A. Tontini, G. Tarzia and P. Traldi, 2004. Tandem mass spectrometric data-FAAH inhibitory activity relationships of some carbamic acid O-aryl esters. *J Mass Spectrom* 39, 1450-1455. PMID: 15578755
108. **D. Piomelli**, 2004. THC: moderation during implantation. *Nature Medicine* 10, 19-20. PMID: 14702623
109. J. LoVerme, J. Fu, G. Astarita, G. La Rana, R. Russo, A. Calignano and **D. Piomelli**, 2005. The nuclear receptor peroxisome proliferator-activated receptor- α mediates the anti-inflammatory actions of palmitoylethanolamide. *Mol Pharmacol* 67, 15-19. PMID: 15465922
110. J. LoVerme, S. Gaetani, J. Fu, F. Oveisi, K. Burton and **D. Piomelli**, 2005. Regulation of food intake by oleoylethanolamide. *Cell Mol Life Sci* 62, 708-716. PMID: 15770421
111. D. Fegley, S. Gaetani, A. Duranti, A. Tontini, M. Mor, G. Tarzia and **D. Piomelli**, 2005. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. *J Pharmacol Exp Ther* 313, 352-358. PMID: 15579492

112. J. Fu, F. Oveisi, S. Gaetani, E. Lin and **D. Piomelli**, 2005. Oleoylethanolamide, an endogenous PPAR- α agonist, lowers body weight and hyperlipidemia in obese rats. **Neuropharmacology** 48, 1147-1153. PMID: 15910890
113. A. Makriyannis, R. Mechoulam and **D. Piomelli**, 2005. Therapeutic opportunities through modulation of the endocannabinoid system. **Neuropharmacology** 48, 1068-1071. PMID: 15885714
114. A.G. Hohmann, R.L. Suplita II, N.M. Bolton, M.H. Neely, D. Fegley, R. Mangieri, J.F. Krey, J.M. Walker, P.V. Holmes, J.D. Crystal, A. Duranti, A. Tontini, M. Mor, G. Tarzia and **D. Piomelli**, 2005. An endocannabinoid mechanism for stress-induced analgesia. **Nature** 435, 1108-1112. PMID: 15973410
115. **D. Piomelli**, 2005. The endocannabinoid system: a drug discovery perspective. **Curr Opin Investig Drugs** 6, 672-679. PMID: 16044662
116. M.V. Solbrig, R. Adrian, J. Baratta, **D. Piomelli** and A. Giuffrida, 2005. A role for endocannabinoids in viral-induced dyskinetic and convulsive phenomena. **Exp Neurol** 194, 355-362. PMID: 16022863
117. J. LoVerme, G. La Rana, R. Russo, A. Calignano and **D. Piomelli**, 2005. The search for the palmitoylethanolamide receptor. **Life Sci** 77, 1685-1698. PMID: 15963531
118. R. Rapaka, A. Makriyannis, V. Di Marzo and **D. Piomelli**, 2005. Targeted lipidomics: endocannabinoids and other endolipid modulators. **Life Sci** 77, 1517-1518.
119. **D. Piomelli**, 2005. The challenge of brain lipidomics. **Prostaglandins Other Lipid Mediat.** 77, 23-34. PMID: 16099388
120. R.S. Rapaka, **D. Piomelli**, S. Spiegel, N. Bazan and E.A. Dennis, 2005. Targeted lipidomics: signaling lipids and drugs of abuse. **Prostaglandins Other Lipid Mediat.** 77, 223-234. PMID: 16099407
121. J.K. Makara, M. Mor, D. Fegley, S.I. Szabó, S. Kathuria, G. Astarita, A. Duranti, A. Tontini, G. Tarzia, S. Rivara, T.F. Freund and **D. Piomelli**, 2005. Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. **Nat Neurosci** 8, 1139-1141. PMID: 16116451
122. M.D. Van Sickle, M. Duncan, P.J. Kingsley, A. Mouihate, P. Urbani, K. Mackie, N. Stella, A. Makriyannis, **D. Piomelli**, J.S. Davison, L.J. Marnett, V. Di Marzo, Q.J. Pittman, K.D. Patel and K.A. Sharkey, 2005. Identification and functional characterization of brainstem cannabinoid CB₂ receptors. **Science** 310, 329-332. PMID: 16224028
123. K.M. Jung, R. King AR, C. Stapleton, J. Kim, D. Fegley, M. Wallace, K. Mackie and **D. Piomelli**, 2005. Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. **Mol Pharmacol** 68, 1196-1202. PMID: 16051747
124. A. Lodola, M. Mor, J.C. Hermann, G. Tarzia, **D. Piomelli** and A.J. Mulholland, 2005. QM/MM modelling of oleamide hydrolysis in fatty acid amide hydrolase (FAAH) reveals a new mechanism of nucleophile activation. **Chem Commun**, 4399-4401. PMID: 16136230
125. G. Gobbi, F.R. Bambico, R. Mangieri, M. Bortolato, P. Campolongo, M. Solinas, T. Cassano, M.G. Morgese, G. Debonnel, A. Duranti, A. Tontini, G. Tarzia, M. Mor, V. Trezza, S.R. Goldberg, V.

Cuomo, and **D. Piomelli**, 2005. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. *Proc Natl Acad Sci U S A* 102, 18620-18625. PMCID: PMC1317988

126. I. Grant, A. Makriyannis, R. Mechoulam and **D. Piomelli**, eds, 2005. Future Directions in Cannabinoid Therapeutics: "From the Bench to the Clinic", *Neuropharmacology*, Elsevier Ltd, Vol. 48.

127. A. Jayamanne, R. Greenwood, V.A. Mitchell, S. Aslan, **D. Piomelli** and C.W. Vaughan, 2006. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. *Br J Pharmacol* 147, 281-288. PMCID: PMC1751298

128. H.F. Su, A. Samsamshariat, J. Fu, Y.-X. Shan, Y.-H. Chen, **D. Piomelli** and P.H. Wang, 2006. Oleylethanolamide activates Ras-Erk pathway and improves myocardial function in doxorubicin-induced heart failure. *Endocrinology* 147, 827-834. PMID: 16269455

129. R.L. Suplita II, T. Gutierrez, D. Fegley, **D. Piomelli** and A. Hohmann, 2006. Endocannabinoids at the spinal level regulate, but do not mediate, nonopioid stress-induced analgesia. *Neuropharmacology* 50, 372-379. PMID: 16316669

130. G. Tarzia, A. Duranti, G. Gatti, G. Piersanti, A. Tontini, S. Rivara, A. Lodola, P.V. Plazzi, M. Mor, S. Kathuria and **D. Piomelli**, 2006. Synthesis and structure-activity relationships of FAAH inhibitors: cyclohexylcarbamic acid biphenyl esters with chemical modulation at the proximal phenyl ring. *Chem Med Chem* 1, 130-139. PMID: 16892344

131. K. Connell, N. Bolton, D. Olsen, **D. Piomelli** and A.G. Hohmann, 2006. Role of the basolateral nucleus of the amygdala in endocannabinoid-mediated stress-induced analgesia. *Neurosci Lett* 397, 180-184. PMID: 16378681

132. G. Astarita, B.C. Rourke, J.B. Andersen, J. Fu, J.H. Kim, A.F. Bennett, J.W. Hicks and **D. Piomelli**, 2006. Postprandial increase of oleylethanolamide mobilization in small intestine of the Burmese python (*Python molurus*). *Am J Physiol Regul Integr Comp Physiol* 290, R1407-R1412. PMID: 16373434

133. I. Katona, G.M. Urbán, M. Wallace, C. Ledent, K.-M. Jung, **D. Piomelli**, K. Mackie and T.F. Freund, 2006. Molecular composition of the endocannabinoid system at glutamatergic synapses. *J Neurosci* 26, 5628-5637. PMCID: PMC1698282

134. G. La Rana, R. Russo, P. Campolongo, M. Bortolato, R.A. Mangieri, V. Cuomo, A. Iacono, G. Mattace Raso, R. Meli, **D. Piomelli** and A. Calignano, 2006. Modulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404 [N-(4-hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide]. *J Pharmacol Exp Ther* 317, 1365-1371. PMID: 16510698

135. **D. Piomelli**, G. Tarzia, A. Duranti, A. Tontini, M. Mor, T.R. Compton, O. Dasse, E.P. Monaghan, J.A. Parrott and D. Putman, 2006. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). *CNS Drug Rev* 12, 21-38. PMID: 16834756

136. G. Astarita, B. Di Giacomo, S. Gaetani, F. Oveisi, T.R. Compton, S. Rivara, G. Tarzia, M. Mor and **D. Piomelli**, 2006. Pharmacological characterization of hydrolysis-resistant analogs of oleylethanolamide with potent anorexiatic properties. *J Pharmacol Exp Ther* 318, 563-570. PMID: 16702440

137. M.V. Storozhuk, S.Y. Ivanova and **D. Piomelli**, 2006. Presence of depolarization-induced suppression of inhibition in a fraction of GABAergic synaptic connections in rat neocortical cultures. **Neurosci Behav Physiol** 36, 709-713. PMID: 16841150
138. J. LoVerme, M. Guzmán, S. Gaetani and **D. Piomelli**, 2006. Cold exposure stimulates synthesis of the bioactive lipid oleoylethanolamide in rat adipose tissue. **J Biol Chem** 281, 22815-22818. PMID: 16785227
139. J.R. Clapper, A. Duranti, A. Tontini, M. Mor, G. Tarzia and **D. Piomelli**, 2006. The fatty-acid amide hydrolase inhibitor URB597 does not affect triacylglycerol hydrolysis in rat tissues. **Pharmacol Res** 54, 341-344. PMID: 16935521
140. A. Pintor, M.T. Tebano, A. Martire, R. Grieco, M. Galluzzo, M.L. Scattoni, A. Pèzzola, R. Coccurello, F. Felici, V. Cuomo, **D. Piomelli**, G. Calamandrei and P. Popoli, 2006. The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum. **Neuropharmacology** 51, 1004-1012. PMID: 16895732
141. J. Guindon, J. LoVerme, A. De Léan, **D. Piomelli** and P. Beaulieu, 2006. Synergistic antinociceptive effects of anandamide, an endocannabinoid, and nonsteroidal anti-inflammatory drugs in peripheral tissue: a role for endogenous fatty-acid ethanolamides? **Eur J Pharmacol** 550, 68-77. PMID: 17027744
142. J. LoVerme, R. Russo, G. La Rana, J. Fu, J. Farthing, G. Mattace-Raso, R. Meli, A. Hohmann, A. Calignano and **D. Piomelli**, 2006. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor- α . **J Pharmacol Exp Ther** 319, 1051-1061. PMID: 16997973
143. M. Bortolato, P. Campolongo, R.A. Mangieri, M.L. Scattoni, R. Frau, V. Trezza, G. La Rana, R. Russo, A. Calignano, G.L. Gessa, V. Cuomo and **D. Piomelli**, 2006. Anxiolytic-like properties of the anandamide transport inhibitor AM404. **Neuropsychopharmacology** 31, 2652-2659. PMID: 16541083
144. S.K. Cross-Mellor, K.P. Ossenkopp, **D. Piomelli** and L. Parker, 2007. Effects of the FAAH inhibitor, URB597, and anandamide on lithium-induced taste reactivity responses: a measure of nausea in the rat. **Psychopharmacology** 190, 135-143 (lead article for 2007). PMID: 17111174
145. A. Lodola, M. Mor, J. Zurek, G. Tarzia, **D. Piomelli**, J.N. Harvey and A.J. Mulholland, 2007. Conformational effects in enzyme catalysis: reaction via a high energy conformation in fatty acid amide hydrolase. **Biophys J** 92, L20-22. PMCID: PMC1751413
146. J. Fu, G. Astarita, S. Gaetani, J. Kim, B.F. Cravatt, K. Mackie and **D. Piomelli**, 2007. Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine. **J Biol Chem** 282, 1518-1528. PMCID: PMC1764767
147. D. Schreiber, S. Harlfinger, B.M. Nolden, C.W. Gerth, U. Jaehde, E. Schömig, J. Klosterkötter, A. Giuffrida, G. Astarita, **D. Piomelli** and F.M. Leweke, 2007. Determination of anandamide and other fatty acyl ethanolamides in human serum by electrospray tandem mass spectrometry. **Anal Biochem** 361, 162-168. PMID: 17196922
148. M. Solinas, G. Tanda, Z. Justinova, C.E. Wertheim, S. Yasar, **D. Piomelli**, S.K. Vadivel, A. Makriyannis and S.R. Goldberg, 2007. The endogenous cannabinoid anandamide produces delta-9-

tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport. *J Pharm Exp Ther* 321, 370-380. PMID: 17210800

149. B. Ferrer, F.J. Bermúdez-Silva, A. Bilbao, L. Alvarez-Jaimes, I. Sanchez-Vera, A. Giuffrida, A. Serrano, E. Baixeras, S. Khaturia, M. Navarro, L.H. Parsons, **D. Piomelli** and F. Rodríguez de Fonseca, 2007. Regulation of brain anandamide by acute administration of ethanol. *Biochem J* 404, 97-104. PMCID: PMC1868843

150. R. Russo, J. LoVerme, G. La Rana, T.R. Compton, J. Parrott, A. Duranti, A. Tontini, M. Mor, G. Tarzia, A. Calignano and **D. Piomelli**, 2007. The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. *J Pharm Exp Ther* 322, 236-242. PMID: 17412883

151. R. Russo, J. LoVerme, G. La Rana, G. D'Agostino, O. Sasso, A. Calignano and **D. Piomelli**, 2007. Synergistic antinociception by the cannabinoid receptor agonist anandamide and the PPAR- α receptor agonist GW7647. *Eur J Pharmacol* 566, 117-119. PMCID: PMC1997313

152. M. Bortolato, R.A. Mangieri, J. Fu, J.H. Kim, O. Arguello, A. Duranti, A. Tontini, M. Mor, G. Tarzia and **D. Piomelli**, 2007. Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. *Biol Psychiatry* 62, 1103-1110. PMID: 17511970

153. J. Guindon, J. LoVerme, **D. Piomelli** and P. Beaulieu, 2007. The antinociceptive effects of local injections of propofol in rats are mediated in part by cannabinoid CB₁ and CB₂ receptors. *Anesth Analg* 104, 1563-1569. PMID: 17513659

154. G. D'Agostino, G. La Rana, R. Russo, O. Sasso, A. Iacono, E. Esposito, G. Mattace Raso, S. Cuzzocrea, J. LoVerme, **D. Piomelli**, R. Meli and A. Calignano, 2007. Acute intracerebroventricular administration of palmitoylethanolamide, an endogenous peroxisome proliferator-activated receptor- α agonist, modulates carrageenan-induced paw edema in mice. *J Pharmacol Exp Ther* 322, 1137-1143. PMID: 17565008

155. F.M. Leweke, A. Giuffrida, D. Koethe, D. Schreiber, B.M. Nolden, L. Kranaster, M.A. Neatby, M. Schneider, C.W. Gerth, M. Hellmich, J. Klosterkötter and **D. Piomelli**, 2007. Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. *Schizophr Res* 94, 29-36. PMID: 17566707

156. K.M. Jung, G. Astarita, C. Zhu, M. Wallace, K. Mackie and **D. Piomelli**, 2007. A key role for diacylglycerol lipase- α in metabotropic glutamate receptor-dependent endocannabinoid mobilization. *Mol Pharmacol* 72, 612-621. PMID: 17584991

157. A. Vila, A. Rosengarth, **D. Piomelli**, B. Cravatt and L.J. Marnett, 2007. Hydrolysis of prostaglandin glycerol esters by the endocannabinoid-hydrolyzing enzymes, monoacylglycerol lipase and fatty acid amide hydrolase. *Biochemistry* 46, 9578-9585. PMID: 17649977

158. A. Cippitelli, A. Bilbao, M.A. Gorriti, M. Navarro, M. Massi, **D. Piomelli**, R. Ciccocioppo, and F. Rodríguez De Fonseca, 2007. The anandamide transport inhibitor AM404 reduces ethanol self-administration. *Eur J Neurosci* 26, 476-486. PMID: 17650118

159. **D. Piomelli**, G. Astarita and R. Rapaka, 2007. A neuroscientist's guide to lipidomics. *Nat Rev Neurosci* 8, 743-754. PMID: 17882252

160. R.A. Mangieri and **D. Piomelli**, 2007. Enhancement of endocannabinoid signaling and the pharmacotherapy of depression. *Pharmacol Res* 56, 360-366. PMCID: PMC2104793
161. G. Tarzia, F. Antonietti, A. Duranti, A. Tontini, M. Mor, S. Rivara, P. Traldi, G. Astarita, A. King, J.R. Clapper and **D. Piomelli**, 2007. Identification of a bioactive impurity in a commercial sample of 6-methyl-2-p-tolylaminobenzo[d][1,3]oxazin-4-one (URB754). *Ann Chim* 97, 887-894. PMID: 17970304
162. G. Valitutti, A. Duranti, A. Lodola, M. Mor, G. Piersanti, **D. Piomelli**, S. Rivara, A. Tontini, G. Tarzia and P. Traldi, 2007. Correlation between energetics of collisionally activated decompositions, interaction energy and biological potency of carbamate FAAH inhibitors. *J Mass Spectrom* 42, 1624-1627. PMID: 18085570
163. A.R. King, A. Duranti, A. Tontini, S. Rivara, A. Rosengarth, J.R. Clapper, G. Astarita, J.A. Geaga, H. Luecke, M. Mor, G. Tarzia and **D. Piomelli**, 2007. URB602 inhibits monoacylglycerol lipase and selectively blocks 2-arachidonoylglycerol degradation in intact brain slices. *Chem Biol* 14, 1357-1365. PMCID: PMC2225625
164. M. Scherma, J. Medalie, W. Fratta, S.K. Vadivel, A. Makriyannis, **D. Piomelli**, E. Mikics, J. Haller, S. Yasar, G. Tanda and S.R. Goldberg, 2008. The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. *Neuropharmacology* 54, 129-140. PMCID: PMC2213536
165. G. Astarita, F. Ahmed and **D. Piomelli**, 2008. Identification of biosynthetic precursors for the endocannabinoid anandamide in the rat brain. *J Lipid Res* 49, 48-57. PMID: 17957091
166. E.M. Rock, C.L. Limebeer, R. Mechoulam, **D. Piomelli** and L.A. Parker, 2008. The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat. *Psychopharmacology* 196, 389-395. PMID: 17992520
167. A. Lodola, M. Mor, S. Rivara, C. Christov, G. Tarzia, **D. Piomelli** and A.J. Mulholland, 2008. Identification of productive inhibitor binding orientation in fatty acid amide hydrolase (FAAH) by QM/MM mechanistic modelling. *Chem Commun*, 214-216. PMID: 18092091
168. G. La Rana, R. Russo, G. D'Agostino, O. Sasso, G.M. Raso, A. Iacono, R. Meli, **D. Piomelli** and A. Calignano, 2008. AM404, an anandamide transport inhibitor, reduces plasma extravasation in a model of neuropathic pain in rat: role for cannabinoid receptors. *Neuropharmacol* 54, 521-529. PMID: 18093621
169. S. Potvin, E. Kouassi, O. Lipp, R.H. Bouchard, M.A. Roy, M.F. Demers, A. Gendron, G. Astarita, **D. Piomelli** and E. Stip, 2008. Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy. *J Psychopharmacol* 22, 262-269. PMID: 18308802
170. T. Genovese, E. Esposito, E. Mazzon, R. Di Paola, R. Meli, P. Bramanti, **D. Piomelli**, A. Calignano and S. Cuzzocrea, 2008. Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury. *J Pharmacol Exp Ther* 326, 12-23. PMID: 18367664
171. M. Solinas, S.R. Goldberg and **D. Piomelli**, 2008. The endocannabinoid system in brain reward processes. *Br J Pharmacol* 154, 369-383. PMCID: PMC2442437

172. J. Fu, J. Kim, F. Oveisi, G. Astarita and **D. Piomelli**, 2008. Targeted enhancement of oleoylethanolamide production in proximal small intestine induces across-meal satiety in rats. *Am J Physiol Regul Integr Comp Physiol* 295, R45-50. PMCID: PMC2494809
173. A. Cippitelli, N. Cannella, S. Braconi, A. Duranti, A. Tontini, A. Bilbao, F. Rodríguez de Fonseca, **D. Piomelli** and R. Ciccocioppo, 2008. Increase of brain endocannabinoid anandamide levels by FAAH inhibition and alcohol abuse behaviours in the rat. *Psychopharmacology* 198, 449-460. PMID: 18446329
174. D. Koethe, M. Bortolato, **D. Piomelli** and F.M. Leweke, 2008. Improvement of general symptoms in a chronic psychotic patient treated with finasteride: case report. *Pharmacopsychiatry* 41, 115-116. PMID: 18484553
175. M. Mor, A. Lodola, S. Rivara, F. Vacondio, A. Duranti, A. Tontini, S. Sanchini, G. Piersanti, J.R. Clapper, A.R. King, G. Tarzia and **D. Piomelli**, 2008. Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl alkylcarbamates. *J Med Chem* 51, 3487-3498. PMCID: PMC3744893
176. A.M. Moise, S.A. Eisenstein, G. Astarita, **D. Piomelli** and A.G. Hohmann, 2008. An endocannabinoid signaling system modulates anxiety-like behavior in male Syrian hamsters. *Psychopharmacology* 200, 333-346. PMCID: PMC2694060
177. M. Scherma, L.V. Panlilio, P. Fadda, L. Fattore, I. Gamaledin, B. Le Foll, Z. Justinova, E. Mikics, J. Haller, J. Medalie, J. Stroik, C. Barnes, S. Yasar, G. Tanda, **D. Piomelli**, W. Fratta and S.R. Goldberg, 2008. Inhibition of anandamide hydrolysis by cyclohexyl carbamic acid 3'-carbamoyl-3-yl ester (URB597) reverses abuse-related behavioral and neurochemical effects of nicotine in rats. *J Pharmacol Exp Ther* 327, 482-490. PMCID: PMC2663803
178. Z. Justinova, R.A. Mangieri, M. Bortolato, S.I. Chefer, A.G. Mukhin, J.R. Clapper, A.R. King, G.H. Redhi, S. Yasar, **D. Piomelli** and S.R. Goldberg, 2008. Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. *Biol Psychiatry* 64, 930-937. PMCID: PMC2701259
179. G.J. Schwartz, J. Fu, G. Astarita, X. Li, S. Gaetani, P. Campolongo, V. Cuomo and **D. Piomelli**, 2008. The lipid messenger OEA links dietary fat intake to satiety. *Cell Metab* 8, 281-288. PMCID: PMC2572640
180. M. Duncan, A.D. Thomas, N.L. Cluny, A. Patel, K.D. Patel, B. Lutz, **D. Piomelli**, S.P. Alexander and K.A. Sharkey, 2008. Distribution and function of monoacylglycerol lipase in the gastrointestinal tract. *Am J Physiol Gastrointest Liver Physiol* 295, G1255-G1265. PMID: 18948437
181. S. Gaetani, W.H. Kaye, V. Cuomo and **D. Piomelli**, 2008. Role of endocannabinoids and their analogues in obesity and eating disorders. *Eat Weight Disord* 13, e42-e48. PMID: 19011363
182. **Piomelli, D.**, 2008. The element of surprise. *Nature Medicine* 14, 720-721. PMID: 18607371
183. G. Valitutti, A. Duranti, M. Mor, G. Piersanti, **D. Piomelli**, S. Rivara, A. Tontini, G. Tarzia and P. Traldi, 2009. The collisional behavior of ESI-generated protonated molecules of some carbamate FAAH inhibitors isosteres and its relationships with biological activity. *J Mass Spectrom* 44, 561-565. PMID: 19034887

184. N.L. Cluny, C.M. Keenan, B. Lutz, **D. Piomelli** and K.A. Sharkey, 2009. The identification of peroxisome proliferator-activated receptor alpha-independent effects of oleoylethanolamide on intestinal transit in mice. **Neurogastroenterol Motil** 21, 420-429. PMID: 19140957
185. J.C. Fehrenbacher, J. Loverme, W. Clarke, K.M. Hargreaves, **D. Piomelli** and B.K. Taylor, 2009. Rapid pain modulation with nuclear receptor ligands. **Brain Res Rev** 60, 114-124. PMCID: PMC3695814
186. J. Loverme, A. Duranti, A. Tontini, G. Spadoni, M. Mor, S. Rivara, N. Stella, C. Xu, G. Tarzia and **D. Piomelli**, 2009. Synthesis and characterization of a peripherally restricted CB₁ cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice. **Bioorganic & Medicinal Chemistry Letters** 19, 639-643. PMCID: PMC3690177
187. D. Koethe, D. Schreiber, A. Giuffrida, C. Mauss, J. Faulhaber, B. Heydenreich, M. Hellmich, R. Graf, J. Klosterkötter, **D. Piomelli** and F.M. Leweke, 2009. Sleep deprivation increases oleoylethanolamide in human cerebrospinal fluid. **J Neural Transm** 116, 301-305. PMCID: PMC2757605
188. G. Astarita and **D. Piomelli**, 2009. Lipidomic analysis of endocannabinoid metabolism in biological samples. **J Chromatogr B Analyt Technol Biomed Life Sci** 877, 2755-2767. PMCID: PMC2723187
189. J.R. Clapper, R.A. Mangieri and **D. Piomelli**, 2009. The endocannabinoid system as a target for the treatment of cannabis dependence. **Neuropharmacology** 56, 235-243. PMCID: PMC2647947
190. L.A. Parker, C.L. Limebeer, E.M. Rock, D.L. Litt, M. Kwiatkowska and **D. Piomelli**, 2009. The FAAH inhibitor URB-597 interferes with cisplatin- and nicotine-induced vomiting in the Suncus murinus (house musk shrew). **Physiol Behav** 97, 121-124. PMCID: PMC3781595
191. D. Koethe, A. Giuffrida, D. Schreiber, M. Hellmich, F. Schultze-Lutter, S. Ruhrmann, J. Klosterkötter, **D. Piomelli** and F.M. Leweke, 2009. Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. **Br J Psychiatry** 194, 371-372. PMID: 19336792
192. R.A. Mangieri, K.I.A. Hong, **D. Piomelli** and R. Sinha, 2009. An endocannabinoid signal associated with desire for alcohol is suppressed in recently abstinent alcoholics. **Psychopharmacology** 205, 63-72. PMCID: PMC2715164
193. G. D'Agostino, G. La Rana, R. Russo, O. Sasso, A. Iacono, E. Esposito, G. Mattace Raso, S. Cuzzocrea, J. LoVerme, **D. Piomelli**, R. Meli and A. Calignano, 2009. Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF- κ B nuclear signalling in dorsal root ganglia. **Eur J Pharmacol** 613, 54-59. PMID: 19386271
194. P. Campolongo, B. Roozendaal, V. Trezza, V. Cuomo, G. Astarita, J. Fu, J.L. McGaugh and **D. Piomelli**, 2009. Fat-induced satiety factor oleoylethanolamide enhances memory consolidation. **Proc Natl Acad Sci U S A** 106, 8027-8031. PMCID: PMC2683095
195. A.R. King, A. Lodola, C. Carmi, J. Fu, M. Mor and **D. Piomelli**, 2009. A critical cysteine residue in monoacylglycerol lipase is targeted by a new class of isothiazolinone-based enzyme inhibitors. **Br J Pharmacol** 157, 974-983. PMCID: PMC2737656

196. F. Vacondio, C. Silva, A. Lodola, A. Fioni, S. Rivara, A. Duranti, A. Tontini, S. Sanchini, J. Clapper, **D. Piomelli**, M. Mor and G. Tarzia, 2009. Structure-property relationships of a class of carbamate-based fatty acid amide hydrolase (FAAH) inhibitors: chemical and biological stability. **ChemMedChem** 9, 1495-1504. PMCID :PMC3517974
197. J.R. Clapper, F. Vacondio, A.R. King, A. Duranti, A. Tontini, C. Silva, S. Sanchini, G. Tarzia, M. Mor and **D. Piomelli**, 2009. A second generation of carbamate-based fatty amide hydrolase inhibitors with improved activity in vivo. **ChemMedChem** 4, 1505-1513. PMCID: PMC3016090
198. A.R. King, E.Y. Dotsey, A. Lodola, K.M. Jung, A. Ghomian, Y. Qiu, J. Fu, M. Mor and **D. Piomelli**, 2009. Discovery of potent and reversible monoacylglycerol lipase inhibitors. **Chem Biol** 16, 1045-1052. PMCID: PMC3034734
199. I.C. Guerrero, G. Astarita, J.P. Jais, D. Sands, A. Nowakowska, J. Colas, I. Sermet-Gaudelus, M. Schuerenberg, **D. Piomelli**, A. Edelman and M. Ollero, 2009. A novel lipidomic strategy reveals plasma phospholipid signatures associated with respiratory disease severity in cystic fibrosis patients. **PLoS One** 4, e7735. PMCID: PMC2768907
200. C. Solorzano, C. Zhu, N. Battista, G. Astarita, A. Lodola, S. Rivara, M. Mor, R. Russo, M. Maccarrone, F. Antonietti, A. Duranti, A. Tontini, S. Cuzzocrea, G. Tarzia and **D. Piomelli**, 2009. Selective N-acyl ethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. **Proc Natl Acad Sci U S A** 106, 20966-20971. PMCID: PMC2791595
201. **D. Piomelli**, 2009. Responses to stress: from the periphery to the brain. **Curr Opin Pharmacol**, 9, 1-2. PMID: 19162545
202. G. Astarita, J. Geaga, F. Ahmed and **D. Piomelli**, 2009. Targeted Lipidomics as a tool to investigate endocannabinoid function. **Int Rev Neurobiol** 85, 35-55. PMID: 19607960
203. S. Gaetani, P. DiPasquale, A. Romano, L. Righetti, T. Cassano, **D. Piomelli** and V. Cuomo, 2009. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs. **Int Rev Neurobiol** 85, 57-72. PMID: 19607961
204. G. Astarita, F. Ahmed and **D. Piomelli**, 2009. Lipidomic analysis of biological samples by liquid chromatography coupled to mass spectrometry. **Methods Mol Biol** 579, 201-219. PMID: 19763477
205. A. Guijarro, J. Fu, G. Astarita and **D. Piomelli**, 2010. CD36 gene deletion decreases oleoylethanolamide levels in small intestine of free-feeding mice. **Pharmacol Res** 61, 27-33. PMCID: PMC2846762
206. C. Touriño, F. Oveisi, J. Lockney, **D. Piomelli** and R. Maldonado, 2010. FAAH deficiency promotes energy storage and enhances the motivation for food. **Int J Obes** 34, 557-568. PMCID: PMC3709605
207. S.A. Eisenstein, J.R. Clapper, P.V. Holmes, **D. Piomelli** and A.G. Hohmann, 2010. A role for 2-arachidonoylglycerol and endocannabinoid signaling in the locomotor response to novelty induced by olfactory bulbectomy. **Pharmacol Res** 61, 419-429. PMCID: PMC2867105

208. N.R. Sciolino, M. Bortolato, S.A. Eisenstein, J. Fu, F. Oveisi, A.G. Hohmann and **D. Piomelli**, 2010. Social isolation and chronic handling alter endocannabinoid signaling and behavioral reactivity to context in adult rats. **Neuroscience** 168, 371-386. PMCID: PMC2882942
209. S. Oddi, F. Fezza, G. Catanzaro, C. De Simone, M. Pucci, **D. Piomelli**, A. Finazzi-Agro and M. Maccarrone, 2010. Pitfalls and solutions in assaying anandamide transport in cells. **J Lipid Res** 51, 2435-2444. PMCID: PMC2903826
210. M.S. Alkaitis, C. Solorzano, R.P. Landry, **D. Piomelli**, J.A. Deleo and E.A. Romero-Sandoval, 2010. Evidence for a role of endocannabinoids, astrocytes and p38 phosphorylation in the resolution of postoperative pain. **PLoS One** 5, e10891. PMCID: PMC2878341
211. S. Gaetani, J. Fu, T. Cassano, P. Dipasquale, A. Romano, L. Righetti, S. Cianci, L. Laconca, E. Giannini, S. Scaccianoce, J. Mairesse, V. Cuomo and **D. Piomelli**, 2010. The fat-induced satiety factor oleoylethanolamide suppresses feeding through central release of oxytocin. **J Neurosci** 30, 8096-8101. PMCID: PMC2900249
212. F.R. Bambico, T. Cassano, S. Dominguez-Lopez, N. Katz, C.D. Walker, **D. Piomelli** and G. Gobbi, 2010. Genetic deletion of fatty acid amide hydrolase alters emotional behavior and serotonergic transmission in the dorsal raphe, prefrontal cortex, and hippocampus. **Neuropsychopharmacology** 35, 2083-2100. PMCID: PMC3055302
213. C. Solorzano, F. Antonietti, A. Duranti, A. Tontini, S. Rivara, A. Lodola, F. Vacondio, G. Tarzia, **D. Piomelli** and M. Mor, 2010. Synthesis and structure-activity relationships of N-(2-Oxo-3-oxetanyl) amides as N-acylethanolamine-hydrolyzing acid amidase inhibitors. **J Med Chem** 53, 5770-5781. PMCID: PMC2932887
214. G. Astarita, K.M. Jung, N.C. Berchtold, V.Q. Nguyen, D.L. Gillen, E. Head, C.W. Cotman and **D. Piomelli**, 2010. Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer's disease. **PLoS One** 5, pii:e12538. PMCID: PMC2935886
215. M.P. Murphy, J. Morales, T.L. Beckett, G. Astarita, **D. Piomelli**, A. Weidner, C.M. Studzinski, A.L. Dowling, X. Wang, H. Levine III, R.J. Kryscio, Y. Lin, E. Barrett and E. Head, 2010. Changes in cognition and amyloid- β processing with long term cholesterol reduction use atorvastatin in aged dogs. **J Alzheimers Dis** 22, 135-150. PMID: 20847439
216. J.R. Clapper, G. Moreno-Sanz, R. Russo, A. Guijarro, F. Vacondio, A. Duranti, A. Tontini, S. Sanchini, N.R. Sciolino, J.M. Spradley, A.G. Hohmann, A. Calignano, M. Mor, G. Tarzia and **D. Piomelli**, 2010. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. **Nat Neurosci** 13, 1265-1270. PMCID: PMC3260554
217. B. Grimaldi, M.M. Bellet, S. Katada, G. Astarita, J. Hirayama, R.H. Amin, J.G. Granneman, **D. Piomelli**, T. Leff and P. Sassone-Corsi, 2010. PER2 controls lipid metabolism by direct regulation of PPAR γ . **Cell Metabolism** 12, 509-520. PMCID: PMC4103168
218. L. Luo, E. Rodriguez. K. Jerbi, J.P. Lachaux, J. Martinerie, M. Corbatta, G.L. Shulman, **D. Piomelli**, G.G. Turrigiano, S.B. Nelson, M. Joëls, E.R. de Kloet, F. Holsboer, D.M. Amodio, C.D. Frith, M.L. Block, L. Zecca, J.S. Hong, R. Dantzer, K.W. Kelley and A.D. Bud Craig, 2010. Ten Years of Nature Reviews Neuroscience: insights from the highly cited. **Nat Rev Neurosci** 11, 718-726. PMCID: PMC3395239

219. P. Mascia, M. Pistis, Z. Justinova, L.V. Panlilio, A. Luchicchi, S. Lecca, M. Scherma, W. Fratta, C. Barnes, G.H. Redhi, S. Yasar, B. Le Foll, G. Tanda, **D. Piomelli** and S.R. Goldberg, 2011. Blockade of nicotine reward and reinstatement by activation of alpha-type peroxisome proliferator-activated receptors. **Biol Psychiatry** 69, 633-641. PMCID: PMC2994947
220. T. Cassano, S. Gaetani, T. Macheda, L. Laconca, A. Romano, M.G. Morgese, C.S. Cimmino, F. Chiarotti, F.R. Bambico, G. Gobbi, V. Cuomo and **D. Piomelli**, 2011. Evaluation of the emotional phenotype and serotonergic neurotransmission of fatty acid amide hydrolase-deficient mice. **Psychopharmacology** 214, 465-476. PMCID: PMC3045513
221. A. Ludanyi, S.S. Hu, M. Yamazaki, A. Tanimura, **D. Piomelli**, M. Watanabe, M. Kano, K. Sakimura, Z. Magloczky, K. Mackie, T.F. Freund and I. Katona, 2011. Complementary synaptic distribution of enzymes responsible for synthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in the human hippocampus. **Neuroscience** 174, 50-63. PMCID: PMC3678284
222. R. Jumpertz, A. Guijarro, R.E. Pratley, **D. Piomelli** and J. Krakoff, 2011. Central and peripheral endocannabinoids and cognate acylethanolamides in humans: association with race, adiposity and energy expenditure. **J Clin Endocrinol Metab** 96, 787-791. PMCID: PMC3047230
223. H. Wang, G. Astarita, M.D. Taussig, K.G. Bharadwaj, N.V. DiPatrizio, K.-A. Nave, **D. Piomelli**, I.J. Goldberg and R.H. Eckel, 2011. Deficiency of lipoprotein lipase in neurons modifies the regulation of energy balance and leads to obesity. **Cell Metab** 13, 105-113. PMCID: PMC3034302
224. J. Guindon, A. Guijarro, **D. Piomelli** and A.G. Hohmann, 2011. Peripheral antinociceptive effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain. **Br J Pharmacol** 163, 1464-1478. PMCID: PMC3165956
225. C. Zhu, C. Solorzano, S. Sahar, N. Realini, E. Fung, P. Sassone-Corsi and **D. Piomelli**, 2011. Proinflammatory stimuli control NAPE-PLD expression in macrophages. **Mol Pharmacol** 79, 786-792. PMCID: PMC3063731
226. A. Lodola, L. Capoferri, S. Rivara, E. Chudyk, J. Sirirak, E. Dyguda-Kazimierowicz, W. A. Sokalski, M. Mileni, G. Tarzia, **D. Piomelli**, M. Mor and A.J. Mulholland, 2011. Understanding the role of carbamate reactivity in fatty acid amide hydrolase inhibition by QM/MM mechanistic modelling. **Chem Commun (Camb)**. 47, 2517-2519. PMID: 21240393
227. M. Ollero, G. Astarita, C. Guerrero, I. Sermet-Gaudelus, S. Trudel, **D. Piomelli** and A. Edelman, 2011. Plasma lipidomics reveals potential prognostic signatures within a cohort of cystic fibrosis patients. **J Lipid Res** 52, 1011-1022. PMCID: PMC3073467
228. A. Di Sabatino, N. Battista, P. Biancheri, C. Rapino, L. Rovedatti, G. Astarita, A. Vanoli, E. Dainese, M. Guerci, **D. Piomelli**, S.L. Pender, T.T. Macdonald, M. Maccarrone and G.R. Corazza, 2011. The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease. **Mucosal Immunol** 4, 574-583. PMID: 21471961
229. J. Fu, N.V. DiPatrizio, A. Guijarro, G.J. Schwartz, X. Li, S. Gaetani, G. Astarita and **D. Piomelli**, 2011. Sympathetic activity controls fat-induced oleoylethanolamide signaling in small intestine. **J Neurosci** 31, 5730-5736. PMCID: PMC3084524
230. K.M. Jung, G. Astarita, D. Thongkham and **D. Piomelli**, 2011. Diacylglycerol lipase- α and - β control neurite outgrowth in Neuro-2a cells through distinct molecular mechanisms. **Mol Pharmacol** 80, 60-77. PMCID: PMC3127538

231. G. Astarita and **D. Piomelli**, 2011. Towards a whole-body systems [multi-organ] lipidomics in Alzheimer's Disease. **Prostaglandins Leukot Essent Fatty Acids** 85, 197-203. PMCID: PMC3161165
232. N.V. DiPatrizio, G. Astarita, G. Schwartz, X. Li and **D. Piomelli**, 2011. Endocannabinoid signal in the gut controls dietary fat intake. **Proc Natl Acad Sci U S A** 108, 12904-12908. PMCID: PMC3150876
233. F. Vacondio, C. Silva, A. Lodola, C. Carmi, S. Rivara, A. Duranti, A. Tontini, S. Sanchini, J.R. Clapper, **D. Piomelli**, G. Tarzia and M. Mor, 2011. Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of *N*-alkyl chain on rat plasma and liver stability. **Eur J Med Chem** 46, 4466-4473. PMCID: PMC3714604
234. R. Yang, G. Fredman, S. Krisnamoorthy, N. Agrawal, D. Irimia, **D. Piomelli** and C.N. Serhan, 2011. Decoding functional metabolomics with docosahexaenoyl ethanolamide (DHEA) identifies novel bioactive signals. **J Biol Chem** 286, 31532-31541. PMCID: PMC3173121
235. G. Moreno-Sanz, B. Barrera, A. Guijarro, I. d'Elia, J.A. Otero, A.I. Alvarez, T. Bandiera, G. Merino and **D. Piomelli**, 2011. The ABC membrane transporter ABCG2 prevents access of FAAH inhibitor URB937 to the central nervous system. **Pharmacol Res** 64, 359-363. PMCID: PMC3729352
236. G. Palermo, D. Branduardi, M. Masetti, A. Lodola, M. Mor, **D. Piomelli**, A. Cavalli and M. De Vivo, 2011. Covalent inhibitors of fatty acid amide hydrolase (FAAH): A rationale for the activity of piperidine and piperazine aryl ureas. **J Med Chem** 54, 6612-6623. PMCID: PMC3774108
237. G. Astarita, K.-M. Jung, V. Vasilevko, N.V. DiPatrizio, S.K. Martin, D.H. Cribbs, E. Head, C.W. Cotman and **D. Piomelli**, 2011. Elevated stearoyl-CoA desaturase in brains of patients with Alzheimer's disease. **PLoS ONE** 6, e24777. PMCID: PMC3202527
238. G. Astarita and **D. Piomelli**, 2011. Lipidomics of Alzheimer's disease: a liver peroxisomal dysfunction in the metabolism of omega-3 fatty acids. **Oléagineux Corps gras Lipides** 18, 218-223.
239. S. Snigdha, N. Berchtold, G. Astarita, T. Saing, **D. Piomelli** and C.W. Cotman, 2011. Dietary and behavioral interventions protect against age related activation of caspase cascades in the canine brain. **PLoS One** 6, e24652. PMCID: PMC3172245
240. J. Fu, G. Bottegon, O. Sasso, R. Bertorelli, W. Rocchia, M. Masetti, A. Guijarro, A. Lodola, A. Armirotti, G. Garau, A. Reggiani, M. Mor, A. Cavalli and **D. Piomelli**, 2011. A catalytically silent FAAH-1 variant drives anandamide transport in neurons. **Nat Neurosci** 15, 64-69. PMCID: PMC3245783
241. A. Cippitelli, G. Astarita, A. Duranti, G. Caprioli, M. Ubaldi, S. Stopponi, M. Kallupi, G. Sagratini, F. Rodriguez de Fonseca, **D. Piomelli** and R. Ciccocioppo, 2011. Endocannabinoid regulation of acute and protracted nicotine withdrawal: effect of FAAH inhibition. **PLoS One** 6, e28142. PMCID: PMC3227620
242. M. Ollero, I.C. Guerrero, G. Astarita, **D. Piomelli** and A. Edelman, 2011. New lipidomic approaches in cystic fibrosis. **Methods Mol Biol** 742, 265-278. PMID: 21547738
243. **D. Piomelli**, 2011. A thickening network of lipids. **Pain** 153, 3-4. PMID: 22019134

244. S. Snigdha, G. Astarita, **D. Piomelli** and C.W. Cotman, 2012. Effects of diet and behavioral enrichment on free fatty acids in the aged canine brain. *Neuroscience* 202, 326-333. PMCID: PMC3447971
245. K.M. Jung, G. Astarita, S. Yasar, V. Vasilevko, D.H. Cribbs, E. Head, C.W. Cotman and **D. Piomelli**, 2012. An amyloid β (42)-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer's disease. *Neurobiol Aging* 33, 1522-1532. PMCID: PMC3154439
246. F.M. Leweke, **D. Piomelli**, F. Pahlisch, D. Muhl, C.W. Gerth, C. Hoyer, J. Klosterkötter, M. Hellmich and D. Koethe, 2012. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. *Translational Psychiatry* 2, e94. PMCID: PMC3316151
247. A. Armirotti, E. Romeo, S. Ponzano, L. Mengatto, M. Dionisi, C. Karacsonyi, F. Bertozzi, G. Garau, G. Tarozzo, A. Reggiani, T. Bandiera, G. Tarzia, M. Mor and **D. Piomelli**, 2012. β -lactones inhibit N-acyl ethanolamine acid amidase by S-acylation of the catalytic N-terminal cysteine. *ACS Med Chem Letters* 3, 422-426. PMCID: PMC4025845
248. E.P. Newberry, S.M. Kennedy, Y. Xie, J. Luo, R.M. Crooke, M.J. Graham, J. Fu, **D. Piomelli** and N.O. Davidson, 2012. Decreased body weight and hepatic steatosis with altered fatty acid ethanolamide metabolism in aged L-Fabp $-/-$ mice. *J Lipid Res* 53, 744-754. PMCID: PMC3307651
249. A. Lodola, D. Branduardi, M. De Vivo, L. Capoferri, M. Mor, **D. Piomelli** and A. Cavalli, 2012. A catalytic mechanism for cysteine N-terminal nucleophile hydrolases, as revealed by free energy simulations. *PLoS One* 7, e32397. PMCID: PMC3289653
250. K.M Jung, J.R. Clapper, J. Fu, G. D'Agostino, A. Guijarro, D. Thongkham, A. Avanesian, G. Astarita, N.V. DiPatrizio, A. Frontini, S. Cinti, S. Diano and **D. Piomelli**, 2012. 2-arachidonoylglycerol signaling in forebrain regulates systemic energy metabolism. *Cell Metab* 7, 299-310. PMCID: PMC3729112
251. O. Sasso, R. Bertorelli, T. Bandiera, R. Scarpelli, G. Colombano, A. Armirotti, G. Moreno-Sanz, A. Reggiani and **D. Piomelli**, 2012. Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions. *Pharmacol Res* 65, 553-563. PMCID: PMC3738192
252. A. Duranti, A. Tontini, F. Antonietti, F. Vacondio, A. Fioni, C. Silva, A. Lodola, S. Rivara, C. Solorzano, **D. Piomelli**, G. Tarzia and M. Mor, 2012. N-(2-oxo-3-oxetanyl)carbamic acid esters as N-acyl ethanolamine acid amidase inhibitors: synthesis, structure-activity and structure-property relationships. *J Med Chem* 55, 4824-2436. PMID: 22515328
253. N.V. DiPatrizio and **D. Piomelli**, 2012. The thrifty lipids: endocannabinoids and the neural control of energy conservation. *Trends Neurosci* 35, 403-411. PMCID: PMC3744874
254. L. Gregg, K.M. Jung, J.M. Spradley, R. Nyilas, R.L. Suplita II, A. Zimmer, M. Watanabe, K. Mackie, I. Katona, **D. Piomelli** and A.G. Hohmann, 2012. Activation of type-5 metabotropic glutamate receptors and diacylglycerol lipase- α initiates 2-arachidonoylglycerol formation and endocannabinoid-mediated analgesia. *J Neurosci* 32, 9457-9468. PMCID: PMC3652685

255. R. Jumpertz, A. Guijarro, R.E. Pratley, C.C. Mason, **D. Piomelli** and J. Krakoff, 2012. Associations of fatty acids in cerebrospinal fluid with peripheral glucose concentrations and energy metabolism. *PLoS ONE* 7, e41503. PMCID: PMC3404019
256. V. Vaidyanathan, R.A. Bastarrachea, P.B. Higgins, V.S. Voruganti, S. Kamath, N.V. DiPatrizio, **D. Piomelli**, A.G. Comuzzie and E.J. Parks, 2012. Selective cannabinoid-1 receptor blockade significantly benefits fatty acid and triglyceride metabolism in weight-stable nonhuman primates. *Am J Physiol Endocrinol Metab* 303, E624-634. PMCID: PMC3468508
257. G. Moreno-Sanz, O. Sasso, A. Guijarro, O. Oluyemi, R. Bertorelli, A. Reggiani and **D. Piomelli**, 2012. Pharmacological characterization of the peripheral FAAH inhibitor URB937 in female rodents: interaction with the Abcg2 transporter in the blood-placenta barrier. *Br J Pharmacol* 167, 1620-1628. PMCID: PMC3525865
258. S. Carloni, D. Alonso-Alconada, S. Girelli, A. Duranti, A. Tontini, **D. Piomelli**, E. Hilario, A. Alvarez and W. Balduini, 2012. Pretreatment with the monoacylglycerol lipase inhibitor URB602 protects from the long-term consequences of a neonatal hypoxic-ischemic brain injury in rats. *Pediatr Res* 72, 400-406. PMID: 22821058
259. I.A. Khasabova, Y. Xiong, L.G. Coicou, **D. Piomelli** and V. Seybold, 2012. Peroxisome proliferator-activated receptor α mediates acute effects of palmitoylethanolamide on sensory neurons. *J Neurosci* 32, 12735-12743. PMCID: PMC3462371
260. K.M. Jung, M. Sepers, C.M. Hemstridge, O. Lassalle, D. Neuhofer, H. Martin, M. Ginger, A. Frick, N.V. DiPatrizio, K. Mackie, I. Katona, **D. Piomelli** and O.J. Manzoni, 2012. Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. *Nat Commun* 3, 1080. PMCID: PMC3657999
261. E. Simoni, S. Daniele, G. Bottegoni, D. Pizzirani, M.L. Tincavelli, L. Goldoni, G. Tarozzo, A. Reggiani, C. Martini, **D. Piomelli**, C. Melchiorre, M. Rosini and A. Cavalli, 2012. Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease. *J Med Chem* 55, 9708-9721. PMID: 23033965
262. A.D. Favia, D. Habrant, R. Scarpelli, M. Migliore, C. Ablani, S.M. Bertozzi, M. Dionisi, G. Tarozzo, **D. Piomelli**, A. Cavalli and M. De Vivo, 2012. Identification and characterization of carprofen as a multitarget fatty acid amide hydrolase/cyclooxygenase inhibitor. *J Med Chem* 55, 8807-8826. PMCID: PMC3764917
263. P. Busquet, V. Capurro, A. Cavalli, D. Piomelli, A. Reggiani, R. Bertorelli, 2012. Synergistic effects of galantamine and memantine in attenuating scopolamine-induced amnesia in mice. *J Pharmacol Sci* 120, 305-309. PMID: 23149577
264. N.A. Abumrad, **D. Piomelli**, K. Yurko-Mauro, A. Merrill, M.T. Clandinin and C.N. Serhan, 2012. Moving beyond "good fat, bad fat": the complex roles of dietary lipids in cellular function and health: session abstracts. *Adv Nutr*, 3, 60-68. PMCID: PMC3262616.
265. O. Sasso, G. Moreno-Sanz, C. Martucci, N. Realini, M. Dionisi, L. Mengatto, A. Duranti, G. Tarozzo, G. Tarzia, M. Mor, R. Bertorelli, A. Reggiani and **D. Piomelli**, 2013. Antinociceptive effects of the N-acylethanolamine acid amidase inhibitor ARN077 in rodent pain models. *Pain* 154, 350-360. PMCID: PMC3723234

266. L. Bertolacci, E. Romeo, M. Veronesi, P. Magotti, C. Albani, M. Dionisi, C. Lambruschini, R. Scarpelli, A. Cavalli, M. De Vivo, **D. Piomelli** and G. Garau, 2013. A binding site for non-steroidal anti-inflammatory drugs in FAAH. *J Am Chem Soc* 135, 22-25. PMCID: PMC3562592
267. N. Realini, C. Solorzano, C. Pagliuca, D. Pizzirani, A. Armirotti, R. Luciani, M.P. Costi, T. Bandiera and **D. Piomelli**, 2013. Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity. *Sci Rep* 3, 1035. PMCID: PMC3539145
268. A. Lodola, L. Capoferri, S. Rivara, G. Tarzia, **D. Piomelli**, A.J. Mulholland and M. Mor, 2013. Quantum mechanics/molecular mechanics modeling of fatty acid amide hydrolase reactivation distinguishes substrate from irreversible covalent inhibitors. *J Med Chem* 56, 2500-2512. PMCID: PMC3724458
269. V. Capurro, P. Busquet, J.P. Lopes, R. Bertorelli, G. Tarozzo, M.L. Bolognesi, **D. Piomelli**, A. Reggiani and A. Cavalli, 2013. Pharmacological characterization of memoquin, a multi-target compound for the treatment in Alzheimer's disease. *PLoS One* 8, e56870. PMCID: PMC3575497
270. N.V. DiPatrizio, A. Joslin, K.M. Jung and **D. Piomelli**, 2013. Endocannabinoid signaling in the gut mediates preference for dietary unsaturated fats. *FASEB J* 27, 2513-2520. PMCID: PMC3659363
271. J.P. Lopes, G. Tarozzo, A. Reggiani, **D. Piomelli** and A. Cavalli, 2013. Galantamine potentiates the neuroprotective effect of memantine against NMDA-induced excitotoxicity. *Brain Behav* 3, 67-74. PMCID: PMC3607148
272. **D. Piomelli**, 2013. A fatty gut feeling. *Trends Endocrinol Metab* 24, 332-341. PMCID: PMC3778443
273. D. Pizzirani, C. Pagliuca, N. Realini, D. Branduradi, G. Bottegoni, M. Mor, F. Bertozzi, R. Scarpelli, **D. Piomelli** and T. Bandiera, 2013. Discovery of a new class of highly potent inhibitors of acid ceramidase: synthesis and structure-activity relationship (SAR). *J Med Chem* 56, 3518-3530. PMID: 23614460
274. A. Neumeister, M.D. Normandin, R.H. Pietrzak, **D. Piomelli**, M.Q. Zheng, A. Guijarro-Anton, M.N. Potenza, C.R. Bailey, S.F. Lin, S. Najafzadeh, J. Ropchan, S. Henry, S. Corsi-Travali, R.E. Carson and Y. Huang, 2013. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. *Mol Psychiatry* 18, 1034-1040. PMCID: PMC3752332
275. C. Lambruschini, M. Veronesi, E. Romeo, G. Garau, T. Bandiera, **D. Piomelli**, R. Scarpelli and C. Dalvit, 2013. Development of fragment-based n-FABS NMR screening applied to the membrane enzyme FAAH. *Chem Biochem* 14, 1611-1619. PMID: 23918626
276. S. Ponzano, F. Bertozzi, L. Mengatto, M. Dionisi, A. Armirotti, E. Romeo, A. Berteotti, C. Fiorelli, G. Tarozzo, A. Reggiani, A. Duranti, G. Tarzia, M. Mor, A. Cavalli, **D. Piomelli** and T. Bandiera, 2013. Synthesis and structure-activity relationship (SAR) of 2-methyl-4-oxo-3-oxetanyl carbamic acid esters, a class of potent n-acylethanolamine acid amidase (NAAA) inhibitors. *J Med Chem* 56, 6917-6934. PMID: 23991897
277. L.D. O'Brien, C.L. Limebeer, E.M. Rock, G. Bottegoni, **D. Piomelli** and L.A. Parker, 2013. Anandamide transport inhibition by ARN272 attenuates nausea-induced behaviour in rats, and vomiting in shrews (*Suncus murinus*). *Br J Pharmacol* 170, 1130-1136. PMCID: PMC3949659

278. J.M. Rasmussen, S. Entringer, A. Nguyen, T.G. van Erp, J. Burns, A. Guijarro, F. Oveisi, J.M. Swanson, **D. Piomelli**, P.D. Wadhwa, C. Buss, S.G. Potkin, 2013. Brown adipose tissue quantification in human neonates using water-fat separated MRI. *PLoS One* 8, e77907. PMCID: PMC3813555
279. G. Moreno-Sanz, A. Duranti, L. Melzig, C. Fiorelli, G.F. Ruda, G. Colombano, P. Mestichelli, S. Sanchini, A. Tontini, M. Mor, T. Bandiera, R. Scarpelli, G. Tarzia and **D. Piomelli**, 2013. Synthesis and structure-activity relationship studies of o-biphenyl-3-yl carbamates as peripherally restricted fatty acid amide hydrolase inhibitors. *J Med Chem* 56, 5917-5930. PMCID: PMC4062305
280. **D. Piomelli**, 2014. More surprises lying ahead. The endocannabinoids keep us guessing. *Neuropharmacology* 76, 228-234. PMCID: PMC3855347
281. K.J. Llewellyn, A. Nalbandian, K.M. Jung, C. Nguyen, A. Avanesian, T. Mozaffar, **D. Piomelli** and V.E. Kimonis, 2014. Lipid-enriched diet rescues lethality and slows down progression in murine model of VCP-associated disease. *Hum Mol Genet* 23, 1333-1344. PMCID: PMC3919004
282. M. Iorio, O. Sasso, S.I. Maffioli, R. Bertorelli, P. Monciardini, M. Sosio, F. Bonezzi, M. Summa, C. Brunati, R. Bordoni, G. Corti, G. Tarozzo, **D. Piomelli**, A. Reggiani and S. Donadio, 2014. A glycosylated, labionin-containing lanthipeptide with marked antinociceptive activity. *ACS Chem Biol* 9, 398-404. PMID: 24191663
283. M. Veronesi, E. Romeo, C. Lambruschini, **D. Piomelli**, T. Bandiera, R. Scarpelli, G. Garau, C. Dalvit, 2014. Fluorine NMR-based screening on cell membrane extracts. *Chem Med Chem* 9, 286-289. PMID: 24339446
284. E.A. Holman, A. Guijarro, J. Lim and **D. Piomelli**, 2014. Effects of acute stress on cardiac endocannabinoids, lipogenesis, and inflammation in rats. *Psychosom Med* 76, 20-28. PMCID: PMC3988664
285. R. Vitale, G. Ottonello, R. Petracca, S.M. Bertozzi, S. Ponzano, A. Armirotti, A. Berteotti, M. Dionisi, A. Cavalli, **D. Piomelli**, T. Bandiera and F. Bertozzi, 2014. Synthesis, structure-activity, and structure-stability relationships of 2-substituted-N-(4-oxo-3-oxetanyl) n-acyl ethanolamine acid amidase (NAAA) inhibitors. *Chem Med Chem* 9, 323-336. PMID: 24403170
286. S. Sahar, S. Masubuchi, K. E. Ekel-Mahan, S. Vollmer, L. Galla, N. Ceglia, S. Masri, T.K. Barth, B. Grimaldi, O. Oluyemi, G. Astartia, W.C. Hallows, **D. Piomelli**, A. Imhof, P. Baldi, J.M. Denu and P. Sassone-Corsi, 2014. Circadian control of fatty acid elongation by SIRT1-mediated deacetylation of acetyl-CoA synthetase 1. *J Biol Chem* 289, 6091-6097. PMCID: PMC3937675
287. **D. Piomelli** and O. Sasso, 2014. Peripheral gating of pain signals by endogenous lipid mediators. *Nat Neurosci* 17, 164-174. PMCID: PMC4020413
288. A. De Simone, G.F. Ruda, C. Albani, G. Tarozzo, T. Bandiera, **D. Piomelli**, A. Cavalli and G. Bottegoni, 2014. Applying a multitarget rational drug design strategy: the first set of modulators with potent and balanced activity toward dopamine D3 receptor and fatty acid amide hydrolase. *Chem Commun (Camb)* 50, 4904-4907. PMCID: PMC4038168
289. A. Armirotti, A. Basit, N. Realini, C. Caltagirone, P. Bossù, G. Spalletta and **D. Piomelli**, 2014. Sample preparation and orthogonal chromatography for broad polarity range plasma metabolomics.

Application to human subjects with neurodegenerative dementia. **Anal Biochem** 455C, 48-54. PMID: 24708938

290. T. Bandiera, S. Ponzano and **D. Piomelli**, 2014. Advances in the discovery of N-acylethanolamine acid amidase inhibitors. **Pharmacol Res** 86C, 11-17. PMID: PMC4117721

291. R.H. Pietrzak, Y. Huang, S. Corsi-Travali, M.Q. Zheng, S.F. Lin, S. Henry, M.N. Potenza, **D. Piomelli**, R.E. Carson and A. Neumeister, 2014. Cannabinoid type 1 receptor availability in the amygdala mediates threat processing in trauma survivors. **Neuropsychopharmacology** 39, 2519-2528. PMID: PMC4207337

292. Fiasella, A. Nuzzi, M. Summa, A. Armirotti, G. Tarozzo, G. Tarzia, M. Mor, F. Bertozzi, T. Bandiera and **D. Piomelli**, 2014. 3-aminoazetidin-2-one derivatives as N-acylethanolamine acid amidase (NAAA) inhibitors suitable for systemic administration. **ChemMedChem** 9, 1602-1614. PMID: PMC4224963

293. A.B. Tinoco, A. Armirotti, E. Isorna, M.J. Delgado, **D. Piomelli** and N. dePedro, 2014. Role of oleoylethanolamide as a feeding regular in goldfish. **J Expt Bio** 217, 2761-2769. PMID: 24855680

294. G. Moreno-Sanz, B. Barrera, A. Armirotti, S.M. Bertozzi, R. Scarpelli, T. Bandiera, J.G. Prieto, A. Duranti, G. Tarzia, G. Merino and **D. Piomelli**, 2014. Structural determinants of peripheral O-arylcarbamate FAAH inhibitors render them dual substrates for Abcb1 and Abcg2 and restrict their access to the brain. **Pharmacol Res** 87C, 87-93. PMID: PMC4134960

295. **D. Piomelli**, A.G. Hohmann, V. Seybold and B.D. Hammock, 2014. A lipid gate for the peripheral control of pain. **J. Neurosci** 34, 15184-15191. PMID: PMC4228127

296. S. Ponzano, A. Berteotti, R. Petracca, R. Vitale, L. Mengatto, T. Bandiera, A. Cavalli, **D. Piomelli**, F. Bertozzi and G. Bottegoni, 2014. Synthesis, biological evaluation, and 3D QSAR study of 2-Methyl-4-oxo-3-oxetanylcabamic acid esters as N-acylethanolamine acid amidase (NAAA) inhibitors. **J Med Chem** 57, 10101-10111. PMID: 25380517

297. G. Colombano, C. Albani, G. Ottonello, A. Ribeiro, R. Scarpelli, G. Tarozzo, J. Daglian, K.M. Jung and **D. Piomelli**, 2015. O-(triazolyl)methyl carbamates as a novel and potent class of fatty acid amide hydrolase (FAAH) inhibitors. **ChemMedChem** 10, 380-395. PMID: PMC4384654

298. D. Pizzirani, A. Bach, N. Realini, A. Armirotti, L. Mengatto, I. Bauer, S. Giroto, C. Pagliuca, M. De Vivo, M. Summa, A. Ribeiro and **D. Piomelli**, 2015. Benzoxazolone carboxamides: potent and systemically active inhibitors of intracellular acid ceramidase. **Angew Chem Int Ed Engl.** 54, 485-489. PMID: PMC4502975

299. R. Greco, T. Bandiera, A. Mangione, C. Demartini, F. Siani, G. Nappi, G. Sandrini, A. Guijarro, A. Armirotti, **D. Piomelli** and C. Tassorelli, 2015. Effects of peripheral FAAH blockade on NTG-induced hyperalgesia-evaluation of URB937 in an animal model of migraine. **Cephalalgia** 35, 1065-1076. PMID: 25608877

300. Greco R, Bandiera T, Mangione AS, Demartini C, Nappi G, Sandrini G, **Piomelli D**, Tassorelli C., 2015. P007. Inhibition of monoacylglycerol lipase activity modulates the activation of brain structures relevant for migraine pathogenesis. **J Headache Pain.** doi: 10.1186/1129-2377-16-S1-A165. PMID: PMC4759149

301. N.V. DiPatrizio and **D. Piomelli**, 2015. Intestinal lipid-derived signals that sense dietary fat. **J Clin Invest** 125, 891-898. PMID: 25642767. PMCID: PMC4362267
302. G. Astarita, A. Avanesian, B. Grimaldi, N. Realini, Z. Justinova, L.V. Panlilio, A. Basit, S.R. Goldberg and **D. Piomelli**, 2015. Methamphetamine accelerates cellular senescence through stimulation of de novo ceramide biosynthesis. **PLoS One** 10, e0116961. PMCID: PMC4324822
303. P. Magotti, I. Bauer, M. Igarashi, M. Babagoli, R. Marotta, **D. Piomelli** and G. Garau, 2015. Structure of human N-acylphosphatidyletanolamine-hydrolyzing phospholipase D: regulation of fatty acid ethanolamine biosynthesis by bile acids. **Structure** 23, 598-604. PMCID: PMC4351732
304. M. Niki, M. Jyotaki, R. Yoshida, K. Yasumatsu, N. Shigemura, N.V. DiPatrizio, **D. Piomelli** and Y. Ninomiya, 2015. Modulation of sweet taste sensitivities by endogenous leptin and endocannabinoids in mice. **J Physiol** 593, 2527-2545. PMCID: PMC4461413
305. A. Basit, **D. Piomelli** and A. Armirotti, 2015. Rapid evaluation of 25 key sphingolipids and phosphosphingolipids in human plasma by LC-MS/MS. **Anal Bioanal Chem** 407, 5189-5198. PMCID: PMC4471391
306. Z. Justinova, L.V. Panlilio, G. Moreno-Sanz, G.H. Redhi, A. Auber, M.E. Secci, P. Mascia, T. Bandiera, A. Armirotti, R. Bertorelli, S.I. Chefer, C. Barnes, S. Yasar, **D. Piomelli** and S.R. Goldberg, 2015. Effects of fatty acid amide hydrolase (FAAH) inhibitors in non-human primate models of nicotine reward and relapse. **Neuropsychopharmacology** 40, 2185-2197. PMCID: PMC4613608
307. O. Sasso, M. Migliore, D. Habrant, A. Armirotti, C. Albani, M. Summa, G. Moreno-Sanz, R. Scarpelli and **D. Piomelli**, 2015. Multitarget fatty acid amide hydrolase/cyclooxygenase blockade suppresses intestinal inflammation and protects against nonsteroidal anti-inflammatory drug-dependent gastrointestinal damage. **FASEB J** 29, 2616-2627. PMCID: PMC4447230
308. A. Ribeiro, S. Pontis, L. Mengatto, A. Armirotti, V. Chiurchiu, V. Capurro, A. Fiasella, A. Nuzzi, E. Romeo, G. Moreno-Sanz, M. Maccarrone, A. Reggiani, G. Tarzia, M. Mor, F. Bertozzi, T. Bandiera and **D. Piomelli**, 2015. A potent systemically active N-acyl ethanolamine acid amidase inhibitor that suppresses inflammation and human macrophage activation. **ACS Chem Biol** 10, 1838-1846. PMCID: PMC4546552
309. O. Sasso, K. Wagner, C. Morisseau, B. Inceoglu, B.D. Hammock and **D. Piomelli**, 2015. Peripheral FAAH and soluble epoxide hydrolase inhibitors are synergistically antinociceptive. **Pharmacol Res** 97, 7-15. PMCID: PMC4464910
310. E.Y. Dotsey, K.M. Jung, A. Basit, D. Wei, J. Daglian, F. Vacondio, A. Armirotti, M. Mor and **D. Piomelli**, 2015. Peroxide-dependent MGL sulfenylation regulates 2-AG-mediated endocannabinoid signalling in brain neurons. **Chem Biol** 22, 619-628. PMCID: PMC4459529
311. M. Igarashi, N.V. DiPatrizio, V. Narayanaswami and **D. Piomelli**, 2015. Feeding-induced oleoylethanolamide mobilization is disrupted in the gut of diet-induced obese rodents. **Biochem Biophys Acta** 1851, 1218-1226. PMCID: PMC4516666
312. E. Romeo, S. Ponzano, A. Armirotti, M. Summa, F. Bertozzi, G. Garau, T. Bandiera and **D. Piomelli**, 2015. Activity-based probe for N-acyl ethanolamine acid amidase. **ACS Chem Biol** 10, 2057-2064. PMCID: PMC4575644

313. T. Yu, M.D. Taussig, N.V. DiPatrizio, G. Astarita, **D. Piomelli**, B.C. Bergman, M.L. Dell'Acqua, R.H. Eckel and H. Wang, 2015. Deficiency of lipoprotein lipase in neurons decreases AMPA receptor phosphorylation and leads to neurobehavioral abnormalities in mice. **PLoS One** 10, e0135113. PMCID: PMC4532501
314. N.V. DiPatrizio, M. Igarashi, V. Narayanaswami, C. Murray, J. Gancayco, A. Russell, K.M. Jung and **D. Piomelli**, 2015. Fasting stimulates 2-AG biosynthesis in the small intestine: role of cholinergic pathways. **Am J Physiol Regul Integr Comp Physiol** 309, R805-R813. PMCID: PMC4666947
315. D. Wei, D. Lee, C. Cox, C. Karsten, O. Penagarikano, D.H. Geschwind, C.M. Gall and **D. Piomelli**, 2015. Endocannabinoid signaling mediates oxytocin-driven social reward. **Proc Natl Acad Sci U S A** 112, 14084-14089. PMCID: PMC4653148
316. A. Bach, D. Pizzirani, N. Realini, V. Vozella, D. Russo, I. Penna, L. Melzig, R. Scarpelli and **D. Piomelli**, 2015. Benzoxazolone carboxamides as potent acid ceramidase inhibitors: synthesis and structure-activity relationship (SAR) studies. **J Med Chem** 58, 9258-9272. PMID: 26560855
317. A. Bilbao, A. Serrano, A. Cippitelli, F.J. Pavón, A. Giuffrida, J. Suárez, N. García-Marchena, E. Baixeras, R. Gómez de Heras, L. Orio, F. Alén, R. Ciccocioppo, B.F. Cravatt, L.H. Parsons, **D. Piomelli** and F. Rodríguez de Fonseca, 2016. Role of the satiety factor oleoylethanolamide in alcoholism. **Addict Biol** 21, 859-872. PMCID: PMC4668242
318. L. Scalvini, **D. Piomelli** and M. Mor, 2016. Monoglyceride lipase: structure and inhibitors. **Chem Phys Lipids** 197, 13-24. PMCID: PMC4728057
- 316.* J. Lim, M. Igarashi, K.M. Jung, S. Butini, G. Campiani and **D. Piomelli**, 2016. Endocannabinoid modulation of predator stress-induced long-term anxiety in rats. **Neuropsychopharmacology** 41, 1329-1339. PMCID: PMC4793117
- *Recommended for F1000 Prime as being of special significance in the field.
317. R. Scarpelli, O. Sasso and **D. Piomelli**, 2016. A double whammy: targeting both fatty acid amide hydrolase (FAAH) and cyclooxygenase (COX) to treat pain and inflammation. **ChemMedChem** 11, 1242-1251. PMCID: PMC4840092
318. N. Realini, F. Palese, D. Pizzirani, S. Pontis, A. Basit, A. Bach, A. Ganesan and **D. Piomelli**, 2016. Acid ceramidase in melanoma: expression, localization and effects of pharmacological inhibition. **J Biol Chem** 291, 2422-2434. PMCID: PMC4732224
319. L.V. Panlilio, E.B. Thorndike, S.P. Nikas, S.O. Alapafuja, T. Bandiera, B.F. Cravatt, A. Makriyannis, **D. Piomelli**, S.R. Goldberg and Z. Justinova, 2016. Effects of fatty acid amide hydrolase (FAAH) inhibitors on working memory in rats. **Psychopharmacology (Berl)** 233, 1879-1888. PMCID: PMC4846548
320. S. Pontis, A. Ribeiro, O. Sasso and **D. Piomelli**, 2016. Macrophage-derived lipid agonists of PPAR- α as intrinsic controllers of inflammation. **Crit Rev Biochem Mol Biol** 51, 7-14. PMID: 26585314
321. M. Veronesi, F. Giacomina, E. Romeo, B. Castellani, G. Ottonello, C. Lambruschini, G. Garau, R. Scarpelli, T. Bandiera, **D. Piomelli** and C. Dalvit, 2016. Fluorine nuclear magnetic resonance-based assay in living mammalian cells. **Anal Biochem** 495, 52-59. PMID: 26686030

322. F. Bonezzi, O. Sasso, S. Pontis, N. Realini, E. Romeo, S. Ponzano, A. Nuzzi, A. Fiasella, F. Bertozzi and **D. Piomelli**, 2016. An important role for N-acylethanolamine acid amidase in the complete Freund's adjuvant rat model of arthritis. *J Pharmacol Exp Ther* 356, 656-663. PMID: 26769918

323.* M. Migliore, D. Habrant, O. Sasso, C. Albani, S.M. Bertozzi, A. Armirotti, **D. Piomelli** and R. Scarpelli, 2016. Potent multitarget FAAH-COX inhibitors: design and structure-activity relationships studies. *Eur J Med Chem* 109, 216-237. PMID: PMC4752335

*Co-corresponding author

324. A. Nuzzi, A. Fiasella, J.A. Ortega, C. Pagliuca, S. Ponzano, D. Pizzirani, S.M. Bertozzi, G. Ottonello, G. Tarozzo, A. Reggiani, T. Bandiera, F. Bertozzi and **D. Piomelli**, 2016. Potent α -amino- β -lactam carbamic acid ester as NAAA inhibitors. Synthesis and structure-activity relationship (SAR) studies. *Eur J Med Chem* 111, 138-159. PMID: 26866968

325. D. Wei, D. Lee, D. Li, J. Daglian, K.M. Jung and **D. Piomelli**, 2016. A role for the endocannabinoid 2-arachidonoyl-*sn*-glycerol for social and high-fat food reward in male mice. *Psychopharmacology* 233, 1911-1919. PMID: PMC5118226

326. M. Brindisi, S. Maramai, S. Gemma, S. Brogi, A. Grillo, L. Di Cesare Mannelli, E. Gabellieri, S. Lamponi, S. Saponara, B. Gorelli, D. Tedesco, T. Bonfiglio, C. Landry, K.M. Jung, A. Armirotti, L. Luongo, A. Ligresti, F. Piscitelli, C. Bertucci, M.P. Dehouck, G. Campiani, S. Maione, C. Ghelardini, A. Pittaluga, **D. Piomelli**, V. Di Marzo and S. Butini, 2016. Development and pharmacological characterization of selective blockers of 2-arachidonoyl glycerol degradation with efficacy in rodents models of multiple sclerosis and pain. *J Med Chem* 59, 22-2632. PMID: 26888301

327. M. Jacome-Sosa, C. Vacca, R. Mangat, A. Diane, R.C. Nelson, M.J. Reaney, J. Shen, J.M. Curtis, D.F. Vine, C.J. Field, M. Igarashi, **D. Piomelli**, S. Banni and S.D. Proctor, 2016. Vaccenic acid suppresses intestinal inflammation by increasing the endocannabinoid anandamide and non-cannabinoid signaling molecules in a rat model of the metabolic syndrome. *J Lipid Res* 57, 638-649. PMID: 26891736

328. L. Goldoni, T. Beringhelli, W. Rocchia, N. Realini and **D. Piomelli**, 2016. A simple and accurate protocol for absolute polar metabolite quantification in cell cultures using q-NMR. *Anal Biochem* 501, 26-34. PMID: 26898303

329.* A. Basit, S. Pontis, **D. Piomelli** and A. Armirotti, 2016. Ion mobility mass spectrometry enhances low-abundance species detection in untargeted lipidomics. *Metabolomics* 12, 50. PMID: PMC4744830

*Co-corresponding author

330. H. Wang, M.D. Taussig, N.V. DiPatrizio, K. Bruce, **D. Piomelli** and R.H. Eckel, 2016. Obesity development in neuron-specific lipoprotein lipase deficient mice is not responsive to increased dietary fat content or change in fat composition. *Metabolism* 65, 987-997. NIHMSID: NIHMS758010

331. L. Goldini, T. Beringhelli, W. Rocchia, N. Realini and **D. Piomelli**, 2016. Absolute nutrient concentration measurements in cell culture media: (1)H q-NMR spectra and data to compare the efficiency of pH-controlled protein precipitation versus CPMG or post-processing filtering approaches. *Data Brief* 8, 387-393. PMID: PMC4909824

332. M. Migliore, S. Pontis, A.L. Fuentes de Arriba, N. Realini, E. Torrente, A. Armirotti, E. Romeo, S. Di Martino, D. Russo, D. Pizzirani, M. Summa, M. Lanfranco, G. Ottonello, P. Busquet, K.M. Jung,

- M. Garcia-Guzman, R. Heim, R. Scarpelli and **D. Piomelli**, 2016. Second-generation non-covalent NAAA inhibitors are protective in a model of multiple sclerosis. *Angew Chem Int Ed Engl.* 55, 11193-11197. PMCID: PMC5009002
333. O. Sasso, S. Pontis, A. Armirotti, G. Cardinali, D. Kovacs, M. Migliore, M. Summa, G. Moreno-Sanz, M. Picardo and **D. Piomelli**, 2016. Endogenous N-acyl taurines regulate skin wound healing. *Proc Natl Acad Sci U S A* 113, E4397-E4406. PMCID: PMC4968764
334. L. Scalvini, F. Vacondio, M. Bassi, D. Pala, A. Lodola, S. Rivara, K.M. Jung, **D. Piomelli** and M. Mor, 2016. Free-energy studies reveal a possible mechanism for oxidation-dependent inhibition of MGL. *Sci Rep* 6, 31046. PMCID: PMC9479315
335. W. Wang, B.H. Trieu, L.C. Palmer, Y. Jia, D.T. Pham, K-M. Jung, C.A. Karseten, C.B. Merrill, K. Mackie, C.M. Gall, **D. Piomelli** and G. Lynch, 2016. A primary cortical input to hippocampus expresses a pathway-specific and endocannabinoid-depedent form of long-term potentiation. *eNeuro* 3, e0160. PMCID: PMC4976302
336. E. Margheritis, B. Castellani, P. Magotti, S. Peruzzi, E. Romeo, F. Natali, S. Mostarda, A. Gioiello, **D. Piomelli** and G. Garau, 2016. Bile acid recognition by NAPE-PLD. *ACS Chem Biol* 11, 2908-2914. PMCID: PMC5074845
337. A. Di Pardo, E. Amico, A. Basit, A. Armirotti, F. Scalabrì, G. Pepe, M. D'Esposito, BM Park, S Jeong, **D. Piomelli**, V Maglione, 2016. B37 Aberrant sphingosine-1-phosphate metabolism as druggable target in huntington's disease. *Journal of Neurology, Neurosurgery & Psychiatry* 87 (Suppl 1), A22-A22
338. H. Moradi, F. Oveisi, E. Khanifar, G. Moreno-Sanz, N.D. Vaziri and **D. Piomelli**, 2016. Increased renal 2-arachidonoylglycerol level is associated with improved renal function in a mouse model of acute kidney injury. *Cannabis and Cannabinoid Research* 1, 218-228. PMCID: PMC5531066
339. Eleonora Diamanti, Giovanni Bottegoni, Luca Goldoni, Natalia Realini, Chiara Pagliuca, Fabio Bertozzi, **Daniele Piomelli**, Daniela Pizzirani, 2016. Pyrazole-Based Acid Ceramidase Inhibitors: Design, Synthesis, and Structure–Activity Relationships. *Synthesis* 48 (17), 2739-2756.
340. G Cardinali, D Kovacs, V Maresca, O Sasso, **D Piomelli**, M Picardo, 2016. 566 The cross-talk between lipid mediators and growth factors in the control of wound healing. *Journal of Investigative Dermatology* 136 (9), S257.
341. Romeo E, Pontis S, Ponzano S, Bonezzi F, Migliore M, Di Martino S, Summa M, **Piomelli D.**, 2016. Preparation and In Vivo Use of an Activity-based Probe for N-acylethanolamine Acid Amidase. *J Vis Exp* 117. PMID: 27911411
342. Lee SH, Dudok B, Parihar VK, Jung KM, Zöldi M, Kang YJ, Maroso M, Alexander AL, Nelson GA, **Piomelli D**, Katona I, Limoli CL, Soltesz I., 2016. Neurophysiology of space travel: energetic solar particles cause cell type-specific plasticity of neurotransmission. *Brain Struct Funct.* 1-13. PMID: 27905022
343. Petracca R, Ponzano S, Bertozzi SM, Sasso O, **Piomelli D**, Bandiera T, Bertozzi F., 2016. Progress in the development of β -lactams as N-Acylethanolamine Acid Amidase (NAAA) inhibitors: Synthesis and SAR study of new, potent N-O-substituted derivatives. *Eur J Med Chem.* 126:561-575. PMID:27915171

344. Igarashi M, Narayanaswami V, Kimonis V, Galassetti PM, Oveisi F, Jung KM, **Piomelli D**, 2016. Dysfunctional oleoylethanolamide signaling in a mouse model of Prader-Willi syndrome. **Pharmacol Res.** 117:75-81. PMID:28007570
345. den Hoedt S, Janssen CI, Astarita G, **Piomelli D**, Leijten FP, Crivelli SM, Verhoeven AJ, de Vries HE, Walter J, Martinez-Martinez P, Sijbrands EJ, Kiliaan AJ, Mulder MT., 2016. Pleiotropic Effect of Human ApoE4 on Cerebral Ceramide and Saturated Fatty Acid Levels. **J Alzheimers Dis.** 1-12. PMID:28035926
346. Marrone MC, Morabito A, Giustizieri M, Chiurchiù V, Leuti A, Mattioli M, Marinelli S, Riganti L, Lombardi M, Murana E, Totaro A, **Piomelli D**, Ragozzino D, Oddi S, Maccarrone M, Verderio C, Marinelli S. TRPV1 channels are critical brain inflammation detectors and neuropathic pain biomarkers in mice. **Nat Commun.** 2017. May 10;8:15292. PMCID: PMC5436240.
347. Wang W, Jia Y, Pham DT, Palmer LC, Jung KM, Cox CD, Rumbaugh G, **Piomelli D**, Gall CM, Lynch G. Atypical Endocannabinoid Signaling Initiates a New Form of Memory-Related Plasticity at a Cortical Input to Hippocampus. **Cereb Cortex.** 2017. May 17:1-14. PubMed PMID:28520937.
348. Khurana L, Mackie K, **Piomelli D**, Kendall DA. Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities. **Neuropharmacology.** 2017 Sep 15;124:3-12. PMCID:PMC5540789.
349. Wei D, Allsop S, Tye K, **Piomelli D**. Endocannabinoid Signaling in the Control of Social Behavior. **Trends Neurosci.** 2017 Jul;40(7):385-396. May 26. Review. PubMed PMID: 28554687.
350. Heintz S, Piaggi P, Vinales KL, Basolo A, Spranger J, **Piomelli D**, Krakoff J, Jumpertz von Schwartzberg R. Specific skeletal muscle sphingolipid compounds in energy expenditure regulation and weight gain in Native Americans of Southwestern heritage. **Int J Obes (Lond).** 2017 Oct;41(10):1585-1593. PMCID: PMC5626585.
351. Scheggia D, Zamberletti E, Realini N, Mereu M, Contarini G, Ferretti V, Managò F, Margiani G, Brunoro R, Rubino T, De Luca MA, **Piomelli D**, Parolaro D, Papaleo F. Remote memories are enhanced by COMT activity through dysregulation of the endocannabinoid system in the prefrontal cortex. **Mol Psychiatry.** 2017 Jun 20. 126. PMID: 28630452.
352. Merrill CB, Basit A, Armirotti A, Jia Y, Gall CM, Lynch G, **Piomelli D**. Patch clamp-assisted single neuron lipidomics. **Sci Rep** 2017 Jul 13;7(1):5318. PMCID: PMC5509708.
353. Lai M, Realini N, La Ferla M, Passalacqua I, Matteoli G, Ganesan A, Pistello M, Mazzanti CM, **Piomelli D**. Complete Acid Ceramidase ablation prevents cancer-initiating cell formation in melanoma cells. **Sci Rep.** 2017 Aug 7;7(1):7411 PMCID: PMC5547127.
354. Rock EM, Moreno-Sanz G, Limebeer CL, Petrie GN, Angelini R, **Piomelli D**, Parker LA. Suppression of acute and anticipatory nausea by peripherally restricted fatty acid amide hydrolase inhibitor in animal models: role of PPAR α and CB(1) receptors. **Br J Pharmacol.** 2017 Nov;174(21):3837-3847. Sep 20. PMID: 28805944.
355. Vozella V, Basit A, Misto A, **Piomelli D**. Age-dependent changes in nervonic acid-containing sphingolipids in mouse hippocampus. **Biochim Biophys Acta.** 2017 Dec;1862(12):1502-1511. Aug 30. PubMed PMID: 28855145.

356. Angelini R, Argueta DA, **Piomelli D**, DiPatrizio NV. Identification of a widespread palmitoylethanolamide contamination in standard laboratory glassware. **Cannabis Cannabinoid Res.** 2017 Jun 1;2(1):123-132. PMCID: PMC5510777.
357. Schoch H, Huerta MY, Ruiz CM, Farrell MR, Jung KM, Huang JJ, Campbell RR, **Piomelli D**, Mahler SV. Adolescent cannabinoid exposure effects on natural reward seeking and learning in rats. **Psychopharmacology (Berl)**. 2017 Oct 11. PMID: 29022083.
358. Petracca R, Romeo E, Baggelaar MP, Artola M, Pontis S, Ponzano S, Overkleeft HS, van der Stelt M, **Piomelli D**. Novel activity-based probes for N-acyl ethanolamine acid amidase. **Chem Commun (Camb)**. 2017 Oct 16. PMID: 29035406
359. Sasso O, Summa M, Armirotti A, Pontis S, De Mei C, **Piomelli D**. The N-acyl ethanolamine acid amidase inhibitor ARN077 suppresses inflammation and pruritus in a mouse model of allergic dermatitis. **J Invest Dermatol**. 2017 Oct 17. [Epub ahead of print] PMID: 29054595
360. Wang W, Cox BM, Jia Y, Le AA, Cox CD, Jung KM, Hou B, **Piomelli D**, Gall CM, Lynch G. Treating a novel plasticity defect rescues episodic memory in Fragile X model mice. **Mol Psychiatry**. 2017 Nov 14. [Epub ahead of print] PMID: 29133950
361. Castellani B, Diamanti E, Pizzirani D, Tardia P, Maccesi M, Realini N, Magotti P, Garau G, Bakkum T, Rivara S, Mor M, **Piomelli D**. Synthesis and characterization of the first inhibitor of N-acylphosphatidylethanolamine phospholipase D (NAPE-PLD). **Chemical communications** (Cambridge, England). 2017; 53(95):12814-12817. PMCID: PMC5730275
362. Schoch H, Huerta MY, Ruiz CM, Farrell MR, Jung KM, Huang JJ, Campbell RR, **Piomelli D**, Mahler SV. Adolescent cannabinoid exposure effects on natural reward seeking and learning in rats. **Psychopharmacology**. 2018; 235(1):121-134. PubMed [journal] PMID: 29022083.
363. Heinitz S, Basolo A, Piaggi P, **Piomelli D**, Jumpertz von Schwartzberg R, Krakoff J. Peripheral endocannabinoids associated with energy expenditure in Native Americans of Southwestern heritage. **J Clin Endocrinol Metab**. 2018 Mar 1;103(3):1077-1087. doi: 10.1210/jc.2017-02257. PMID: 29300902
364. Goodman MC, Xu S, Rouzer CA, Banerjee S, Ghebreselasie K, Migliore M, **Piomelli D**, Marnett LJ. Dual cyclooxygenase-fatty acid amide hydrolase inhibitor exploits novel binding interactions in the cyclooxygenase active site. **J Biol Chem**. 2018 Mar 2;293(9):3028-3038. doi: 10.1074/jbc.M117.802058. Epub 2018 Jan 11. PMID: 29326169
365. Koethe D, Pahlisch F, Hellmich M, Rohleder C, Mueller JK, Meyer-Lindenberg A, Torrey EF, **Piomelli D**, Leweke FM. Familial abnormalities of endocannabinoid signaling in schizophrenia. **World J Biol Psychiatry**. 2018 Mar 22:1-9. doi: 10.1080/15622975.2018.1449966. [Epub ahead of print] PMID: 29521179
366. Greco R, Demartini C, Zanaboni AM, **Piomelli D**, Tassorelli C. Endocannabinoid System and Migraine Pain: An Update. **Front Neurosci**. 2018 Mar 19;12:172. doi: 10.3389/fnins.2018.00172. PMID: 29615860
367. Heinitz S, Basolo A, **Piomelli D**, Krakoff J, Piaggi P. Endocannabinoid Anandamide Mediates the Effect of Skeletal Muscle Sphingomyelins on Human Energy Expenditure. **J Clin Endocrinol Metab**. 2018 Aug 2. doi: 10.1210/jc.2018-00780. [Epub ahead of print] PMID: 30113648

368. Spadoni G, Bedini A, Furiassi L, Mari M, Mor M, Scalvini L, Lodola A, Ghidini A, Lucini V, Dugnani S, Scaglione F, **Piomelli D**, Jung KM, Supuran CT, Lucarini L, Durante M, Sgambellone S, Masini E, Rivara S. Identification of Bivalent Ligands with Melatonin Receptor Agonist and Fatty Acid Amide Hydrolase (FAAH) Inhibitory Activity That Exhibit Ocular Hypotensive Effect in the Rabbit. **J Med Chem**. 2018 Sep 13;61(17):7902-7916. doi: 10.1021/acs.jmedchem.8b00893. Epub 2018 Sep 4. PMID: 30126274
369. Danandeh A, Vozella V, Lim J, Oveisi F, Ramirez GL, Mears D, Wynn G, **Piomelli D**. Effects of fatty acid amide hydrolase inhibitor URB597 in a rat model of trauma-induced long-term anxiety. **Psychopharmacology** (Berl). 2018 Sep 24. doi: 10.1007/s00213-018-5020-7. PMID: 30251159
370. Misto A, Provensi G, Vozella V, Passani MB, **Piomelli D**. Mast Cell-Derived Histamine Regulates Liver Ketogenesis via Oleoylethanolamide Signaling. **Cell Metabolism** 2018 Oct 4. pii: S1550-4131(18)30579-5. doi: 10.1016/j.cmet.2018.09.014. PMID: 30318340
371. Gorelik A, Gebai A, Illes K, **Piomelli D**, Nagar B. Molecular mechanism of activation of the immunoregulatory amidase NAAA. **Proc Natl Acad Sci U S A**. 2018 Oct 23;115(43):E10032-E10040. doi: 10.1073/pnas.1811759115. PMID: 30301806
372. Vozella V, Basit A, Piras F, Realini N, Armirotti A, Bossù P, Assogna F, Sensi SL, Spalletta G, **Piomelli D**. Elevated plasma ceramide levels in post-menopausal women: a cross-sectional study. **Aging** (Albany NY) 2019 Jan 8;11(1):73-88. doi: 10.18632/aging.101719.
373. Vozella V, Zibardi C, Ahmed F, **Piomelli D**. Fast and Sensitive Quantification of Δ^9 -Tetrahydrocannabinol and Its Main Oxidative Metabolites by Liquid Chromatography/Tandem Mass Spectrometry. **Cannabis Cannabinoid Res**. 2019 Jun 14;4(2):110-123. doi: 10.1089/can.2018.0075. eCollection 2019. PMID: 31236476
374. Vozella V, Realini N, Misto A, **Piomelli D**. Fast and Sensitive Quantification of Δ^9 -Tetrahydrocannabinol and Its Main Oxidative Metabolites by Liquid Chromatography/Tandem Mass Spectrometry. **Cannabis Cannabinoid Res**. 2019 Jun 14;4(2):110-123. doi: 10.1089/can.2018.0075. eCollection 2019. PMID: 31236476
375. Vozella V, Realini N, Misto A, **Piomelli D**. Feeding Stimulates Sphingosine-1-Phosphate Mobilization in Mouse Hypothalamus. **Int J Mol Sci**. 2019 Aug 17;20(16). pii: E4008. doi: 10.3390/ijms 20164008. PMID: 31426457
376. Granzotto A, Bomba M, Castelli V, Navarra R, Massetti N, d'Aurora M, Onofri M, Cicalini I, Del Boccio P, Gatta V, Cimini A, **Piomelli D**, Sensi SL. Inhibition of de novo ceramide biosynthesis affects aging phenotype in an in vitro model of neuronal senescence. **Aging** (Albany NY). 2019 Aug 29;11(16):6336-6357. doi: 10.18632/aging.102191. Epub 2019 Aug 29. PMID: 31467258
377. Vozella V, Ahmed F, Choobchian P, Merrill CB, Zibardi C, Tarzia G, Mor M, Duranti A, Tontini A, Rivara S, **Piomelli D**. Pharmacokinetics, pharmacodynamics and safety studies on URB937, a peripherally restricted fatty acid amide hydrolase inhibitor, in rats. **J Pharm Pharmacol**. 2019 Dec;71(12):1762-1773. doi: 10.1111/jphp.13166. Epub 2019 Oct 3. PMID: 31579946
378. Moradi H, Park C, Igarashi M, Streja E, Argueta DA, Soohoo M, Daglian J, You AS, Rhee CM, Kashyap ML, DiPatrizio NV, Vaziri ND, Kalantar-Zadeh K, **Piomelli D**. Serum Endocannabinoid Levels in Patients With End-Stage Renal Disease. **J Endocr Soc**. 2019 Aug 5;3(10):1869-1880. doi: 10.1210/js.2019-00242. eCollection 2019 Oct 1. PMID: 31583368

379. Greco R, Demartini C, Zanaboni AM, Tumelero E, Reggiani A, Misto A, **Piomelli D**, Tassorelli C. FAAH inhibition as a preventive treatment for migraine: A pre-clinical study. *Neurobiol Dis.* 2020 Feb;134:104624. doi: 10.1016/j.nbd.2019.104624. Epub 2019 Oct 17. PMID: 31629892
380. Palese F, Pontis S, Realini N, **Piomelli D**. A protective role for N-acylphosphatidylethanolamine phospholipase D in 6-OHDA-induced neurodegeneration. *Sci Rep.* 2019 Nov 4;9(1):15927. doi: 10.1038/s41598-019-51799-1. PMID: 31685899
381. Castelli R, Scalvini L, Vacondio F, Lodola A, Anselmi M, Vezzosi S, Carmi C, Bassi M, Ferlenghi F, Rivara S, Møller IR, Rand KD, Daglian J, Wei D, Dotsey EY, Ahmed F, Jung KM, Stella N, Singh S, Mor M, **Piomelli D**. Benzisothiazolinone Derivatives as Potent Allosteric Monoacylglycerol Lipase Inhibitors That Functionally Mimic Sulfenylation of Regulatory Cysteines. *J Med Chem.* 2020 Feb 13;63(3):1261-1280. doi: 10.1021/acs.jmedchem.9b01679. Epub 2019 Dec 2. PMID: 31714779
382. Moradi H, Park C, Streja E, Argueta DA, DiPatrizio NV, You AS, Rhee CM, Vaziri ND, Kalantar-Zadeh K, **Piomelli D**. Circulating Endocannabinoids and Mortality in Hemodialysis Patients. *Am J Nephrol.* 2020;51(2):86-95. doi: 10.1159/000505444. Epub 2020 Jan 14. PMID: 31935741
383. Linciano P, Cullia G, Borsari C, Santucci M, Ferrari S, Witt G, Gul S, Kuzikov M, Ellinger B, Santarém N, Cordeiro da Silva A, Conti P, Bolognesi ML, Roberti M, Prati F, Bartoccini F, Retini M, Piersanti G, Cavalli A, Goldoni L, Bertozzi SM, Bertozzi F, Brambilla E, Rizzo V, **Piomelli D**, Pinto A, Bandiera T, Costi MP. Identification of a 2,4-diaminopyrimidine scaffold targeting Trypanosoma brucei pteridine reductase 1 from the LIBRA compound library screening campaign. *Eur J Med Chem.* 2020 Mar 1;189:112047. doi: 10.1016/j.ejmech.2020.112047. Epub 2020 Jan 10. PMID: 31982652
384. Macías-Triana L, Romero-Cordero K, Tatum-Kuri A, Vera-Barrón A, Millán-Aldaco D, Arankowsky-Sandoval G, **Piomelli D**, Murillo-Rodríguez E. Exposure to the cannabinoid agonist WIN 55, 212-2 in adolescent rats causes sleep alterations that persist until adulthood. *Eur J Pharmacol.* 2020 May 5;874:172911. doi: 10.1016/j.ejphar.2020.172911. Epub 2020 Feb 8. PMID: 32045604
385. Fotio Y, Palese F, Guaman Tipan P, Ahmed F, **Piomelli D**. Inhibition of fatty acid amide hydrolase in the CNS prevents and reverses morphine tolerance in male and female mice. *Br J Pharmacol.* 2020 Feb 19. doi: 10.1111/bph.15031. [Epub ahead of print] PMID: 32077093
386. Dey D, Parihar VK, Szabo GG, Klein PM, Tran J, Moayyad J, Ahmed F, Nguyen QA, Murry A, Merriott D, Nguyen B, Goldman J, Angulo MC, **Piomelli D**, Soltesz I, Baulch JE, Limoli CL. Neurological Impairments in Mice Subjected to Irradiation and Chemotherapy. *Radiat Res.* 2020 Mar 5. doi: 10.1667/RR15540.1. [Epub ahead of print] PMID: 32134362
387. **Piomelli D**, Scalvini L, Fotio Y, Lodola A, Spadoni G, Tarzia G, Mor M. N-Acylethanolamine Acid Amidase (NAAA): Structure, Function, and Inhibition. *J Med Chem.* 2020 Mar 26. doi: 10.1021/acs.jmedchem.0c00191. [Epub ahead of print] PMID: 32191459
388. Carloni S, Crinelli R, Palma L, Álvarez FJ, **Piomelli D**, Duranti A, Balduini W, Alonso-Alconada D. The Synthetic Cannabinoid URB447 Reduces Brain Injury and the Associated White Matter Demyelination after Hypoxia-Ischemia in Neonatal Rats. *ACS Chem Neurosci.* 2020 Apr 22. doi: 10.1021/acschemneuro.0c00047. [Epub ahead of print] PMID: 32271539
389. Torrens A, Vozella V, Huff H, McNeil B, Ahmed F, Ghidini A, Mahler SV, Huestis MA, Das A, **Piomelli D**. Comparative Pharmacokinetics of Δ9-Tetrahydrocannabinol in Adolescent and Adult

Male Mice. **J Pharmacol Exp Ther.** 2020 Apr 28. pii: jpet.120.265892. doi: 10.1124/jpet.120.265892. [Epub ahead of print] PMID: 32345621

390. Ivy D, Palese F, Vozella V, Fotio Y, Yalcin A, Ramirez G, Mears D, Wynn G, **Piomelli D.** Cannabinoid CB2 receptors mediate the anxiolytic-like effects of monoacylglycerol lipase inhibition in a rat model of predator-induced fear. **Neuropsychopharmacology.** 2020 Jul;45(8):1330-1338. doi: 10.1038/s41386-020-0696-x. Epub 2020 May 6. PMID: 32375160

391. Pontis S, Palese F, Summa M, Realini N, Lanfranco M, De Mei C, Piomelli D. N-Acylethanolamine Acid Amidase contributes to disease progression in a mouse model of multiple sclerosis. **Pharmacol Res.** 2020 Oct;160:105064. doi: 10.1016/j.phrs.2020.105064. Epub 2020 Jul 4. PMID: 32634582

392. Ruiz CM, Torrens A, Castillo E, Perrone CR, Cevallos J, Inshishian VC, Harder EV, Justeson DN, Huestis MA, Swarup V, Piomelli D, Mahler SV. Pharmacokinetic, behavioral, and brain activity effects of Δ^9 -tetrahydrocannabinol in adolescent male and female rats. **Neuropsychopharmacology.** 2021 Apr;46(5):959-969. doi: 10.1038/s41386-020-00839-w. Epub 2020 Sep 14. PMID: 32927465

393. Fotio Y, Ciccocioppo R, **Piomelli D.** N-acylethanolamine acid amidase (NAAA) inhibition decreases the motivation for alcohol in Marchigian Sardinian alcohol-preferring rats. **Psychopharmacology** (Berl). 2021 Jan;238(1):249-258. doi: 10.1007/s00213-020-05678-7. Epub 2020 Oct 10. PMID: 33037452

394. Greco R, Demartini C, Zanaboni A, Casini I, De Icco R, Reggiani A, Misto A, **Piomelli D,** Tassorelli C. **Neurobiol Dis.** 2021 Jan;147:105157. doi: 10.1016/j.nbd.2020.105157. Epub 2020 Oct 28. PMID: 33129939

395. Jung KM, Lin L, **Piomelli D.** The endocannabinoid system in the adipose organ. **Rev Endocr Metab Disord.** 2021 Jan 2. doi: 10.1007/s11154-020-09623-z. Online ahead of print. PMID: 33387286

396. Weiss L, Jung KM, Nalbandian A, Llewellyn K, Yu H, Ta L, Chang I, Migliore M, Squire E, Ahmed F, **Piomelli D,** Kimonis V. Ceramide contributes to pathogenesis and may be targeted for therapy in VCP inclusion body myopathy. **Hum Mol Genet.** 2021 Feb 25;29(24):3945-3953. doi: 10.1093/hmg/ddaa248. PMID: 33410456

397. Hundahl C, Kotzbeck P, Burm HB, Christiansen SH, Torz L, Helge AW, Madsen MP, Ratner C, Serup AK, Thompson JJ, Eichmann TO, Pers TH, Woldbye DPD, **Piomelli D,** Kiens B, Zechner R, Skov LJ, Holst B. Hypothalamic hormone-sensitive lipase regulates appetite and energy homeostasis. **Mol Metab.** 2021 May;47:101174. doi: 10.1016/j.molmet.2021.101174. Epub 2021 Feb 5. PMID: 33549847

398. Pai AY, Wenziger C, Streja E, Argueta DA, DiPatrizio NV, Rhee CM, Vaziri ND, Kalantar-Zadeh K, **Piomelli D,** Moradi H. Impact of Circulating N-Acylethanolamine Levels with Clinical and Laboratory End Points in Hemodialysis Patients. **Am J Nephrol.** 2021;52(1):59-68. doi: 10.1159/000513381. Epub 2021 Feb 18. PMID: 33601382

399. Palese F, Pontis S, Realini N, **Piomelli D.** NAPE-specific phospholipase D regulates LRRK2 association with neuronal membranes. **Adv Pharmacol.** 2021;90:217-238. doi: 10.1016/bs.apha.2020.09.003. Epub 2020 Oct 6. PMID: 33706934

400. Mabou Tagne A, Fotio Y, Lin L, Squire E, Ahmed F, Rashid TI, Karimian Azari E, **Piomelli D**. Palmitoylethanolamide and hemp oil extract exert synergistic anti-nociceptive effects in mouse models of acute and chronic pain. **Pharmacol Res.** 2021 May;167:105545. doi: 10.1016/j.phrs.2021.105545. Epub 2021 Mar 12. PMID: 33722712
401. Lai M, La Rocca V, Amato R, Freer G, Costa M, Spezia PG, Quaranta P, Lombardo G, **Piomelli D**, Pistello M. Ablation of Acid Ceramidase Impairs Autophagy and Mitochondria Activity in Melanoma Cells. **Int J Mol Sci.** 2021 Mar 23;22(6):3247. doi: 10.3390/ijms22063247. PMID: 33806766
402. Fotio Y, Sasso O, Ciccocioppo R, **Piomelli D**. Antinociceptive Profile of ARN19702, (2-Ethylsulfonylphenyl)-[(2S)-4-(6-fluoro-1,3-benzothiazol-2-yl)-2-methylpiperazin-1-yl]methanone, a Novel Orally Active N-Acylethanolamine Acid Amidase Inhibitor, in Animal Models. **J Pharmacol Exp Ther.** 2021 Aug;378(2):70-76. doi: 10.1124/jpet.121.000674. Epub 2021 May 13. PMID: 33986036
403. Lai M, Amato R, La Rocca V, Bilgin M, Freer G, Spezia P, Quaranta P, **Piomelli D**, Pistello M. Acid ceramidase controls apoptosis and increases autophagy in human melanoma cells treated with doxorubicin. **Sci Rep.** 2021 May 27;11(1):11221. doi: 10.1038/s41598-021-90219-1. PMID: 34045496
404. Mabou Tagne A, Fotio Y, Ibne Rashid T, **Piomelli D**. Persistent Exposure to $\Delta 9$ -Tetrahydrocannabinol during Adolescence Does Not Affect Nociceptive Responding in Adult Mice. **J Pharmacol Exp Ther.** 2021 Sep;378(3):215-221. doi: 10.1124/jpet.121.000740. Epub 2021 Jun 28. PMID: 34183435
405. Ghidini A, Scalvini L, Palese F, Lodola A, Mor M, **Piomelli D**. Different roles for the acyl chain and the amine leaving group in the substrate selectivity of N-Acylethanolamine acid amidase. **J Enzyme Inhib Med Chem.** 2021 Dec;36(1):1411-1423. doi: 10.1080/14756366.2021.1912035. PMID: 34256657
406. Mabou Tagne A, Fotio Y, Alan Springs Z, Su S, **Piomelli D**. Frequent $\Delta 9$ -tetrahydrocannabinol exposure during adolescence impairs sociability in adult mice exposed to an aversive painful stimulus. **Eur Neuropsychopharmacol.** 2021 Aug 3;53:19-24. doi: 10.1016/j.euroneuro.2021.07.007. PMID: 34358818
407. Ruiz CM, Torrens A, Lallai V, Castillo E, Manca L, Martinez MX, Justeson DN, Fowler CD, **Piomelli D**, Mahler SV. Pharmacokinetic and pharmacodynamic properties of aerosolized ("vaped") THC in adolescent male and female rats. **Psychopharmacology (Berl).** 2021 Sep 8. doi: 10.1007/s00213-021-05976-8. PMID: 34495367
408. **Piomelli D**, Tagne AM. Endocannabinoid-Based Therapies. **Annu Rev Pharmacol Toxicol.** 2021 Sep 13. doi: 10.1146/annurev-pharmtox-052220-021800. PMID: 34516291
409. Y Fotio, KM Jung, F Palese, A Obenaus, A Mabou Tagne, L Lin, T Ibne Rashid, R Pacheco, AA Jullienne, J Ramirez, M Mor, G Spadoni, C Jang, A G Hohmann, **D Piomelli** NAAA-regulated lipid signaling governs the transition from acute to chronic pain. **Science Advances**, 2021, Oct 22;7(43):eabi8834. doi: 10.1126/sciadv.abi8834. Epub 2021 Oct 22.
410. Le AA, Quintanilla J, Amani M, **Piomelli D**, Lynch G, Gall CM. Persistent sexually dimorphic effects of adolescent THC exposure on hippocampal synaptic plasticity and episodic memory in rodents. **Neurobiol Dis.** 2022 Jan;162:105565. doi: 10.1016/j.nbd.2021.105565. Epub 2021 Nov 25.

411. Ward SJ, Lichtman AH, **Piomelli D**, Parker LA. Cannabinoids and Cancer Chemotherapy-Associated Adverse Effects. *J Natl Cancer Inst Monogr*. 2021 Nov 28;2021(58):78-85. doi: 10.1093/jncimonographs/lgab007.
412. Uc A, Andersen DK, Apkarian AV, Bellin MD, Colloca L, Drewes AM, Dunbar EK, Forsmark CE, Goodman MT, Kapural L, Koob GF, Palermo TM, Pandol SJ, Pasricha P, Phillips AE, **Piomelli D**, Saloman JL, Schwarzenberg SJ, Singh VK, Sowa G, Strouse T, Treisman GJ, Windsor JA, Yadav D. Pancreatic Pain-Knowledge Gaps and Research Opportunities in Children and Adults: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop. *Pancreas*. 2021 Aug 1;50(7):906-915. doi: 10.1097/MPA.0000000000001899.
413. Du K, Sun L, Luo Z, Cao Y, Sun Q, Zhang K, Faizy A, **Piomelli D**, Lu X, Shan J, Yang Q. Reduced DMPC and PMPC in lung surfactant promote SARS-CoV-2 infection in obesity. *Metabolism*. 2022 Jun;131:155181. doi: 10.1016/j.metabol.2022.155181. Epub 2022 Mar 18. PMID: 35311662; PMCID: PMC8930181.
414. Torrens A, Roy P, Lin L, Vu C, Grimes D, Inshishian VC, Montesinos JS, Ahmed F, Mahler SV, Huestis MA, Das A, **Piomelli D**. Comparative Pharmacokinetics of Δ^9 -Tetrahydrocannabinol in Adolescent and Adult Male and Female Rats. *Cannabis Cannabinoid Res*. 2022 Mar 28. doi: 10.1089/can.2021.0205. Epub ahead of print. PMID: 35353551.
415. Lin L, Mabou Tagne A, Squire EN, Lee HL, Fotio Y, Ramirez J, Zheng M, Torrens A, Ahmed F, Ramos R, Plikus MV, **Piomelli D**. Diet-Induced Obesity Disrupts Histamine-Dependent Oleoylethanolamide Signaling in the Mouse Liver. *Pharmacology*. 2022;107(7-8):423-432. doi: 10.1159/000524753. Epub 2022 Jun 10. PMID: 35691287.
416. Lee HL, Jung KM, Fotio Y, Squire E, Palese F, Lin L, Torrens A, Ahmed F, Mabou Tagne A, Ramirez J, Su S, Wong CR, Jung DH, Scarfone VM, Nguyen PU, Wood M, Green K, **Piomelli D**. Frequent Low-Dose Δ^9 -Tetrahydrocannabinol in Adolescence Disrupts Microglia Homeostasis and Disables Responses to Microbial Infection and Social Stress in Young Adulthood. *Biol Psychiatry*. 2022 May 10:S0006-3223(22)01237-9. doi: 10.1016/j.biopsych.2022.04.017. Epub ahead of print. PMID: 35750512.
417. Palese F, Pontis S, Realini N, Torrens A, Ahmed F, Assogna F, Pellicano C, Bossù P, Spalletta G, Green K, **Piomelli D**. Targeting NAAA counters dopamine neuron loss and symptom progression in mouse models of parkinsonism. *Pharmacol Res*. 2022 Aug;182:106338. doi: 10.1016/j.phrs.2022.106338. Epub 2022 Jun 30. PMID: 35781057.
418. Greco R, Demartini C, Zanaboni AM, Francavilla M, Reggiani A, Realini N, Scarpelli R, **Piomelli D**, Tassorelli C. Potentiation of endocannabinoids and other lipid amides prevents hyperalgesia and inflammation in a pre-clinical model of migraine. *J Headache Pain*. 2022 Jul 7;23(1):79. doi: 10.1186/s10194-022-01449-1. PMID: 35799128; PMCID: PMC9264488.
420. Mabou Tagne A, Fotio Y, Uppal PS, **Piomelli D**. Synergistic antinociceptive effects of concomitant NAAA and peripheral FAAH inhibition. *Exp Neurol*. 2022 Nov;357:114194. doi: 10.1016/j.expneurol.2022.114194. Epub 2022 Aug 4. PMID: 35932800.
421. Ahmed F, Torrens A, Mahler SV, Ferlenghi F, Huestis MA, **Piomelli D**. A Sensitive Ultrahigh-Performance Liquid Chromatography/Tandem Mass Spectrometry Method for the Simultaneous Analysis of Phytocannabinoids and Endocannabinoids in Plasma and Brain. *Cannabis Cannabinoid Res*. 2022 Nov 11. doi: 10.1089/can.2022.0216. PMID: 36367975

422. Torrens A, Ruiz CM, Martinez MX, Tagne AM, Roy P, Grimes D, Ahmed F, Lallai V, Inshishian V, Bautista M, Chen YC, Huestis MA, Das A, Fowler CD, Mahler SV, **Piomelli D**. Nasal accumulation and metabolism of Δ^9 -tetrahydrocannabinol following aerosol ('vaping') administration in an adolescent rat model. **Pharmacol Res.** 2023 Jan;187:106600. doi: 10.1016/j.phrs.2022.106600. Epub 2022 Dec 5. PMID: 36481259; PMCID: PMC9845136.
423. Lim J, Lee HL, Nguyen J, Shin J, Getze S, Quach C, Squire E, Jung KM, Mahler SV, Mackie K, **Piomelli D**, Luderer U. Adolescent exposure to low-dose Δ^9 -tetrahydrocannabinol depletes the ovarian reserve in female mice. **Toxicol Sci.** 2023 May 12;193(1):31-47. doi: 10.1093/toxsci/kfad027. PMID: 36912754; PMCID: PMC10176244.
424. Fotio Y, Mabou Tagne A, Jung KM, **Piomelli D**. Fatty acid amide hydrolase inhibition alleviates anxiety-like symptoms in a rat model used to study post-traumatic stress disorder. **Psychopharmacology** (Berl). 2023 Apr 5. doi: 10.1007/s00213-023-06358-y. Epub ahead of print. PMID: 37017699.
425. Maccarrone M, Di Marzo V, Gertsch J, Grether U, Howlett AC, Hua T, Makriyannis A, **Piomelli D**, Ueda N, van der Stelt M. Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years. **Pharmacol Rev.** 2023 Sep;75(5):885-958. doi: 10.1124/pharmrev.122.000600. Epub 2023 May 10. PMID: 37164640; PMCID: PMC10441647.
426. Lin L, Jung KM, Lee HL, Le J, Colletuori G, Wood C, Palese F, Squire E, Ramirez J, Su S, Torrens A, Fotio Y, Tang L, Yu C, Yang Q, Huang L, DiPatrizio N, Jang C, Cinti S, **Piomelli D**. Adolescent exposure to low-dose THC disrupts energy balance and adipose organ homeostasis in adulthood. **Cell Metab.** 2023 Jul 11;35(7):1227-1241.e7. doi: 10.1016/j.cmet.2023.05.002. Epub 2023 Jun 1. PMID: 37267956.
427. Lai M, La Rocca V, Iacono E, Filipponi C, De Carli A, Favaro D, Fonnesu R, Filippini F, Spezia PG, Amato R, Catelli E, Matteo B, Lottini G, Onorati M, Clementi N, Freer G, **Piomelli D**, Pistello M. Inhibiting immunoregulatory amidase NAAA blocks ZIKV maturation in Human Neural Stem Cells. **Antiviral Res.** 2023 Aug;216:105664. doi: 10.1016/j.antiviral.2023.105664. Epub 2023 Jul 4. PMID: 37414288.
428. Carnevali L, Barbetti M, Fotio Y, Ferlenghi F, Vacondio F, Mor M, **Piomelli D**, Sgoifo A. Enhancement of peripheral fatty acyl ethanolamide signaling prevents stress-induced social avoidance and anxiety-like behaviors in male rats. **Psychopharmacology** (Berl). 2023 Nov 7. doi: 10.1007/s00213-023-06473-w. Epub ahead of print. PMID: 37932554.
429. Lee HL, Squire E, Fotio Y, Mabou Tagne A, Lee J, Yoon JJ, Hong Y, Kim LH, Jung KM, **Piomelli D**. Frequent low-impact exposure to THC during adolescence causes persistent sexually dimorphic alterations in the response to viral infection in mice. **Pharmacol Res.** 2024 Jan;199:107049. doi: 10.1016/j.phrs.2023.107049. Epub 2023 Dec 28. PMID: 38159785.
430. English A, Uittenbogaard F, Torrens A, Sarroza D, Slaven AVE, **Piomelli D**, Bruchas MR, Stella N, Land BB. [A preclinical model of THC edibles that produces high-dose cannabimimetic responses.](#) **Elife.** 2024 Jan 12;12. doi: 10.7554/eLife.89867. PMID: 38214701.
431. Butini S, Grether U, Jung KM, Ligresti A, Allarà M, Postmus AGJ, Maramai S, Brogi S, Papa A, Carullo G, Sykes D, Veprintsev D, Federico S, Grillo A, Di Guglielmo B, Ramunno A, Stevens AF, Heer D, Lamponi S, Gemma S, Benz J, Di Marzo V, van der Stelt M, **Piomelli D**, Campiani G. Development of Potent and Selective Monoacylglycerol Lipase Inhibitors. SARs, Structural Analysis,

and Biological Characterization. **J Med Chem**. 2024 Feb 8;67(3):1758-1782. doi: 10.1021/acs.jmedchem.3c01278. Epub 2024 Jan 19. PMID: 38241614.

432. Fotio Y, Mabou Tagne A, Squire E, Lee HL, Phillips CM, Chang K, Ahmed F, Greenberg AS, Villalta SA, Scarfone VM, Spadoni G, Mor M, **Piomelli D**. NAAA-regulated lipid signaling in monocytes controls the induction of hyperalgesic priming in mice. **Nat Commun**. 2024 Feb 24;15(1):1705. doi: 10.1038/s41467-024-46139-5. PMID: 38402219; PMCID: PMC10894261.

433. Jung KM, Lin L, **Piomelli D**. Overactivation of the Endocannabinoid System in Adolescence Disrupts Adult Adipose Organ Function in Mice. **Cells**. 2024 Mar 6;13(5):461. doi: 10.3390/cells13050461. PMID: 38474425; PMCID: PMC10930932.

434. Torrens A, Mabou Tagne A, Tran A, Ahmed F, Huestis MA, **Piomelli D**. Comparative Pharmacokinetics of Δ^9 -Tetrahydrocannabinol in Adolescent and Adult Female Mice. **Cannabis Cannabinoid Res**. 2024 Dec;9(6):1537-1542.

435. Squire E, Lee HL, Jeong W, Lee S, Ravichandiran V, Limoli CL, **Piomelli D**, Parihar VK, Jung KM. Targeting dysfunctional endocannabinoid signaling in a mouse model of Gulf War illness. **Neuropharmacology**. 2024 Dec 15;261:110142.

436. Mabou Tagne A, Fotio Y, Gupta K, Piomelli D. Δ^9 -Tetrahydrocannabinol Alleviates Hyperalgesia in a Humanized Mouse Model of Sickle Cell Disease. **J Pharmacol Exp Ther**. 2024 Oct 18;391(2):174-181.

437. Goodman MT, Lombardi C, Torrens A, Bresee C, Saloman JL, Li L, Yang Y, Fisher WE, Fogel EL, Forsmark CE, Conwell DL, Hart PA, Park WG, Topazian M, Vege SS, Van Den Eeden SK, Bellin MD, Andersen DK, Serrano J, Yadav D, Pandol SJ, **Piomelli D**; Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC). Association of Serum Endocannabinoid Levels with Pancreatitis and Pancreatitis-Related Pain. **Cannabis Cannabinoid Res**. 2024 Sep 18.

438. Lallai V, Lam TT, Garcia-Milian R, Chen YC, Fowler JP, Manca L, **Piomelli D**, Williams K, Nairn AC, Fowler CD. Proteomic Profile of Circulating Extracellular Vesicles in the Brain after Δ^9 -Tetrahydrocannabinol Inhalation. **Biomolecules**. 2024 Sep 10;14(9):1143.

COMMENTARIES AND BOOK REVIEWS

1. **D. Piomelli**, 1999. Le cannabis: de la drogue au médicament. **La Recherche**, 323, 58-64 [in French].

2. **D. Piomelli**, 2000. Le style c'est l'homme même. **La Recherche** 337, 16-17 [in French].

3. **D. Piomelli**, 2009. The case for medical marijuana, review of *Dying to get high: marijuana as medicine* by W. Chapkis and R. Webb. **Nature Medicine** Vol. 15, pp. 840.

4. **D. Piomelli**, 2014. A mighty (ochondrial) fight? **Mol Metab** 3, 345-346. PMCID: PMC4060220.

5. Kazan K, **Piomelli D**, Rohrabacher D, Ajax L., 2017. Understanding Cannabis: Medicine, Society, Government. **Cannabis Cannabinoid Res**. Sep 1;2(1):247-251. PMID: 29082321

6. **D. Piomelli**, Cooper Z, Abrams D, Grant I, Patel S. A, 2017. A guide to the National Academy of science report on cannabis: an exclusive discussion with panel members. **Cannabis Cannabinoid Res.** 2017 Jun 1;2(1):155-159. PMCID: PMC5569624.
7. **D Piomelli**, Weiss S, Boyd G, Pacula RL, Cooper Z. Cannabis and the Opioid Crisis. **Cannabis Cannabinoid Res.** 2018 Apr 1;3(1):108-116. doi: 10.1089/can.2018.29011.rtl. PMID: 29789812
8. **D Piomelli**, Waiting for the Entourage. **Cannabis Cannabinoid Res.** 2019 Sep 23;4(3):137-138. doi: 10.1089/can.2019.29014.dpi. eCollection 2019. PMID: 31579831
9. **D Piomelli**, Next Stop for Fatty Acid Amide Hydrolase Inhibitors, the Clinic? **Biol Psychiatry.** 2020 Mar 15;87(6):485-486. doi: 10.1016/j.biopsych.2019.11.020. No abstract available. PMID: 32081250
10. Balla A, Solomon R, **Piomelli D.** A Decision 85 Years in the Making. **Cannabis Cannabinoid Res.** 2022 Nov 9. doi: 10.1089/can.2022.0283. Online ahead of print. PMID: 36350696

BOOKS AND BOOK CHAPTERS

1. **D. Piomelli**, 1989. Eicosanoids. Entry in The Encyclopedia of Neuroscience, G. Adelman Ed., Birkhauser, Boston.
2. **D. Piomelli**, 1995. Eicosanoids. Entry in The Encyclopedia of Neuroscience, G. Adelman Ed., 2nd Edition, Birkhauser, Boston.
3. **D. Piomelli**, 1995. Arachidonic acid. In Psychopharmacology: The Fourth Generation of Progress, F. E. Bloom and D.J. Kupfer, ed., Raven Press, New York.
4. H. Cadas and **D. Piomelli**, 1995. Anandamide. In Neuropeptides et Neuromédiateurs, J. Epelbaum Ed., Paris, Editions INSERM, pp. 53-62 (in French).
5. **D. Piomelli**, 1996. Arachidonic acid in cell signaling. Chapman and Hall, New York.
6. A. Giuffrida and **D. Piomelli**, 1998. Purification and high resolution analysis of anandamide and other fatty acylethanolamides. In Lipid Second Messengers, R.R. Rubin and S. Laychock Eds., Boca Raton (FL), CRC Press, pp. 113-133.
7. G. Aliotta, **D. Piomelli**, A. Pollio and A. Touwaide, 2003. Piante Medicinali nel Corpus Hippocraticum [Medicinal plants in the Hippocratic Writings] [in Italian]. Guerini e Associati, Milano, p. 485.
8. **D. Piomelli**, 2004. Endocannabinoids, in Encyclopedia of Biological Chemistry, W. J. Lennarz and M.D. Lane, eds, Elsevier, Oxford, Vol. 2, pp. 13-15.
9. **D. Piomelli**, 2006. The endocannabinoid system: from cell biology to therapy. B.K. Madras, C.M. Colvis, J.D. Pollock, J.L. Rutter, D. Shurtleff, M. von Zastrow, eds, Cold Spring Harbor Laboratory Press.
10. M. Bortolato and **D. Piomelli**, 2007. The endocannabinoid system and anxiety responses. Handbook of Anxiety and Fear, Elsevier, Oxford, Vol. 17, pp. 303-324.

11. **D. Piomelli**, 2008. Endocannabinoids. McGraw-Hill Yearbook of Science & Technology 2008, The McGraw-Hill Companies, Inc., pp. 111-114.
12. K.M. Jung, **D. Piomelli**, 2016. Endocannabinoid Signaling: Methods and Protocols. Methods in Molecular Biology, Springer Protocols, Chapter 17: Assay of Monoacylglycerol Lipase activity.
13. **D. Piomelli**, 2017. The Endocannabinoid System: Genetics, Biochemistry, Brain Disorders, and Therapy. Academic Press, Chapter 1. Genetics of the endocannabinoid system.
14. Jung KM, **Piomelli D**. Assay of Monoacylglycerol Lipase Activity. Methods Mol Biol. 2023;2576:285-297. doi: 10.1007/978-1-0716-2728-0_24. PMID: 36152196

PRESS COVERAGE (selected, from 2003 to 2018)

1. National Public Radio/Southern California Public Radio, Interview, August 9, 2018.
<https://www.scpr.org/programs/take-two/2018/08/09/18760/>
2. Orange County Weekly, Featured article and cover: "UC Irvine is now ground zero for cannabis research." July 2018.
3. Nature, interviewed for the news article "Transgenic pot caould soon hit labs", July 12, 2018.
4. The Sacramento Bee, "What are the benefits, risks of marijuana use? Experts are just finding out", January 2018.
5. Los Angeles Times, invited Opinion Editorial "Why we need pot research" Decemeber 21, 2017.
6. Daily Republic "Marijuana's medical value remains uncertain", , September 2016.
7. Green Rush Daily "UC Irvine Professor: Cannabis Shows Promise Treating Opioid Addiction", , September 2016.
8. Nature Medicine "Metabolism in mind: New insights into the 'gut-brain axis' spur commercial efforts to target it", July 2016.
9. National Public Radio "Botched French Drug Trial Followed Rules But Lacked 'Common Sense'", May 2016.
10. Chemical Engineering News "Psychedelic compounds like ecstasy may be good for more than just a high", March 2016.
11. The Scientist, "How Gastric Bypass Can Kill Sugar Cravings", November 2015.
12. BLR Eagle, "Oxytocin and anandamide's relationship to be studied", October 2015.
13. HealthNewsDigest.com "Love Hormone' Helps Produce 'Bliss Molecules' to Boost Pleasure of Social Interactions", October 2015.
14. AAAS, "As Legal Use of Marijuana Spreads, Researchers Seek to Better Assess the Risk and Benefts", May 2015.
15. Medical Daily, "Meth Effects: The Ravaged Faces of Meth Result From Increase In Molecules Causing Cell Death," February 2015.
16. Methamphetamine Addiction, "New Study Shows How Meth Causes You to Rapidly Age", February 2015.
17. Examiner.com, "Researchers find method to reverse aging caused by methamphetamine abuse", February 2015.
18. Daily Mail, "The science behind the faces of meth: Scientists discover how drug causes cells to age and die, giving users their characteristic gaunt look", February 2015.
19. OC Weekly, "UC Irvine and Italian Institute Research Details at Cellular Level the Ravages of Meth on Faces", February 2015.
20. Science Daily, "First inhibitor for enzyme linked to cancers created", November 2014.
21. MNT, "Novel compound seen as enhancing the cancer-killing power of anti-tumor drugs", November 2014.

22. ", Life Science log, "Researchers create first inhibitor for enzyme linked to cancersNovember 2014.
23. Pharmaceutical Technology, "Researchers create new AC inhibitor associated to melanoma, lung and prostate cancers", November 2014.
24. Chamblu Entertainment, "UC Irvine, Italian researchers create first inhibitor for enzyme linked to melanoma, lung and prostate cancers", November 2014.
25. EurekAlert!, "UC Irvine-Italian researchers create first inhibitor for enzyme linked to cancers", November 2014.
26. Science Newsline Medicine, "UC Irvine-Italian researchers create first inhibitor for enzyme linked to cancers", November 2014.
27. ThevisualMD, "UC Irvine-Italian researchers create first inhibitor for enzyme linked to cancers", November 2014.
28. MedicineNet.com, "High-Fat Diets May Spur Overeating, Mouse Study Suggests", August 2014.
29. National Geographic, "Drugged", a documentary, May 2014.
30. CalWatchdog.com, "LA Pot Politics Spread Statewide", May 2014.
31. AlterNet, "Munches Mystery: Why Do Cannabis Users Crave Fatty Food?", May 2014.
32. ABC Local News Channel 7, 'Joey Strain': OC boy with Autism has own strain of medical marijuana", May 2014.
33. Mercola.com, "The Rich Benefits of Eating Chocolate", October 2013.
34. The Quarterly, "Autism: New understanding of Fragile X Syndrome points to new treatment possibilities for Autism", September 2013.
35. COSMOS Magazine, "Unwrapping the Secrets of Chocolate", September 2013.
36. CNN iReport, "Can the Cannabis component Cannabidiol (CBD) cure schizophrenia?", August 2013.
37. Cosmos Magazine, "Has Science Become Mired in Chocolate?", August 2013.
38. Health Day, "High-Fat Diets May Spur Overeating, Mouse study Suggests", August 2013.
39. The Scientist, "Why One Cream Cake Leads to Another", August 2013.
40. The Christian Post, "Marijuana controls blood sugar and treats obesity, claims new study", May 2013.
41. Time magazine, "Marijuana: the next Diabetes drug?", May 2013.
42. TransWorldNews, "Marijuana as treatment for schizophrenia", March 2013.
43. Selecciones Reader's Digest, "El Chocolate a Debate", February 2013.
44. Orange County Register, "UCI Researchers Recognized", February 2013.
45. The Bill Good Show on CKNW Radio, "Autism and Marijuana", January 2013.
46. Brain & Behavior, "Brain & Behavior research foundation announces 10 major research achievements of 2012", December 2012.
47. The Quarterly, "New understanding of fragile X syndrome points to new treatment possibilities", November 2012.
48. Time magazine, "How cannabinoids may slow brain aging", October 2012.
49. Natural News, "Marijuana cannabinoids found to help combat autism", October 2012.
50. MEDCITY News, "Novartis is one lead investor in \$16M financing for startup treating dermatological disorders", October 2012.
51. Citybizlist, "Novartis Ventures co-lead \$16M Series A for Thesan Pharmaceuticals", October 2012.
52. FierceBiotech, "Novo, Novartis back dermatology startup with \$16M A round", October 2012.
53. News Channel 6 ABC, "Thesan Pharmaceuticals announces Series A funding co-led by Novo Ventures and Novartis Venture Funds", October 2012.
54. New University, "Treating 'Fragile X'", October 2012.
55. Daily Pilot, "UCI study homes in on Austism treatment", October 2012.
56. Health Day, "Fragile X Syndrome' researchers boost social skills in mice", September 2012.
57. UC Health, "Boosting marijuana-like chemicals treats fragile X syndrome symptoms", September 2012.

58. ScienceDaily, "Boosting natural marijuana-like brain chemicals treats fragile X syndrome symptoms", September 2012.
59. India Today, "Fragile X syndrome can be corrected through natural marijuana-like brain chemicals: study", September 2012.
60. LAWeekly, "Marijuana as Autism cure? UC Irvine's Daniele Piomelli make smoking hot connection", September 2012.
61. FoxNews, "Marijuana-like brain chemicals could be key to treating fragile X syndrome", September 2012.
62. The Huffington Post, "Marijuana-like chemical may help Autism and fragile X syndrome symptoms", September 2012.
63. "New class of drugs that lower chronic pain in diabetes discovered", Medical Daily, June 2012.
64. "Marijuana compound treats Schizophrenia with few side effects: clinical trial", Time Healthland, May 2012.
65. Phoenix NewTimes News, "Marijuana is a real medicine for a long list of ills", May 2012.
66. The Huffington Post, 'Marijuana' diet pill may be possible, endocannabinoid study suggests', March 2012.
67. ABC News, "Blocking a marijuana-like brain chemical helps mice stay slim", March 2012.
68. Live Science, "Body's 'marijuana' may be key to diet pill", March 2012.
69. MSN News, "Cannabis chemical keeps mice slim", March 2012.
70. Wall Street Daily, "Introducing the high-fat, no exercise diet", March 2012.
71. Everyday Health, "Is there a 'marijuana' diet in your future?", March 2012.
72. OC Weekly, "UC Irvine research shows this is your brain off marijuana so fat can burn", March 2012.
73. BuffaloNews.com, "Can't find your keys? Eat a little fat", January 2012.
74. SciBX, "FLATtening pain", December 2011.
75. The Wall Street Journal, "The Most Unforgettable Meal of My Life", October 2011.
76. Nature Medicine, "Double-duty discovery", August 2011.
77. ABC Newcastle, "A Cure for Obesity?", July 2011.
78. HealthDay, "Binge Eating May Be a High All Its Own", July 2011.
79. Hindustantimes, "Fatty foods trigger marijuana effect", July 2011.
80. Msnbc.com, "For the love of fat: Why we crave chips and fries", July 2011.
81. Healthzone.ca, "High on fatty foods? Call it a gut feeling.," July 2011
82. Takepart, "Ratted Out: Science Finds Source of Fatty Food Cravings", July 2011.
83. Time magazine, "Reverse Engineering the Marijuana 'Munchies': What Causes Binge Eating?", July 2011.
84. Orange County Register (online), "UCI research finds why you keep eating chips", July 2011.
85. Orange County Register (printed), "UCI smokes out a dietary culprit", July 2011.
86. NY Times, "When Fatty Feasts are Driven by Automatic Pilot", July 2011.
87. United Press International, "Why 'you can't eat just one' potato chip", July 2011.
88. The Chronicle Herald, "Why we can't resist fatty foods", July 2011.
89. Herald.ie, "Why you can't resist just one more crisp", July 2011.
90. Orange County Register, "Find out why 15 Million Americans smoke pot", January 2011.
91. ScienceDaily, "Obesity Research Targets Brain's Use of Fatty Acids", January 2011.
92. ASBMB today, "Piomelli Garners Award for Innovative Medication Development Research", November 2010.
93. Orange County Register, "Health vs. high: A closer look at pot", October 2010.
94. National Geographic, "How Drugs Work: The Science Behind Cannabis", documentary, October 2010.
95. NatureNews, "Plan for addition institute splits NIH", October 2010.
96. NIDA News Release, "First NIDA Avant-Garde Awards for Medications Development Research", September 2010.
97. Nature Research Highlights This Week, "No brain pain control", September 2010.

98. Los Angeles Times, "Scientists devise a new approach to an old problem—relieving pain", September 2010.
99. KPCC, "Study finds liver may be part of Alzheimer's puzzle", September 2010.
100. ScienceNews, "Not just a high. Scientists test medicinal marijuana against MS, inflammation and cancer", June 2010.
101. "NARSAD Funding Builds Careers 2009 Distinguished Investigator", NARSAD The Brain and Behavior Research Fund 2009 Annual Report, December 2009.
102. SciBX, "This week in therapeutics", December 2009.
103. Woman's World, "Dancing with the Stars Weight-loss Secrets!", November 2009.
104. The Washington Post, "With medical marijuana on the back burner, what do we know? ", October 2009.
105. Natural News, "Fatty foods boost memory", September 2009.
106. Eating Well, "The Secret to Better Memory", September 2009.
107. ITWire, "Eat good fat for a better memory", May 2009.
108. La Repubblica, "Grassi: ecco la molecola che nutre la memoria", May 2009.
109. Lipidomics Gateway, "Remembering dinner: OEAsy does it", May 2009.
110. CBC News, "Can't curb your enthusiasm for food? Blame the brain", April 2009.
111. ChemMatters, "Chocolate the new Health food. Or is it?", April 2009.
112. Europa Press, "Comer grasas ayuda a fijar los recuerdos a largo plazo", April 2009.
113. Medical News Today, "Dietary Fats Trigger Long-Term Memory Formation", April 2009.
114. FARS News Agency, "Fatty Food Helps Boost Memory", April 2009.
115. "Fatty food is a treat that sticks in our memory", Herald.ie, April 2009.
116. "Fatty foods may boost memory", National Geographic News, April 2009.
117. "Fatty Foods Trigger Meaningful Memories", Ivanhoe Newswire, April 2009.
118. "Fatty Foods: Memory Forming Nutrition," HealthNews, April 2009.
119. "Fatty Foods: Memory Forming Nutrition", Park Tribune, April 2009.
120. "Fetthaltige Lebensmittel machen Gedächtnis fit", Presstext, April 2009.
121. "Gehirn speichert Erinnerung an fettiges Essen", GesundheitProd, April 2009.
122. "Memory pill that could help students and Alzheimer's patients being developed", Telegraph, April 2009.
123. "Nahrungsfett stimuliert Langzeitgedächtnis", Wissenschaft aktuell, April 2009.
124. "Remember facts by cramming with fat", New Scientist, April 2009.
125. "Remembrance of Fat May Be at Root of Cravings", MSN, April 2009.
126. "Instant Appetite Control", Fitness Magazine, February 2009.
127. "End of the line for cannabinoid receptor 1 as an anti-obesity target?", Nature Reviews Drug Discovery, December 2008.
128. "Studies find olive oil may reduce appetite", New University, November 2008.
129. "The long and short of fat", Science-Business eXchange, November 2008.
130. "Fat in olive oil helps halt hunger", The Press Association, October 2008.
131. "Fatty acid in olive oil wards off hunger", US News, October 2008.
132. "If the low-fat fad was bad for waistlines, could this be why?", Los Angeles Times, October 2008.
133. "Olive oil ingredient ups the time between meals", EurekAlert!, October 2008.
134. "Olive oil may hold the key to weight loss", The Globe and Mail, October 2008.
135. "Snacking on nuts or avocado helps curb appetite with their healthy oils, finds study", Mail Online, October 2008.
136. "Study Finds Potential for Appetite-Related Drugs", The Guardian, October 2008.
137. "UCI says some fatty foods quash hunger", Orange County Register, October 2008.
138. "UCI study shows how fatty foods curb hunger", UCI News, October 2008.
139. "Why some fatty foods curb hunger", United Press International, October 2008.
140. "A model solution to depression?", Chemical Biology, November 2007.
141. "Marijuana Chemical May Help Treat", Reuters, November 2007.
142. "Marijuana-like brain chemicals work as antidepressant", PhysOrg.com, November 2007.

143. "Marijuana-like Brain Chemicals Work As Antidepressant", Science Daily, November 2007.
144. "Marijuana-like brain chemicals work as antidepressant", UCI News, November 2007.
145. "Marijuana-like brain transmitter may work as antidepressant", Asian News International, November 2007.
146. "Marijuana-like chemical lifts depression", United Press International, November 2007.
147. "Pot properties may be used to treat depression", Daily Pilot, November 2007.
148. "L'lit trova risorse in California", Il Sole-24 Ore, July 2007.
149. "Organon Announces Acquisition of Kadmus Pharmaceuticals' FAAH Inhibitor Technology", PharmaLive, June 2007.
150. "UC Irvine discovery part of growing pharma effort to create new class of drugs", UCI News, June 2007.
151. "Zimulti's central concerns", BioCentury, June 2007.
152. "Can Pot-like Chemical Treat Parkinson's?", Red Herring, March 2007.
153. "Medical Marijuana", Dan Rather Reports, February 2007.
154. "F.D.A. Dismisses Medical Benefit From Marijuana", New York Times, April 2006.
155. "Endocannabinoids mediate age-old pain suppression", Drug Discovery Today, September 2005.
156. "Il Cervello Produce Farmaci Anti-Ansia", Scienze Tecnologia Medicina, September 2005.
157. "Brain's Own Marijuana-Like Chemicals Relieve Stress-Induced Pain", UCI News, August 2005.
158. "Body's Own 'Cannabis' Helps Pain", BBC News, June 2005.
159. "Body's Pot-Like Chemicals May Help Curb Pain", Fox News Channel, June 2005.
160. "Brain's Marijuana-like Chemicals Postpone Pain", Forbes, June 2005.
161. "Brain's Own Marijuana-Like Chemicals Play Key Role with Stress-Induced Pain Relief", Today@UCI, June 2005.
162. "Brain-Based Pain Relief", Science Concentrates, June 2005.
163. "Endocannabinoids Play Key Role in Stress-Induced Pain Relief", Xagena, June 2005.
164. "Natural Cannabinoids blunt Pain", Join Together, June 2005.
165. "Naturally Produced 'Cannabis' in the Brain Helps with Pain Relief", Medical Research News, June 2005.
166. "New Formula for Pain Relief Drugs", Dailymail.co.uk, June 2005.
167. "New Therapies May Use Body's Marijuana-Like Chemicals", Daily News Central, June 2005.
168. "Pot-Like Brain Chemicals Block Pain", Newsday.com, June 2005.
169. "Scientists Discover the Body's Marijuana-Like Compounds are Crucial for Stress-Induced Pain Relief", Physorg.com, June 2005.
170. "Scientists Discover the Body's Marijuana-Like Compounds are Crucial for Stress-Induced Pain Relief", Rednova.com, June 2005.
171. "Study Shows How Brain Blocks Pain", Athens Banner-Herald, June 2005.
172. "Surprise Role for Endocannabinoids", The Scientist, June 2005.
173. "UC Irvine Researcher Says Brain May Produce Chemical Similar to Marijuana", Metro Networks Communications Inc, June 2005.
174. "UCI Findings May Lead to New Drugs", The Orange County Register, June 2005.
175. "ESI Special Topics", Esi-topics.com, March 2005.
176. "Rapporti tra i cannabinoidi e il cervello, scoperta italo-americana", News Italia Press, October 2004.
177. "Reefer Sanity", Fortune, November 2003.
178. "OEA – A New Player in Appetite Regulation Answers Old Questions", DiabetesControl.com, October 2003.
179. "Un Bruciagrassi nel cacao", La Repubblica, October 2003.